(REV 11-98)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
09/308207

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US97/20873	13 November 1997	13 November 1996

TITLE OF INVENTION: Method For The Recombinant Production of 1,3 Propanediol

APPLICANT(S) FOR DO/EO/US
Dunn-Coleman, Nigel; Diaz-Torres, Maria; Chase, Matthew; Trimbur, Donald

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [ ] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [X] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [X] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.
8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [ ] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [XX] Other items or information: Computer diskette of sequence listing

17. [X] The following fees are submitted:	CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$970.00**	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$840.00**	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$760.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$670.00**	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **$96.00**	
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ 96.00
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	40 - 20 =	20	X **$18.00**	$360.00
Independent claims	- 3 =		X **$78.00**	$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ **$260.00**	$
TOTAL OF ABOVE CALCULATIONS =				$ 450.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also by filed (Note 37 CFR 1.9, 1.27, 1.28).				$
SUBTOTAL =				$
Processing fee of **$130.00** for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$
TOTAL NATIONAL FEE =				$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$
TOTAL FEES ENCLOSED =				$
			Amount to be: refunded	$
			charged	$ 450.00

a. [ ] A check in the amount of $_____ to cover the above fees is enclosed.

b. [X] Please charge my Deposit Account No. 07-1048 in the amount of $ 450.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1048. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

SIGNATURE

Debra J. Glaister
NAME

33,888
REGISTRATION NUMBER

69 Rec'd PCT/PTO 13 MAY 1998 9/308207 PCT/US97/20873

METHOD FOR THE RECOMBINANT PRODUCTION OF 1,3-PROPANEDIOL

Related Applications

The present application is a continuation-in-part application of United States Provisional Application 60/030,601 filed November 13, 1996, hereby incorporated herein in its entirety.

Field of Invention

The present invention relates to the field of molecular biology and specifically to improved methods for the production of 1,3-propanediol in host cells. In particular, the present invention describes components of gene clusters associated with 1,3-propanediol production in host cells, including protein X, and protein 1, protein 2 and protein 3. More specifically the present invention describes the expression of cloned genes encoding protein X , protein 1, protein 2 and protein 3, either separately or together, for the enhanced production of 1,3-propanediol in host cells.

Background

1,3-Propanediol is a monomer having potential utility in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds.

A variety of chemical routes to 1,3-propanediol are known. For example ethylene oxide may be converted to 1,3-propanediol over a catalyst in the presence of phosphine, water, carbon monoxide, hydrogen and an acid, by the catalytic solution phase hydration of acrolein followed by reduction, or from hydrocarbons such as glycerol, reacted in the presence of carbon monoxide and hydrogen over catalysts having atoms from group VIII of the periodic table. Although it is possible to generate 1,3-propanediol by these methods, they are expensive and generate waste streams containing environmental pollutants.

It has been known for over a century that 1,3-propanediol can be produced from the fermentation of glycerol. Bacterial strains able to produce 1,3-propanediol have been found, for example, in the groups *Citrobacter*, *Clostridium*, *Enterobacter*, *Ilyobacter*, *Klebsiella*, *Lactobacillus*, and *Pelobacter*. In each case studied, glycerol is converted to 1,3-propanediol in a two step, enzyme catalyzed reaction sequence. In the first step, a dehydratase catalyzes the conversion of glycerol to 3-hydroxypropionaldehyde (3-HP) and water (Equation 1). In the second step, 3-HP is reduced to 1,3-propanediol by a NAD^+-linked oxidoreductase (Equation 2).

$$\text{Glycerol} \rightarrow \text{3-HP} + H_2O \qquad \text{(Equation 1)}$$

$$\text{3-HP} + \text{NADH} + H^+ \rightarrow \text{1,3-Propanediol} + NAD^+ \qquad \text{(Equation 2)}$$

The 1,3-propanediol is not metabolized further and, as a result, accumulates in high concentration in the media. The overall reaction consumes a reducing equivalent in the form of a cofactor, reduced b-nicotinamide adenine dinucleotide (NADH), which is oxidized to nicotinamide adenine dinucleotide (NAD^+).

The production of 1,3-propanediol from glycerol is generally performed under anaerobic conditions using glycerol as the sole carbon source and in the absence of other exogenous reducing equivalent acceptors. Under these conditions, in for example, strains of *Citrobacter*, *Clostridium*, and *Klebsiella*, a parallel pathway for glycerol operates which first involves oxidation of glycerol to dihydroxyacetone (DHA) by a NAD^+- (or $NADP^+$-) linked glycerol dehydrogenase (Equation 3). The DHA, following phosphorylation to dihydroxyacetone phosphate (DHAP) by a DHA kinase (Equation 4), becomes available for biosynthesis and for supporting ATP generation via, for example, glycolysis.

$$\text{Glycerol} + NAD^+ \rightarrow \text{DHA} + \text{NADH} + H^+ \qquad \text{(Equation 3)}$$

$$\text{DHA} + \text{ATP} \rightarrow \text{DHAP} + \text{ADP} \qquad \text{(Equation 4)}$$

In contrast to the 1,3-propanediol pathway, this pathway may provide carbon and energy to the cell and produces rather than consumes NADH.

In *Klebsiella pneumoniae* and *Citrobacter freundii*, the genes encoding the functionally linked activities of glycerol dehydratase (*dhaB*), 1,3-propanediol oxidoreductase (*dhaT*), glycerol dehydrogenase (*dhaD*), and dihydroxyacetone kinase (*dhaK*) are encompassed by the *dha* regulon. The *dha* regulons from *Citrobacter* and *Klebsiella* have been expressed in *Escherichia coli* and have been shown to convert glycerol to 1,3-propanediol. Glycerol dehydratase (E.C. 4.2.1.30) and diol [1,2-propanediol] dehydratase (E.C. 4.2.1.28) are related but distinct enzymes that are encoded by distinct genes. In *Salmonella typhimurium* and *Klebsiella pneumoniae*, diol dehydratase is associated with the *pdu* operon, see Bobik et al., 1992, J. Bacteriol. 174:2253-2266 and United States patent 5,633,362. Tobimatsu, et al., 1996, J. Biol. Chem. 271: 22352-22357 disclose the *K. pneumoniae* gene encoding glycerol dehydratase protein X identified as ORF 4; Segfried et al., 1996, J. Bacteriol. 178: 5793-5796 disclose the *C. freundii* glycerol dehydratase gene encoding protein X identified as ORF Z. Tobimatsu et al., 1995, J. Biol. Chem. 270:7142-7148 disclose the diol dehydratase submits α, β and γ and illustrate the presence of orf 4. Luers (1997, FEMS Microbiology Letters 154:337-345) disclose the amino acid sequence of protein 1, protein 2 and protein 3 of *Clostridium pasteurianum*.

Biological processes for the preparation of glycerol are known. The overwhelming majority of glycerol producers are yeasts, but some bacteria, other fungi and algae are also known to produce glycerol. Both bacteria and yeasts produce glycerol by converting glucose or other carbohydrates through the fructose-1,6-bisphosphate pathway in glycolysis or by the Embden Meyerhof Parnas pathway, whereas, certain algae convert dissolved carbon dioxide or bicarbonate in the chloroplasts into the 3-carbon intermediates of the Calvin cycle. In a series of steps, the 3-carbon intermediate, phosphoglyceric acid, is converted to glyceraldehyde 3-phosphate which can be readily interconverted to its keto isomer dihydroxyacetone phosphate and ultimately to glycerol.

Specifically, the bacteria *Bacillus licheniformis* and *Lactobacillus lycopersica* synthesize glycerol, and glycerol production is found in the halotolerant algae *Dunaliella sp.* and *Asteromonas gracilis* for protection against high external salt concentrations (Ben-Amotz et al., *Experientia* 38, 49-52, (1982)). Similarly, various osmotolerant yeasts synthesize glycerol as a protective measure. Most strains of *Saccharomyces* produce some glycerol during alcoholic fermentation, and this can be increased physiologically by the application of osmotic stress (Albertyn et al., *Mol. Cell. Biol.* 14, 4135-4144, (1994)). Earlier this century commercial glycerol production was achieved by the use of *Saccharomyces* cultures to which "steering reagents" were added such as sulfites or alkalis. Through the formation of an inactive complex, the steering agents block or inhibit the conversion of acetaldehyde to ethanol; thus, excess reducing equivalents (NADH) are available to or "steered" towards DHAP for reduction to produce glycerol. This method is limited by the partial inhibition of yeast growth that is due to the sulfites. This limitation can be partially overcome by the use of alkalis which create excess NADH equivalents by a different mechanism. In this practice, the alkalis initiated a Cannizarro disproportionation to yield ethanol and acetic acid from two equivalents of acetaldehyde.

The gene encoding glycerol-3-phosphate dehydrogenase (DAR1, GPD1) has been cloned and sequenced from *S. diastaticus* (Wang et al., *J. Bact.* 176, 7091-7095, (1994)). The DAR1 gene was cloned into a shuttle vector and used to transform *E. coli* where expression produced active enzyme. Wang et al. (supra) recognize that DAR1 is regulated by the cellular osmotic environment but do not suggest how the gene might be used to enhance 1,3-propanediol production in a recombinant organism.

Other glycerol-3-phosphate dehydrogenase enzymes have been isolated: for example, sn-glycerol-3-phosphate dehydrogenase has been cloned and sequenced from *S. cerevisiae* (Larason et al., *Mol. Microbiol.* 10, 1101, (1993)) and Albertyn et al., (*Mol. Cell. Biol.* 14, 4135, (1994)) teach the cloning of GPD1 encoding a glycerol-3-phosphate dehydrogenase from *S. cerevisiae*. Like Wang et al. (supra), both Albertyn et al. and Larason et al. recognize the osmo-sensitivity of the regulation of this gene but do not suggest how the gene might be used in the production of 1,3-propanediol in a recombinant organism.

As with G3PDH, glycerol-3-phosphatase has been isolated from *Saccharomyces cerevisiae* and the protein identified as being encoded by the GPP1 and GPP2 genes (Norbeck et al., *J. Biol. Chem.* 271, 13875,(1996)). Like the genes encoding G3PDH, it appears that GPP2 is osmosensitive.

Although biological methods of both glycerol and 1,3-propanediol production are known, it has never been demonstrated that the entire process can be accomplished by a single recombinant organism.

Neither the chemical nor biological methods described above for the production of 1,3-propanediol are well suited for industrial scale production since the chemical processes are energy intensive and the biological processes require the expensive starting material, glycerol. A

method requiring low energy input and an inexpensive starting material is needed. A more desirable process would incorporate a microorganism that would have the ability to convert basic carbon sources such as carbohydrates or sugars to the desired 1,3-propanediol end-product.

Although a single organism conversion of fermentable carbon source other than glycerol or dihydroxyacetone to 1,3-propanediol would be desirable, it has been documented that there are significant difficulties to overcome in such an endeavor. For example, Gottschalk et al. (EP 373 230) teach that the growth of most strains useful for the production of 1,3-propanediol, including *Citrobacter freundii*, *Clostridium autobutylicum*, *Clostridium butylicum*, and *Klebsiella pneumoniae*, is disturbed by the presence of a hydrogen donor such as fructose or glucose. Strains of *Lactobacillus brevis* and *Lactobacillus buchner*, which produce 1,3-propanediol in co-fermentations of glycerol and fructose or glucose, do not grow when glycerol is provided as the sole carbon source, and, although it has been shown that resting cells can metabolize glucose or fructose, they do not produce 1,3-propanediol. (Veiga DA Cunha et al., *J. Bacteriol. 174*, 1013 (1992)). Similarly, it has been shown that a strain of *Ilyobacter polytropus*, which produces 1,3-propanediol when glycerol and acetate are provided, will not produce 1,3-propanediol from carbon substrates other than glycerol, including fructose and glucose. (Steib et al., *Arch. Microbiol. 140*, 139 (1984)). Finally Tong et al. (*Appl. Biochem. Biotech. 34*, 149 (1992)) has taught that recombinant *Escherichia coli* transformed with the *dha* regulon encoding glycerol dehydratase does not produce 1,3-propanediol from either glucose or xylose in the absence of exogenous glycerol.

Attempts to improve the yield of 1,3-propanediol from glycerol have been reported where co-substrates capable of providing reducing equivalents, typically fermentable sugars, are included in the process. Improvements in yield have been claimed for resting cells of *Citrobacter freundii* and *Klebsiella pneumoniae* DSM 4270 cofermenting glycerol and glucose (Gottschalk et al., *supra.*, and Tran-Dinh et al., DE 3734 764); but not for growing cells of *Klebsiella pneumoniae* ATCC 25955 cofermenting glycerol and glucose, which produced no 1,3-propanediol (I-T. Tong, Ph.D. Thesis, University of Wisconsin-Madison (1992)). Increased yields have been reported for the cofermentation of glycerol and glucose or fructose by a recombinant *Escherichia coli*; however, no 1,3-propanediol is produced in the absence of glycerol (Tong et al., *supra.*). In these systems, single organisms use the carbohydrate as a source of generating NADH while providing energy and carbon for cell maintenance or growth. These disclosures suggest that sugars do not enter the carbon stream that produces 1,3-propanediol. In no case is 1,3-propanediol produced in the absence of an exogenous source of glycerol. Thus the weight of literature clearly suggests that the production of 1,3-propanediol from a carbohydrate source by a single organism is not possible.

The weight of literature regarding the role of protein X in 1,3-propanediol production by a host cell is at best confusing. Prior to the availability of gene information, McGee et al., 1982, Biochem. Biophys. Res. Comm. 108: 547-551, reported diol dehydratase from *K. pneumoniae* ATCC 8724 to be composed of four subunits identified by size (60K, 51K, 29K, and 15K daltons) and N-terminal amino acid sequence. In direct contrast to McGee, Tobimatsu et al.1995, *supra*, report the cloning, sequencing and expression of diol dehydratase from the same organism and find no evidence linking the 51K dalton polypeptide to dehydrase. Tobimatsu et al.1996, *supra*, conclude that the protein X polypeptide is not a subunit of glycerol dehydratase, in contrast to GenBank Accession Number U30903 where protein X is described as a large subunit of glycerol dehydratase. Seyfried et al., *supra*, report that a deletion of 192 bp from the 3' end of *orfZ* (protein X) had no effect on enzyme activity and conclude that orfZ does not encode a subunit required for dehydratase activity. Finally, Skraly, F.A. (1997, Thesis entitiled "Metabolic Engineering of an Improved 1,3-Propanediol Fermentation") disclose a loss of glycerol dehydratase activity in one experiment where recombinant ORF3 (proteinX) was disrupted creating a large fusion protein but not in another experiment where 1,3-propanediol production from glycerol was diminished compared to a control where ORF3 was intact.

The problem to be solved by the present invention is the biological production of 1,3-propanediol by a single recombinant organism from an inexpensive carbon substrate such as glucose or other sugars in commercially feasible quantities. The biological production of 1,3-propanediol requires glycerol as a substrate for a two step sequential reaction in which a dehydratase enzyme (typically a coenzyme B_{12}-dependent dehydratase) converts glycerol to an intermediate, 3-hydroxypropionaldehyde, which is then reduced to 1,3-propanediol by a NADH-(or NADPH) dependent oxidoreductase. The complexity of the cofactor requirements necessitates the use of a whole cell catalyst for an industrial process which utilizes this reaction sequence for the production of 1,3-propanediol. Furthermore, in order to make the process economically viable, a less expensive feedstock than glycerol or dihydroxyacetone is needed and high production levels are desirable. Glucose and other carbohydrates are suitable substrates, but, as discussed above, are known to interfere with 1,3-propanediol production. As a result no single organism has been shown to convert glucose to 1,3-propanediol.

Applicants have solved the stated problem and the present invention provides for bioconverting a fermentable carbon source directly to 1,3-propanediol using a single recombinant organism. Glucose is used as a model substrate and the bioconversion is applicable to any existing microorganism. Microorganisms harboring the genes encoding protein X and protein 1, protein 2 and protein 3 in addition to other proteins associated with the production of 1,3-propanediol, are able to convert glucose and other sugars through the glycerol degradation pathway to 1,3-propanediol with good yields and selectivities. Furthermore, the present invention

may be generally applied to include any carbon substrate that is readily converted to 1) glycerol, 2) dihydroxyacetone, or 3) C_3 compounds at the oxidation state of glycerol (e.g., glycerol 3-phosphate) or 4) C_3 compounds at the oxidation state of dihydroxyacetone (e.g., dihydroxyacetone phosphate or glyceraldehyde 3-phosphate).

Summary of the Invention

The present invention relates to improved methods for the production of 1,3-propanediol from a single microorganism. The present invention is based, in part, upon the unexpected discovery that the presence of a gene encoding protein X in a microorganism containing at least one gene encoding a dehydratase activity and capable of producing 1,3-propanediol is associated with the *in vivo* reactivation of dehydratase activity and increased production of 1,3-propanediol in the microorganism. The present invention is also based, in part, upon the unexpected discovery that the presence of a gene encoding protein X and at least one gene encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3 in host cells containing at least one gene encoding a dehydratase activity and capable of producing 1,3-propanediol is associated with *in vivo* reactivation of the dehydratase activity and increased yields of 1,3-propanediol in the microorganism.

Accordingly, the present invention provides an improved method for the production of 1,3-propanediol from a microorganism capable of producing 1,3-propanediol, said microorganism comprising at least one gene encoding a dehydratase activity, the method comprising the steps of introducing a gene encoding protein X into the organism to create a transformed organism; and culturing the transformed organism in the presence of at least one carbon source capable of being converted to 1,3 propanediol in said transformed host organism and under conditions suitable for the production of 1,3 propanediol wherein the carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and a one carbon substrate.

In a preferred embodiment, the method for improved production of 1,3-propanediol further comprises introducing at least one gene encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3 into the organism. The microorganism may further comprise at least one of (a) a gene encoding a glycerol-3-phosphate dehydrogenase activity; (b) a gene encoding a glycerol-3-phosphatase activity; and (c) a gene encoding 1,3-propanediol oxidoreductase activity into the microorganism. Gene(s) encoding a dehydratase activity, protein X, proteins 1, 2 or 3 or other genes necessary for the production of 1,3-propanediol may be stably maintained in the host cell genome or may be on replicating plasmids residing in the host microorganism.

The method optionally comprises the step of recovering the 1,3 propanediol. In one aspect of the present invention, the carbon source is glucose.

The microorganism is selected from the group of genera consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*.

In one aspect, protein X is derived from a glyceol dehydratase gene cluster and in another aspect, protein X is derived from a diol dehydratase gene cluster. The gene encoding the dehydratase activity may be homologous to the microorganism or heterologous to the microorganism. In one embodiment, the glycerol dehydratase gene cluster is derived from an organism selected from the genera consisting of Klebsiella and Citrobactor. In another embodiment, the diol dehydratase gene cluster is derived from an organism selected from the genera consisting of Klebsiella, Clostridium and Salmonella.

In another aspect, the present invention provides a recombinant microorganism comprising at least one gene encoding a dehydratase activity; at least one gene encoding a glycerol-3-phosphatase; and at least one gene encoding protein X, wherein said microorganism is capable of producing 1,3-propanediol from a carbon source. The carbon source may be selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and a one carbon substrate. In a further embodiment, the microorganism further comprises a gene encoding a cytosolic glycerol-3-phosphate dehydrogenase. In another embodiment, the recombinant microorganism further comprises at least one gene encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3. The microorganism is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*. In one aspect, protein X is derived from a glycerol dehydratase gene cluster. In another aspect, protein X is derived from a diol dehydratase gene cluster. In one aspect, the dehydratase activity is heterologous to said microorganism and in another aspect, the dehydratase activity is homologous to said microorganism.

The present invention also provides a method for the *in vivo* reactivation of a dehydratase activity in a microorganism capable of producing 1,3-propanediol and containing at least one gene encoding a dehydratase activity, comprising the step of introducing a gene encoding protein X into said microorganism. The microorganism is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*,

Hansenula, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*.

In one aspect, the gene encoding the dehydratase activity is heterologous to said microorganism and in another aspect, the gene encoding the dehydratase activity is homologous to said microorganism. In one embodiment, the gene encoding protein X is derived from a glycerol dehydratase gene cluster and in another embodiment, the gene encoding protein X is derived from a diol dehydratase gene cluster.

The present invention also provides expression vectors and host cells containing genes encoding protein X, protein 1, protein 2 and protein 3.

One advantage of the method of production of 1,3-propanediol according to the present invention is the unexpected increased production of 1,3-propanediol in a host cell capable of producing 1,3-propanediol in the presence of nucleic acid encoding protein X as compared to the host cell lacking nucleic acid encoding protein X. As demonstrated *infra*, a host cell containing nucleic acid encoding dhaB 1, 2 and 3 and protein X is able to produce significanty more 1,3-propanediol than a host cell containing nucleic acid encoding dhaB 1, 2 and 3 and lacking X.

Another advantage of the present invention as demonstrated *infra*, is that the presence of nucleic acid encoding protein X along with nucleic acid encoding at least one of protein 1, protein 2 and protein 3 in a host cell capable of producing 1,3-propanediol gives the unexpected result of increased production of 1,3-propanediol in the host cell over 1,3-propanediol production in the host cell lacing nucleic acid encoding protein X along with nucleic acid encoding at least one of protein 1, protein 2 and protein 3.

Yet another advantage of the method of production of the present invention as shown *infra* is the *in vivo* reactivation of the dehydratase activity in a microorganism that is associated with the presence of nucleic acid encoding protein X in the microorganism.

Brief Description of the Drawings

Figure 1 illustrates components of the glycerol dehydratase gene cluster from *Klebsiella pneumoniae* on plasmid pHK28-26 (SEQ ID NO:19). In this figure, orfY encodes protein 1, orfX encodes protein 2 and orfW encodes protein 3. DhaB-X refers to protein X.

Figures 2A-2G illustrates the nucleotide and amino acid sequence of *Klebsiella pneumoniae* glycerol dehydratase protein X (dhab4) (SEQ ID NO:59).

Figure 3 illustrates the amino acid alignment of *Klebsiella pneumonia* protein 1 (SEQ ID NO: 61) and *Citrobacter freundii* protein1 (SEQ ID NO: 60) (designated in Figure 3 as orfY).

Figure 4 illustrates the amino acid alignment of *Klebsiella pneumonia* protein 2 (SEQ ID NO: 63) and *Citrobacter freundii* protein 2 (SEQ ID NO: 62) (designated in Figure 4 as orfX).

Figure 5 illustrates the amino acid alignment of *Klebsiella pneumonia* protein 3 (SEQ ID NO: 64) and *Citrobacter freundii* protein 3 (SEQ ID NO: 65) (designated in Figure 5 as orfW).

Figure 6 illustrates the in situ reactivation comparison of plasmids pHK28-26 (which contains dhaB subunits 1, 2 and 3 as well as protein X and the open reading frames encoding protein 1, protein 2 and protein 3) vs. pDT24 (which contains dhaB subunits 1, 2 and 3 as well as protein X) in *E.coli* DH5α cells.

Figure 7 illustrate the in situ reactivation comparison of plasmids pM7 (containing genes encoding dhaB subunits 1, 2 and 3 and protein X) vs. Plasmid pM11 (containing genes encoding dhaB subunits 1, 2 and 3) in *E.coli* DH5α cells.

Figures 8A-8E illustrates the nucleic acid (SEQ ID NO: 66) and amino acid (SEQ ID NO: 67) sequence of K. pneumoniae diol dehydratase gene cluster protein X.

Figure 9 illustrates a standard 10 liter fermentation for 1,3 propandiol production using E. coli FM5/pDT24 (FM5 described in Amgen patent US 5,494,816 , ATCC accession No. 53911).

Figure 10 illustrates a standard 10 liter fermentation for 1,3 propandiol production using E. coli DH5alpha/pHK28-26.

Brief Description of Biological Deposits and Sequence Listing

The transformed *E. coli* W2042 (comprising the *E. coli* host W1485 and plasmids pDT20 and pAH42) containing the genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) was deposited on 26 September 1996 with the ATCC under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purpose of Patent Procedure and is designated as ATCC 98188.

S. cerevisiae YPH500 harboring plasmids pMCK10, pMCK17, pMCK30 and pMCK35 containing genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) was deposited on 26 September 1996 with the ATCC under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for the Purpose of Patent Procedure and is designated as ATCC 74392.

E.coli DH5α containing pKP1 which has about 35kb of a *Klebsiella* genome which contains the glycerol dehydratase, protein X and proteins 1, 2 and 3 was deposited on 18 April 1995 with the ATCC under the terms of the Budapest Treaty and was designated ATCC 69789. *E.coli* DH5α containing pKP4 containing a portion of the Klebsiella genome encoding diol dehydratase enzyme, including protein X was deposited on 18 April 1995 with the ATCC under the terms of the Budapest Treaty and was designated ATCC 69790.

"ATCC" refers to the American Type Culture Collection international depository located at 12301 Parklawn Drive, Rockville, MD 20852 U.S.A. The designations refer to the accession number of the deposited material.

Detailed Description of the Invention

The present invention relates to the production of 1,3-propanediol in a single microorganism and provides improved methods for production of 1,3-propanediol from a fermentable carbon source in a single recombinant organism. The method incorporates a microorganism capable of producing 1,3-propanediol comprising either homologous or heterologous genes encoding dehydratase (*dhaB*), at least one gene encoding protein X and optionally at least one of the genes encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3. Optionally, the microorganism contains at least one gene encoding glycerol-3-phosphate dehydrogenase, glycerol-3-phosphatase and 1, 3-propanediol oxidoreductase (*dhaT*). The recombinant microorganism is contacted with a carbon substrate and 1,3-propanediol is isolated from the growth media.

The present method provides a rapid, inexpensive and environmentally responsible source of 1,3-propanediol monomer useful in the production of polyesters and other polymers.

The following definitions are to be used to interpret the claims and specification.

The term "dehydratase gene cluster" or "gene cluster" refers to the set of genes which are associated with 1,3-propanediol production in a host cell and is intended to encompass glycerol dehydratase gene clusters as well as diol dehydratase gene clusters. The dha regulon refers to a glycerol dehydratase gene cluster, as illustrated in Figure 1 which includes regulatory regions.

The term "regenerating the dehydratase activity" or "reactivating the dehydratase activity" refers to the phenomenon of converting a dehydratase not capable of catalysis of a substrate to one capable of catalysis of a substrate or to the phenomenon of inhibiting the inactivation of a dehydratase or the phenomenon of extending the useful halflife of the dehydratase enzyme *in vivo*.

The terms "glycerol dehydratase" or "dehydratase enzyme" or "dehydratase activity" refer to the polypeptide(s) responsible for an enzyme activity that is capable of isomerizing or converting a glycerol molecule to the product 3-hydroxypropionaldehyde. For the purposes of the present invention the dehydratase enzymes include a glycerol dehydratase (GenBank U09771, U30903) and a diol dehydratase (GenBank D45071) having preferred substrates of glycerol and 1,2-propanediol, respectively. Glycerol dehydratase of *K. pneumoniae* ATCC 25955 is encoded by the genes *dhaB1*, *dhaB2*, and *dhaB3* identified as SEQ ID NOS:1, 2 and 3, respectively. The *dhaB1, dhaB2*, and *dhaB3* genes code for the a, b, and c subunits of the glycerol dehydratase enzyme, respectively.

The phrase "protein X of a dehydratase gene cluster" or "dhaB protein X" or "protein X" refers to a protein that is comparable to protein X of the *Klebsiella pneumoniae* dehydratase gene cluster as shown in Figure 2 or alternatively comparable to protein X of *Klebsiella pneumoniae* diol dehydratase gene cluster as shown in Figure 8. Preferably protein X is capable of increasing

the production of 1,3-propanediol in a host organism over the production of 1,3-propanediol in the absence of protein X in the host organism. Being comparable means that DNA encoding the protein is either in the same structural location as DNA encoding *Klebsiella* protein X with respect to Klebsiella dhaB1, dhaB2 and dhaB3, i.e., DNA encoding protein X is 3' to nucleic acid encoding dhaB1-B3, or that protein X has overall amino acid similarity to either Klebsiella diol or glycerol dehydratase protein X. The present invention encompasses protein X molecules having at least 50%; or at least 65 %; or at least 80%; or at least 90% or at least 95% similarity to the protein X of *K. pneumoniae* glycerol or diol dehydratase or the *C. freundii* protein X.

Included within the term "protein X" is protein X, also referred to as ORF Z, from *Citrobacter* dha regulon (Segfried M. 1996, J. Bacteriol. 178: 5793:5796). The present invention also encompasses amino acid variations of protein X from any microorganism as long as the protein X variant retains its essential functional characteristics of increasing the production of 1,3-propanediol in a host organism over the production of 1,3-propanediol in the host organism in the absence of protein X.

A portion of the *Klebsiella* genome encoding the glycerol dehydratase enzyme activity as well as protein X was transformed into *E.coli* and the transformed *E.coli* was deposited on 18 April 1995 with the ATCC under the terms of the Budapest Treaty and was designated as ATCC accession number 69789. A portion of the *Klebsiella* genome encoding the diol dehydratase enzyme activity as well as protein X was transformed into *E.coli* and the transformed *E.coli* was deposited on 18 April 1995 with the ATCC under the terms of the Budapest Treaty and was designated as ATCC accession number 69790.

Klebsiella glycerol dehydratase protein X is found at bases 9749-11572 of SEQ ID NO:19, counting the first base of dhaK as position number 1. Citrobacter freundii (ATCC accession number CFU09771) nucleic acid encoding protein X is found between positions 11261 and 13072.

The present invention encompasses genes encoding dehydratase protein X that are recombinantly introduced and replicate on a plasmid in the host organism as well as genes that are stably maintained in the host genome. The present invention encompasses a method for enhanced production of 1,3-propanediol wherein the gene encoding protein X is transformed in a host cell together with genes encoding the dehydratase activity and/or other genes necessary for the production of 1,3-propanediol. The gene encoding protein X, dehydratase activity and/or other genes may be on the same or different expression cassettes. Alternatively, the gene encoding protein X may be transformed separately, either before or after genes encoding the dehydratase activity and/or other activities. The present invention encompasses host cell having endogenous nucleic acid encoding protein X as well as host cell lacking endogenous nucleic acid encoding protein X.

The terms "protein 1", protein 2" and "protein 3" refer to the proteins encoded in a microorganism that are comparable to protein 1 (SEQ ID NO: 60 or SEQ ID NO: 61)(also referred to as orfY), protein 2 (SEQ ID NO: 62 or SEQ ID NO: 63) (also referred to as orfX) and protein 3 (SEQ ID NO: 64 or SEQ ID NO: 65) (also referred to as orfW), respectively.

Preferably, in the presence of protein X, at least one of proteins 1, 2 and 3 is capable of increasing the production of 1,3-propanediol in a host organism over the production of 1,3-propanediol in the absence of protein X and at least one of proteins 1, 2 and 3 in the host organism. Being comparable means that DNA encoding the protein is either in the same structural location as DNA encoding the respective proteins, as shown in Figure 1, or that the respective proteins have overall amino acid similarity to the respective SEQ ID NOS shown in Figures 3, 4 and 5.

The present invention encompasses protein 1 molecules having at least 50%; or at least 65 %; or at least 80%; or at least 90% or at least 95% similarity to SEQ ID NO: 60 or SEQ ID NO: 61. The present invention encompasses protein 2 molecules having at least 50%; or at least 65 %; or at least 80%; or at least 90% or at least 95% similarity to SEQ ID NO: 62 or SEQ ID NO: 63. The present invention encompasses protein 3 molecules having at least 50%; or at least 65 %; or at least 80%; or at least 90% or at least 95% similarity to SEQ ID NO: 64 or SEQ ID NO: 65.

Included within the terms "protein 1", "protein 2" and "protein 3", respectively, are orfY, orfX and orfW from *Clostridium pasteurianum* (Luers, et al., *supra*) as well as molecules having at least 50%; or at least 65 %; or at least 80%; or at least 90% or at least 95% similarity to *C. pasterurianum* orfY, orfX or orfW. The present invention also encompasses amino acid variations of proteins 1, 2 and 3 from any microorganism as long as the protein variant, in combination with protein X, retains its essential functional characteristics of increasing the production of 1,3-propanediol in a host organism over the production of 1,3-propanediol in the host organism in their absence.

The present invention encompasses a method for enhanced production of 1,3-propanediol wherein the gene(s) encoding at least one of protein 1, protein 2 and protein 3 is transformed in a host cell together with genes encoding protein X, the dehydratase activity and/or other genes necessary for the production of 1,3-propanediol. The gene(s) encoding at least on of proteins 1, 2 and 3, protein X, dehydratase activity and/or other genes may be on the same or different expression cassettes. Alternatively, the gene(s) encoding at least one of proteins 1, 2 and 3 may be transformed separately, either before or after genes encoding the dehydratase activity and/or other activities. The present invention encompasses host cell having endogenous nucleic acid encoding protein 1, protein 2 or protein 3 as well as host cell lacking endogenous nucleic acid encoding the proteins.

The terms "oxidoreductase" or "1,3-propanediol oxidoreductase" refer to the polypeptide(s) responsible for an enzyme activity that is capable of catalyzing the reduction of 3-hydroxypropionaldehyde to 1,3-propanediol. 1,3-Propanediol oxidoreductase includes, for example, the polypeptide encoded by the *dhaT* gene (GenBank U09771, U30903) and is identified as SEQ ID NO:4.

The terms "glycerol-3-phosphate dehydrogenase" or "G3PDH" refer to the polypeptide(s) responsible for an enzyme activity capable of catalyzing the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). *In vivo* G3PDH may be NADH-, NADPH-, or FAD-dependent. Examples of this enzyme activity include the following: NADH-dependent enzymes (EC 1.1.1.8) are encoded by several genes including GPD1 (GenBank Z74071x2) or GPD2 (GenBank Z35169x1) or GPD3 (GenBank G984182) or DAR1 (GenBank Z74071x2); a NADPH-dependent enzyme (EC 1.1.1.94) is encoded by *gpsA* (GenBank U32164, G466746 (cds 197911-196892), and L45246); and FAD-dependent enzymes (EC 1.1.99.5) are encoded by GUT2 (GenBank Z47047x23) or glpD (GenBank G147838) or glpABC (GenBank M20938).

The terms "glycerol-3-phosphatase" or "sn-glycerol-3-phosphatase" or "d,l-glycerol phosphatase" or "G3P phosphatase" refer to the polypeptide(s) responsible for an enzyme activity that is capable of catalyzing the conversion of glycerol-3-phosphate to glycerol. G3P phosphatase includes, for example, the polypeptides encoded by GPP1 (GenBank Z47047x125) or GPP2 (GenBank U18813x11).

The term "glycerol kinase" refers to the polypeptide(s) responsible for an enzyme activity capable of catalyzing the conversion of glycerol to glycerol-3-phosphate or glycerol-3-phosphate to glycerol, depending on reaction conditions. Glycerol kinase includes, for example, the polypeptide encoded by GUT1 (GenBank U11583x19).

The terms "GPD1", "DAR1", "OSG1", "D2830", and "YDL022W" will be used interchangeably and refer to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and characterized by the base sequence given as SEQ ID NO:5.

The term "GPD2" refers to a gene that encodes a cytosolic glycerol-3-phosphate dehydrogenase and characterized by the base sequence given as SEQ ID NO:6.

The terms "GUT2" and "YIL155C" are used interchangably and refer to a gene that encodes a mitochondrial glycerol-3-phosphate dehydrogenase and characterized by the base sequence given in SEQ ID NO:7.

The terms "GPP1", "RHR2" and "YIL053W" are used interchangably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and characterized by the base sequence given as SEQ ID NO:8.

The terms "GPP2", "HOR2" and "YER062C" are used interchangably and refer to a gene that encodes a cytosolic glycerol-3-phosphatase and characterized by the base sequence given as SEQ ID NO:9.

The term "GUT1" refers to a gene that encodes a cytosolic glycerol kinase and characterized by the base sequence given as SEQ ID NO:10.

The terms "function" or "enzyme function" refer to the catalytic activity of an enzyme in altering the energy required to perform a specific chemical reaction. It is understood that such an activity may apply to a reaction in equilibrium where the production of either product or substrate may be accomplished under suitable conditions.

The terms "polypeptide" and "protein" are used interchangeably.

The terms "carbon substrate" and "carbon source" refer to a carbon source capable of being metabolized by host organisms of the present invention and particularly carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof.

The terms "host cell" or "host organism" refer to a microorganism capable of receiving foreign or heterologous genes and of expressing those genes to produce an active gene product.

The terms "foreign gene", "foreign DNA", "heterologous gene" and "heterologous DNA" refer to genetic material native to one organism that has been placed within a host organism by various means. The gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene.

The terms "recombinant organism" and "transformed host" refer to any organism having been transformed with heterologous or foreign genes or extra copies of homolgous genes. The recombinant organisms of the present invention express foreign genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) for the production of 1,3-propanediol from suitable carbon substrates.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding) and following (3' non-coding) the coding region. The terms "native" and "wild-type" refer to a gene as found in nature with its own regulatory sequences.

The terms "encoding" and "coding" refer to the process by which a gene, through the mechanisms of transcription and translation, produces an amino acid sequence. It is understood that the process of encoding a specific amino acid sequence includes DNA sequences that may involve base changes that do not cause a change in the encoded amino acid, or which involve base changes which may alter one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. It is therefore understood that the

invention encompasses more than the specific exemplary sequences. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which produce silent changes that do not substantially affect the functional properties of the resulting protein molecule are also contemplated. For example, alteration in the gene sequence which reflect the degeneracy of the genetic code, or which result in the production of a chemically equivalent amino acid at a given site, are contemplated. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. In some cases, it may in fact be desirable to make mutants of the sequence in order to study the effect of alteration on the biological activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity in the encoded products. Moreover, the skilled artisan recognizes that sequences encompassed by this invention are also defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 °C), with the sequences exemplified herein.

The term "expression" refers to the transcription and translation to gene product from a gene coding for the sequence of the gene product.

The terms "plasmid", "vector", and "cassette" refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

The terms "transformation" and "transfection" refer to the acquisition of new genes in a cell after the incorporation of nucleic acid. The acquired genes may be integrated into

chromosomal DNA or introduced as extrachromosomal replicating sequences. The term "transformant" refers to the product of a transformation.

The term "genetically altered" refers to the process of changing hereditary material by transformation or mutation.

The term "isolated " refers to a protein or DNA sequence that is removed from at least one component with which it is naturally associated.

The term "homologous" refers to a protein or polypeptide native or naturally occurring in a gram-positive host cell. The invention includes microorganisms producing the homologous protein via recombinant DNA technology.

CONSTRUCTION OF RECOMBINANT ORGANISMS

Recombinant organisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a carbon substrate to 1,3-propanediol may be constructed using techniques well known in the art. As discussed in Example 9, genes encoding Klebsiella dhaB1, dhaB2, dhaB3 and protein X were used to transform *E. coli* DH5a and in Example 10, genes encoding at least one of Klebsiella proteins 1, 2 and 3 as well as at least one gene encoding protein X was used to transform E.coli.

Genes encoding glycerol-3-phosphate dehydrogenase (G3PDH), glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) were isolated from a native host such as *Klebsiella* or *Saccharomyces* and used to transform host strains such as *E. coli* DH5a, ECL707, AA200, or W1485; the *Saccharomyces cerevisiae* strain YPH500; or the *Klebsiella pneumoniae* strains ATCC 25955 or ECL 2106.

Isolation of Genes

Methods of obtaining desired genes from a bacterial genome are common and well known in the art of molecular biology. For example, if the sequence of the gene is known, suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the desired gene sequence. Once the sequence is isolated, the DNA may be amplified using standard primer directed amplification methods such as polymerase chain reaction (PCR) (U.S. 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors.

Alternatively, cosmid libraries may be created where large segments of genomic DNA (35-45kb) may be packaged into vectors and used to transform appropriate hosts. Cosmid vectors are unique in being able to accommodate large quantities of DNA. Generally, cosmid vectors have at least one copy of the *cos* DNA sequence which is needed for packaging and subsequent circularization of the foreign DNA. In addition to the *cos* sequence these vectors will also contain an origin of replication such as ColE1 and drug resistance markers such as a gene resistant to ampicillin or neomycin. Methods of using cosmid vectors for the transformation of

suitable bacterial hosts are well described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbon, NY (1989).

Typically to clone cosmids, foreign DNA is isolated and ligated, using the appropriate restriction endonucleases, adjacent to the *cos* region of the cosmid vector. Cosmid vectors containing the linearized foreign DNA is then reacted with a DNA packaging vehicle such as bacteriophage I. During the packaging process the cos sites are cleaved and the foreign DNA is packaged into the head portion of the bacterial viral particle. These particles are then used to transfect suitable host cells such as *E. coli*. Once injected into the cell, the foreign DNA circularizes under the influence of the *cos* sticky ends. In this manner large segments of foreign DNA can be introduced and expressed in recombinant host cells.

Isolation and cloning of genes encoding glycerol dehydratase (*dhaB*) and 1,3-propanediol oxidoreductase (*dhaT*)

Cosmid vectors and cosmid transformation methods were used within the context of the present invention to clone large segments of genomic DNA from bacterial genera known to possess genes capable of processing glycerol to 1,3-propanediol. Specifically, genomic DNA from *K. pneumoniae* ATCC 25955 was isolated by methods well known in the art and digested with the restriction enzyme Sau3A for insertion into a cosmid vector Supercos 1 and packaged using GigapackII packaging extracts. Following construction of the vector *E. coli* XL1-Blue MR cells were transformed with the cosmid DNA. Transformants were screened for the ability to convert glycerol to 1,3-propanediol by growing the cells in the presence of glycerol and analyzing the media for 1,3-propanediol formation.

Two of the 1,3-propanediol positive transformants were analyzed and the cosmids were named pKP1 and pKP2. DNA sequencing revealed extensive homology to the glycerol dehydratase gene (*dhaB*) from *C. freundii*, demonstrating that these transformants contained DNA encoding the glycerol dehydratase gene. Other 1,3-propanediol positive transformants were analyzed and the cosmids were named pKP4 and pKP5. DNA sequencing revealed that these cosmids carried DNA encoding a diol dehydratase gene.

Isolation of genes encoding protein X, protein 1, protein 2 and protein 3

Although the instant invention utilizes the isolated genes from within a *Klebsiella* cosmid, alternate sources of dehydratase genes and protein X and protein 1, protein 2 and protein 3 include, but are not limited to, *Citrobacter*, *Clostridia*, and *Salmonella*. Tobimatsu, et al., 1996, J. Biol. Chem. 271: 22352-22357 disclose the *K. pneumoniae* glycerol dehydratase operon where protein X is identified as ORF 4; Segfried et al., 1996, J. Bacteriol. 178: 5793-5796 disclose the *C. freundii* glycerol dehydratase operon where protein X is identified as ORF Z. Figure 8 discloses

Klebsiella diol dehydratase protein X and Figures 3, 4 and 5 disclose amino acid sequences of proteins 1, 2 and 3 from *Klebsiella* and *Citrobacter*.

Genes encoding G3PDH and G3P phosphatase

The present invention provides genes suitable for the expression of G3PDH and G3P phosphatase activities in a host cell.

Genes encoding G3PDH are known. For example, GPD1 has been isolated from *Saccharomyces* and has the base sequence given by SEQ ID NO:5, encoding the amino acid sequence given in SEQ ID NO:11 (Wang et al., *supra*). Similarly, G3PDH activity is has also been isolated from *Saccharomyces* encoded by GPD2 having the base sequence given in SEQ ID NO:6, encoding the amino acid sequence given in SEQ ID NO:12 (Eriksson et al., *Mol. Microbiol.* 17, 95, (1995).

It is contemplated that any gene encoding a polypeptide responsible for G3PDH activity is suitable for the purposes of the present invention wherein that activity is capable of catalyzing the conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). Further, it is contemplated that any gene encoding the amino acid sequence of G3PDH as given by any one of SEQ ID NOS:11, 12, 13, 14, 15 and 16 corresponding to the genes GPD1, GPD2, GUT2, gpsA, glpD, and the a subunit of glpABC, respectively, will be functional in the present invention wherein that amino acid sequence encompasses amino acid substitutions, deletions or additions that do not alter the function of the enzyme. It will be appreciated by the skilled person that genes encoding G3PDH isolated from other sources are also be suitable for use in the present invention. For example, genes isolated from prokaryotes include GenBank accessions M34393, M20938, L06231, U12567, L45246, L45323, L45324, L45325, U32164, and U39682; genes isolated from fungi include GenBank accessions U30625, U30876 and X56162; genes isolated from insects include GenBank accessions X61223 and X14179; and genes isolated from mammalian sources include GenBank accessions U12424, M25558 and X78593.

Genes encoding G3P phosphatase are known. For example, GPP2 has been isolated from *Saccharomyces cerevisiae* and has the base sequence given by SEQ ID NO:9 which encodes the amino acid sequence given in SEQ ID NO:17 (Norbeck et al., *J. Biol. Chem.* 271, p. 13875, 1996).

It is contemplated that any gene encoding a G3P phosphatase activity is suitable for the purposes of the present invention wherein that activity is capable of catalyzing the conversion of glycerol-3-phosphate to glycerol. Further, it is contemplated that any gene encoding the amino acid sequence of G3P phosphatase as given by SEQ ID NOS:33 and 17 will be functional in the present invention wherein that amino acid sequence encompasses amino acid substitutions, deletions or additions that do not alter the function of the enzyme. It will be appreciated by the skilled person that genes encoding G3P phosphatase isolated from other sources are also

suitable for use in the present invention. For example, the dephosphorylation of glycerol-3-phosphate to yield glycerol may be achieved with one or more of the following general or specific phosphatases: alkaline phosphatase (EC 3.1.3.1) [GenBank M19159, M29663, U02550 or M33965]; acid phosphatase (EC 3.1.3.2) [GenBank U51210, U19789, U28658 or L20566]; glycerol-3-phosphatase (EC 3.1.3.-) [GenBank Z38060 or U18813x11]; glucose-1-phosphatase (EC 3.1.3.10) [GenBank M33807]; glucose-6-phosphatase (EC 3.1.3.9) [GenBank U00445]; fructose-1,6-bisphosphatase (EC 3.1.3.11) [GenBank X12545 or J03207] or phosphotidyl glycero phosphate phosphatase (EC 3.1.3.27) [GenBank M23546 and M23628].

Genes encoding glycerol kinase are known. For example, GUT1 encoding the glycerol kinase from *Saccharomyces* has been isolated and sequenced (Pavlik et al., *Curr. Genet.* 24, 21, (1993)) and the base sequence is given by SEQ ID NO:10 which encodes the amino acid sequence given in SEQ ID NO:18. It will be appreciated by the skilled artisan that although glycerol kinase catalyzes the degradation of glycerol in nature the same enzyme will be able to function in the synthesis of glycerol to convert glycerol-3-phosphate to glycerol under the appropriate reaction energy conditions. Evidence exists for glycerol production through a glycerol kinase. Under anaerobic or respiration-inhibited conditions, *Trypanosoma brucei* gives rise to glycerol in the presence of Glycerol-3-P and ADP. The reaction occurs in the glycosome compartment (D. Hammond, *J. Biol. Chem.* 260, 15646-15654, (1985)).

Host cells

Suitable host cells for the recombinant production of 1,3-propanediol may be either prokaryotic or eukaryotic and will be limited only by the host cell ability to express active enzymes. Preferred hosts will be those typically useful for production of glycerol or 1,3-propanediol such as *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*. Most preferred in the present invention are *E. coli*, *Klebsiella* species and *Saccharomyces* species.

Adenosyl-cobalamin (coenzyme B_{12}) is an essential cofactor for glycerol dehydratase activity. The coenzyme is the most complex non-polymeric natural product known, and its synthesis *in vivo* is directed using the products of about 30 genes. Synthesis of coenzyme B_{12} is found in prokaryotes, some of which are able to synthesize the compound *de novo*, while others can perform partial reactions. *E. coli*, for example, cannot fabricate the corrin ring structure, but is able to catalyze the conversion of cobinamide to corrinoid and can introduce the 5'-deoxyadenosyl group.

Eukaryotes are unable to synthesize coenzyme B_{12} *de novo* and instead transport vitamin B_{12} from the extracellular milieu with subsequent conversion of the compound to its functional

form of the compound by cellular enzymes. Three enzyme activities have been described for this series of reactions. 1) aquacobalamin reductase (EC 1.6.99.8) reduces Co(III) to Co(II); 2) cob(II)alamin reductase (EC 1.6.99.9) reduces Co(II) to Co(I); and 3) cob(I)alamin adenosyltransferase (EC 2.5.1.17) transfers a 5'deoxyadenosine moiety from ATP to the reduced corrinoid. This last enzyme activity is the best characterized of the three, and is encoded by *cobA* in *S. typhimurium*, *btuR* in *E. coli* and *cobO* in *P. denitrificans*. These three cob(I)alamin adenosyltransferase genes have been cloned and sequenced. Cob(I)alamin adenosyltransferase activity has been detected in human fibroblasts and in isolated rat mitochondria (Fenton et al., *Biochem. Biophys. Res. Commun.* 98, 283-9, (1981)). The two enzymes involved in cobalt reduction are poorly characterized and gene sequences are not available. There are reports of an aquacobalamin reductase from *Euglena gracilis* (Watanabe et al., *Arch. Biochem. Biophys.* 305, 421-7, (1993)) and a microsomal cob(III)alamin reductase is present in the microsomal and mitochondrial inner membrane fractions from rat fibroblasts (Pezacka, *Biochim. Biophys. Acta*, 1157, 167-77, (1993)).

Supplementing culture media with vitamin B_{12} may satisfy the need to produce coenzyme B_{12} for glycerol dehydratase activity in many microorganisms, but in some cases additional catalytic activities may have to be added or increased *in vivo*. Enhanced synthesis of coenzyme B_{12} in eukaryotes may be particularly desirable. Given the published sequences for genes encoding cob(I)alamin adenosyltransferase, the cloning and expression of this gene could be accomplished by one skilled in the art. For example, it is contemplated that yeast, such as *Saccharomyces*, could be constructed so as to contain genes encoding cob(I)alamin adenosyltransferase in addition to the genes necessary to effect conversion of a carbon substrate such as glucose to 1,3-propanediol. Cloning and expression of the genes for cobalt reduction requires a different approach. This could be based on a selection in *E. coli* for growth on ethanolamine as sole N_2 source. In the presence of coenzyme B_{12} ethanolamine ammonia-lyase enables growth of cells in the absence of other N_2 sources. If *E. coli* cells contain a cloned gene for cob(I)alamin adenosyltransferase and random cloned DNA from another organism, growth on ethanolamine in the presence of aquacobalamin should be enhanced and selected for if the random cloned DNA encodes cobalt reduction properties to facilitate adenosylation of aquacobalamin.

Glycerol dehydratase is a multi-subunit enzyme consisting of three protein components which are arranged in an $a_2b_2g_2$ configuration (M. Seyfried et al, J. Bacteriol., 5793-5796 (1996)). This configuration is an inactive apo-enzyme which binds one molecule of coenzyme B_{12} to become the catalytically active holo-enzyme. During catalysis, the holo-enzyme undergoes rapid, first order inactivation, to become an inactive complex in which the coenzyme B_{12} has been converted to hydroxycobalamin (Z. Schneider and J. Pawelkiewicz, ACTA Biochim. Pol. 311-328

(1966)). Stoichiometric analysis of the reaction of glycerol dehydratase with glycerol as substrate revealed that each molecule of enzyme catalyzes 100,000 reactions before inactivation (Z. Schneider and J. Pawelkiewicz, ACTA Biochim. Pol. 311-328 (1966)). In vitro, this inactive complex can only be reactivated by removal of the hydroxycobalamin, by strong chemical treatment with magnesium and sulfite, and replacement with additional coenzyme B_{12} (Z. Schneider et al., J. Biol. Chem. 3388-3396 (1970)). Inactivated glycerol dehydratase in wild type Klebsiella pneumoniae can be reactivated in situ (toluenized cells) in the presence of coenzyme B_{12}, adenosine 5'-triphosphate (ATP), and manganese (S. Honda et al, J. Bacteriol. 1458-1465 (1980)). This reactivation was shown to be due to the ATP dependent replacement of the inactivated cobalamin with coenzyme B_{12} (K. Ushio et al., J. Nutr. Sci. Vitaminol. 225-236 (1982)). Cell extract from toluenized cells which in situ catalyze the ATP, manganese, and coenzyme B_{12} dependent reactivation are inactive with respect to this reactivation. Thus, without strong chemical reductive treatment or cell mediated replacement of the inactivated cofactor, glycerol dehydratase can only catalyzed 100,000 reactions per molecule.

The present invention demonstrates that the presence of protein X is important for in vivo reactivation of the dehydratase and the production of 1,3-propanediol is increased in a host cell capable of producing 1,3-propanediol in the presence of protein X. The present invention also discloses that the presence of protein 1, protein 2 and protein 3, in combination with protein X, also increased the production of 1,3-propanediol in a host cell capable of producing 1,3-propanediol.

In addition to *E. coli* and *Saccharomyces*, *Klebsiella* is a particularly preferred host. Strains of *Klebsiella pneumoniae* are known to produce 1,3-propanediol when grown on glycerol as the sole carbon. It is contemplated that *Klebsiella* can be genetically altered to produce 1,3-propanediol from monosaccharides, oligosaccharides, polysaccharides, or one-carbon substrates.

In order to engineer such strains, it will be advantageous to provide the *Klebsiella* host with the genes facilitating conversion of dihydroxyacetone phosphate to glycerol and conversion of glycerol to 1,3-propanediol either separately or together, under the transcriptional control of one or more constitutive or inducible promoters. The introduction of the DAR1 and GPP2 genes encoding glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase, respectively, will provide *Klebsiella* with genetic machinery to produce 1,3-propanediol from an appropriate carbon substrate.

The genes encoding protein X, protein 1, protein 2 and protein 3 or other enzymes associated with 1,3-propanediol production (e.g., G3PDH, G3P phosphatase, *dhaB* and/or *dhaT*) may be introduced on any plasmid vector capable of replication in *K. pneumoniae* or they may be integrated into the *K. pneumoniae* genome. For example, *K. pneumoniae* ATCC 25955 and

K. pneumoniae ECL 2106 are known to be sensitive to tetracycline or chloramphenicol; thus plasmid vectors which are both capable of replicating in *K. pneumoniae* and encoding resistance to either or both of these antibiotics may be used to introduce these genes into *K. pneumoniae*. Methods of transforming *Klebsiella* with genes of interest are common and well known in the art and suitable protocols, including appropriate vectors and expression techniques may be found in Sambrook, *supra*.

Vectors and expression cassettes

The present invention provides a variety of vectors and transformation and expression cassettes suitable for the cloning, transformation and expression of protein X, protein 1, protein 2 and protein 3 as well as other proteins associated with 1,3-propanediol production, e.g., G3PDH and G3P phosphatase into a suitable host cell. Suitable vectors will be those which are compatible with the bacterium employed. Suitable vectors can be derived, for example, from a bacteria, a virus (such as bacteriophage T7 or a M-13 derived phage), a cosmid, a yeast or a plant. Protocols for obtaining and using such vectors are known to those in the art. (Sambrook et al., Molecular Cloning: A Laboratory Manual - volumes 1,2,3 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989)).

Typically, the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.

Initiation control regions or promoters, which are useful to drive expression of the protein x and protein 1, protein 2 or protein 3 in the desired host cell, are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including but not limited to CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in *Saccharomyces*); AOX1 (useful for expression in *Pichia*); and lac, trp, IP_L, IP_R, T7, tac, and trc (useful for expression in *E. coli*).

Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary, however, it is most preferred if included.

For effective expression of the instant enzymes, DNA encoding the enzymes are linked operably through initiation codons to selected expression control regions such that expression results in the formation of the appropriate messenger RNA.

Transformation of suitable hosts and expression of genes for the production of 1,3-propanediol

Once suitable cassettes are constructed they are used to transform appropriate host cells. Introduction of the cassette containing dhaB activity, dhaB protein X and at least one of protein 1, protein 2 and protein 3 and optionally 1,3-propanediol oxidoreductase (*dhaT*), either separately or together, into the host cell may be accomplished by known procedures such as by transformation (e.g., using calcium-permeabilized cells, electroporation) or by transfection using a recombinant phage virus. (Sambrook et al., *supra.*). In the present invention, E.coli DH5a was transformed with dhaB subunits 1, 2 and 3 and dha protein X.

Additionally, *E. coli* W2042 (ATCC 98188) containing the genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) was created. Additionally, *S. cerevisiae* YPH500 (ATCC 74392) harboring plasmids pMCK10, pMCK17, pMCK30 and pMCK35 containing genes encoding glycerol-3-phosphate dehydrogenase (G3PDH) and glycerol-3-phosphatase (G3P phosphatase), glycerol dehydratase (*dhaB*), and 1,3-propanediol oxidoreductase (*dhaT*) was constructed. Both the above-mentioned transformed *E. coli* and *Saccharomyces* represent preferred embodiments of the invention.

Media and Carbon Substrates:

Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include but are not limited to monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose, or mixtures thereof, and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally, the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. Glycerol production from single carbon sources (e.g., methanol, formaldehyde, or formate) has been reported in methylotrophic yeasts (Yamada et al., *Agric. Biol. Chem.,* 53(2) 541-543, (1989)) and in bacteria (Hunter et.al., *Biochemistry,* 24, 4148-4155, (1985)). These organisms can assimilate single carbon compounds, ranging in oxidation state from methane to formate, and produce glycerol. The pathway of carbon assimilation can be through ribulose monophosphate, through serine, or through xylulose-momophosphate (Gottschalk, Bacterial Metabolism, Second Edition, Springer-Verlag: New York (1986)). The ribulose monophosphate pathway involves the condensation of formate with ribulose-5-phosphate to form a 6 carbon sugar that becomes fructose and eventually the three carbon product glyceraldehyde-3-phosphate. Likewise, the serine pathway assimilates the one-carbon compound into the glycolytic pathway via methylenetetrahydrofolate.

In addition to utilization of one and two carbon substrates, methylotrophic organisms are also known to utilize a number of other carbon-containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., *Microb. Growth C1 Compd.*, [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of *Candida* will metabolize alanine or oleic acid (Sulter et al., *Arch. Microbiol.*, 153(5), 485-9 (1990)). Hence, the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing substrates and will only be limited by the requirements of the host organism.

Although it is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates. More preferred are sugars such as glucose, fructose, sucrose and single carbon substrates such as methanol and carbon dioxide. Most preferred is glucose.

In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for glycerol production. Particular attention is given to Co(II) salts and/or vitamin B_{12} or precursors thereof.

Culture Conditions:

Typically, cells are grown at 30 °C in appropriate media. Preferred growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast Malt Extract (YM) broth. Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by someone skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2':3'-monophosphate or cyclic adenosine 2':5'-monophosphate, may also be incorporated into the reaction media. Similarly, the use of agents known to modulate enzymatic activities (e.g., sulphites, bisulphites and alkalis) that lead to enhancement of glycerol production may be used in conjunction with or as an alternative to genetic manipulations.

Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred as range for the initial condition.

Reactions may be performed under aerobic or anaerobic conditions where anaerobic or microaerobic conditions are preferred.

Batch and Continuous Fermentations:

The present process uses a batch method of fermentation. A classical batch fermentation is a closed system where the composition of the media is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the media is inoculated with the desired organism or organisms and fermentation is permitted to occur adding nothing to the system. Typically, however, a batch fermentation is "batch" with respect to the addition of the carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. The metabolite and biomass compositions of the batch system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.

A variation on the standard batch system is the Fed-Batch fermentation system which is also suitable in the present invention. In this variation of a typical batch system, the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO_2. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Brock, *supra*.

It is also contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation media is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to media being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as

well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *supra*.

The present invention may be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for 1,3-propanediol production.

Alterations in the 1,3-propanediol production pathway:

Representative enzyme pathway. The production of 1,3-propanediol from glucose can be accomplished by the following series of steps. This series is representative of a number of pathways known to those skilled in the art. Glucose is converted in a series of steps by enzymes of the glycolytic pathway to dihydroxyacetone phosphate (DHAP) and 3-phosphoglyceraldehyde (3-PG). Glycerol is then formed by either hydrolysis of DHAP to dihydroxyacetone (DHA) followed by reduction, or reduction of DHAP to glycerol 3-phosphate (G3P) followed by hydrolysis. The hydrolysis step can be catalyzed by any number of cellular phosphatases which are known to be specific or non-specific with respect to their substrates or the activity can be introduced into the host by recombination. The reduction step can be catalyzed by a NAD^+ (or $NADP^+$) linked host enzyme or the activity can be introduced into the host by recombination. It is notable that the *dha* regulon contains a glycerol dehydrogenase (E.C. 1.1.1.6) which catalyzes the reversible reaction of Equation 3.

$$\text{Glycerol} \rightarrow \text{3-HP} + H_2O \qquad \text{(Equation 1)}$$

$$\text{3-HP} + NADH + H^+ \rightarrow \text{1,3-Propanediol} + NAD^+ \qquad \text{(Equation 2)}$$

$$\text{Glycerol} + NAD^+ \rightarrow \text{DHA} + NADH + H^+ \qquad \text{(Equation 3)}$$

Glycerol is converted to 1,3-propanediol via the intermediate 3-hydroxypropionaldehye (3-HP) as has been described in detail above. The intermediate 3-HP is produced from glycerol (Equation 1) by a dehydratase enzyme which can be encoded by the host or can introduced into the host by recombination. This dehydratase can be glycerol dehydratase (E.C. 4.2.1.30), diol dehydratase (E.C. 4.2.1.28), or any other enzyme able to catalyze this transformation. Glycerol dehydratase, but not diol dehydratase, is encoded by the *dha* regulon. 1,3-Propanediol is produced from 3-HP (Equation 2) by a NAD^+- (or $NADP^+$) linked host enzyme or the activity can introduced into the host by recombination. This final reaction in the production of 1,3-propanediol can be catalyzed by 1,3-propanediol dehydrogenase (E.C. 1.1.1.202) or other alcohol dehydrogenases.

Mutations and transformations that affect carbon channeling. A variety of mutant organisms comprising variations in the 1,3-propanediol production pathway will be useful in the present

invention. The introduction of a triosephosphate isomerase mutation (*tpi*-) into the microorganism is an example of the use of a mutation to improve the performance by carbon channeling. Alternatively, mutations which diminish the production of ethanol (*adh*) or lactate (*ldh*) will increase the availability of NADH for the production of 1,3-propanediol. Additional mutations in steps of glycolysis after glyceraldehyde-3-phosphate such as phosphoglycerate mutase (*pgm*) would be useful to increase the flow of carbon to the 1,3-propanediol production pathway. Mutations that effect glucose transport such as PTS which would prevent loss of PEP may also prove useful. Mutations which block alternate pathways for intermediates of the 1,3-propanediol production pathway such as the glycerol catabolic pathway (*glp*) would also be useful to the present invention. The mutation can be directed toward a structural gene so as to impair or improve the activity of an enzymatic activity or can be directed toward a regulatory gene so as to modulate the expression level of an enzymatic activity.

Alternatively, transformations and mutations can be combined so as to control particular enzyme activities for the enhancement of 1,3-propanediol production. Thus it is within the scope of the present invention to anticipate modifications of a whole cell catalyst which lead to an increased production of 1,3-propanediol.

Identification and purification of 1,3-propanediol:

Methods for the purification of 1,3-propanediol from fermentation media are known in the art. For example, propanediols can be obtained from cell media by subjecting the reaction mixture to extraction with an organic solvent, distillation and column chromatography (U.S. 5,356,812). A particularly good organic solvent for this process is cyclohexane (U.S. 5,008,473).

1,3-Propanediol may be identified directly by submitting the media to high pressure liquid chromatography (HPLC) analysis. Preferred in the present invention is a method where fermentation media is analyzed on an analytical ion exchange column using a mobile phase of 0.01 N sulfuric acid in an isocratic fashion.

Identification and purification of G3PDH and G3P phosphatase:

The levels of expression of the proteins G3PDH and G3P phosphatase are measured by enzyme assays, G3PDH activity assay relied on the spectral properties of the cosubstrate, NADH, in the DHAP conversion to G-3-P. NADH has intrinsic UV/vis absorption and its consumption can be monitored spectrophotometrically at 340 nm. G3P phosphatase activity can be measured by any method of measuring the inorganic phosphate liberated in the reaction. The most commonly used detection method used the visible spectroscopic determination of a blue-colored phosphomolybdate ammonium complex.

EXAMPLES

GENERAL METHODS

Procedures for phosphorylations, ligations and transformations are well known in the art. Techniques suitable for use in the following examples may be found in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).

Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, DC. (1994)) or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989). All reagents and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO) unless otherwise specified.

The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "mL" means milliliters, "L" means liters.

ENZYME ASSAYS

Glycerol dehydratase activity in cell-free extracts was determined using 1,2-propanediol as substrate. The assay, based on the reaction of aldehydes with methylbenzo-2-thiazolone hydrazone, has been described by Forage and Foster (*Biochim. Biophys. Acta, 569*, 249 (1979)). The activity of 1,3-propanediol oxidoreductase, sometimes referred to as 1,3-propanediol dehydrogenase, was determined in solution or in slab gels using 1,3-propanediol and NAD^+ as substrates as has also been described. Johnson and Lin, *J. Bacteriol.*, 169, 2050 (1987). NADH or NADPH dependent glycerol 3-phosphate dehydrogenase (G3PDH) activity was determined spectrophotometrically, following the disappearance of NADH or NADPH as has been described. (R. M. Bell and J. E. Cronan, Jr., *J. Biol. Chem.* 250:7153-8 (1975)).

Honda et al. (1980, In Situ Reactivation of Glycerol-Inactivated Coenzyme B_{12}-Dependent Enzymes, Glycerol Dehydratase and Diol Dehydratase. Journal of Bacteriology 143:1458-1465) disclose an assay that measures the reactivation of dehydratases.

Assay for glycerol-3-phosphatase, GPP

The assay for enzyme activity was performed by incubating the extract with an organic phosphate substrate in a bis-Tris or MES and magnesium buffer, pH 6.5. The substrate used was l-a-glycerol phosphate; d,l-a-glycerol phosphate. The final concentrations of the reagents in the assay are: buffer (20 mM, bis-Tris or 50 mM MES); $MgCl_2$ (10 mM); and substrate (20 mM).

If the total protein in the sample was low and no visible precipitation occurs with an acid quench, the sample was conveniently assayed in the cuvette. This method involved incubating an enzyme sample in a cuvette that contained 20 mM substrate (50 mL, 200 mM), 50 mM MES, 10 mM $MgCl_2$, pH 6.5 buffer. The final phosphatase assay volume was 0.5 mL. The enzyme-containing sample was added to the reaction mixture; the contents of the cuvette were mixed and then the cuvette was placed in a circulating water bath at T = 37 °C for 5 to 120 min -- depending on whether the phosphatase activity in the enzyme sample ranged from 2 to 0.02 U/mL. The enzymatic reaction was quenched by the addition of the acid molybdate reagent (0.4 mL). After the Fiske SubbaRow reagent (0.1 mL) and distilled water (1.5 mL) were added, the solution was mixed and allowed to develop. After 10 min, the absorbance of the samples was read at 660 nm using a Cary 219 UV/Vis spectophotometer. The amount of inorganic phosphate released was compared to a standard curve that was prepared by using a stock inorganic phosphate solution (0.65 mM) and preparing 6 standards with final inorganic phosphate concentrations ranging from 0.026 to 0.130 mmol/mL.

Isolation and Identification 1,3-propanediol

The conversion of glycerol to 1,3-propanediol was monitored by HPLC. Analyses were performed using standard techniques and materials available to one skilled in the art of chromatography. One suitable method utilized a Waters Maxima 820 HPLC system using UV (210 nm) and RI detection. Samples were injected onto a Shodex SH-1011 column (8 mm x 300 mm, purchased from Waters, Milford, MA) equipped with a Shodex SH-1011P precolumn (6 mm x 50 mm), temperature controlled at 50 °C, using 0.01 N H_2SO_4 as mobile phase at a flow rate of 0.5 mL/min. When quantitative analysis was desired, samples were prepared with a known amount of trimethylacetic acid as external standard. Typically, the retention times of glycerol (RI detection), 1,3-propanediol (RI detection), and trimethylacetic acid (UV and RI detection) were 20.67 min, 26.08 min, and 35.03 min, respectively.

Production of 1,3-propanediol was confirmed by GC/MS. Analyses were performed using standard techniques and materials available to one of skill in the art of GC/MS. One suitable method utilized a Hewlett Packard 5890 Series II gas chromatograph coupled to a Hewlett Packard 5971 Series mass selective detector (EI) and a HP-INNOWax column (30 m length, 0.25 mm i.d., 0.25 micron film thickness). The retention time and mass spectrum of 1,3-propanediol generated were compared to that of authentic 1,3-propanediol (*m/e*: 57, 58).

An alternative method for GC/MS involved derivatization of the sample. To 1.0 mL of sample (e.g., culture supernatant) was added 30 uL of concentrated (70% v/v) perchloric acid. After mixing, the sample was frozen and lyophilized. A 1:1 mixture of bis(trimethylsilyl)trifluoroacetamide:pyridine (300 uL) was added to the lyophilized material, mixed vigorously and placed at 65 °C for one h. The sample was clarified of insoluble material by

centrifugation. The resulting liquid partitioned into two phases, the upper of which was used for analysis. The sample was chromatographed on a DB-5 column (48 m, 0.25 mm I.D., 0.25 um film thickness; from J&W Scientific) and the retention time and mass spectrum of the 1,3-propanediol derivative obtained from culture supernatants were compared to that obtained from authentic standards. The mass spectrum of TMS-derivatized 1,3-propanediol contains the characteristic ions of 205, 177, 130 and 115 AMU.

EXAMPLE 1

CLONING AND TRANSFORMATION OF *E. COLI* HOST CELLS WITH COSMID DNA FOR THE EXPRESSION OF 1,3-PROPANEDIOL

Media

Synthetic S12 medium was used in the screening of bacterial transformants for the ability to make 1,3-propanediol. S12 medium contains: 10 mM ammonium sulfate, 50 mM potassium phosphate buffer, pH 7.0, 2 mM $MgCl_2$, 0.7 mM $CaCl_2$, 50 uM $MnCl_2$, 1 uM $FeCl_3$, 1 uM ZnCl, 1.7 uM $CuSO_4$, 2.5 uM $CoCl_2$, 2.4 uM Na_2MoO_4, and 2 uM thiamine hydrochloride.

Medium A used for growth and fermentation consisted of: 10 mM ammonium sulfate; 50 mM MOPS/KOH buffer, pH 7.5; 5 mM potassium phosphate buffer, pH 7.5; 2 mM $MgCl_2$; 0.7 mM $CaCl_2$; 50 uM $MnCl_2$; 1 uM $FeCl_3$; 1 uM ZnCl; 1.72 uM $CuSO_4$; 2.53 uM $CoCl_2$; 2.42 uM Na_2MoO_4; 2 uM thiamine hydrochloride; 0.01% yeast extract; 0.01% casamino acids; 0.8 ug/mL vitamin B_{12}; and 50 ug/mL amp. Medium A was supplemented with either 0.2% glycerol or 0.2% glycerol plus 0.2% D-glucose as required.

Cells:

Klebsiella pneumoniae ECL2106 (Ruch et al., *J. Bacteriol.*, 124, 348 (1975)), also known in the literature as *K. aerogenes* or *Aerobacter aerogenes*, was obtained from E. C. C. Lin (Harvard Medical School, Cambridge, MA) and was maintained as a laboratory culture.

Klebsiella pneumoniae ATCC 25955 was purchased from American Type Culture Collection (Rockville, MD).

E. coli DH5a was purchased from Gibco/BRL and was transformed with the cosmid DNA isolated from *Klebsiella pneumoniae* ATCC 25955 containing a gene coding for either a glycerol or diol dehydratase enzyme. Cosmids containing the glycerol dehydratase were identified as pKP1 and pKP2 and cosmid containing the diol dehydratase enzyme were identified as pKP4. Transformed DH5a cells were identified as DH5a-pKP1, DH5a-pKP2, and DH5a-pKP4.

E. coli ECL707 (Sprenger et al., *J. Gen. Microbiol.*, 135, 1255 (1989)) was obtained from E. C. C. Lin (Harvard Medical School, Cambridge, MA) and was similarly transformed with cosmid DNA from *Klebsiella pneumoniae*. These transformants were identified as ECL707-pKP1 and ECL707-pKP2, containing the glycerol dehydratase gene and ECL707-pKP4 containing the diol dehydratase gene.

E. coli AA200 containing a mutation in the *tpi* gene (Anderson et al., *J. Gen Microbiol.*, 62, 329 (1970)) was purchased from the *E. coli* Genetic Stock Center, Yale University (New Haven, CT) and was transformed with *Klebsiella* cosmid DNA to give the recombinant organisms AA200-pKP1 and AA200-pKP2, containing the glycerol dehydratase gene, and AA200-pKP4, containing the diol dehydratase gene.

DH5a:

Six transformation plates containing approximately 1,000 colonies of *E. coli* XL1-Blue MR transfected with *K. pneumoniae* DNA were washed with 5 mL LB medium and centrifuged. The bacteria were pelleted and resuspended in 5 mL LB medium + glycerol. An aliquot (50 uL) was inoculated into a 15 mL tube containing S12 synthetic medium with 0.2% glycerol + 400 ng per mL of vitamin B_{12} + 0.001% yeast extract + 50amp. The tube was filled with the medium to the top and wrapped with parafilm and incubated at 30 °C. A slight turbidity was observed after 48 h. Aliquots, analyzed for product distribution as described above at 78 h and 132 h, were positive for 1,3-propanediol, the later time points containing increased amounts of 1,3-propanediol.

The bacteria, testing positive for 1,3-propanediol production, were serially diluted and plated onto LB-50amp plates in order to isolate single colonies. Forty-eight single colonies were isolated and checked again for the production of 1,3-propanediol. Cosmid DNA was isolated from 6 independent clones and transformed into *E. coli* strain DH5a. The transformants were again checked for the production of 1,3-propanediol. Two transformants were characterized further and designated as DH5a-pKP1 and DH5a-pKP2.

A 12.1 kb EcoRI-SalI fragment from pKP1, subcloned into pIBI31 (IBI Biosystem, New Haven, CT), was sequenced and termed pHK28-26 (SEQ ID NO:19). Sequencing revealed the loci of the relevant open reading frames of the *dha* operon encoding glycerol dehydratase and genes necessary for regulation. Referring to SEQ ID NO:19, a fragment of the open reading frame for *dhaK* encoding dihydroxyacetone kinase is found at bases 1-399; the open reading frame *dhaD* encoding glycerol dehydrogenase is found at bases 983-2107; the open reading frame *dhaR* encoding the repressor is found at bases 2209-4134; the open reading frame *dhaT* encoding 1,3-propanediol oxidoreductase is found at bases 5017-6180; the open reading frame *dhaB1* encoding the alpha subunit glycerol dehydratase is found at bases 7044-8711; the open reading frame *dhaB2* encoding the beta subunit glycerol dehydratase is found at bases 8724-9308; the open reading frame *dhaB3* encoding the gamma subunit glycerol dehydratase is found at bases 9311-9736; and the open reading frame *dhaBX*, encoding a protein of unknown function is found at bases 9749-11572.

Single colonies of *E. coli* XL1-Blue MR transfected with packaged cosmid DNA from *K. pneumoniae* were inoculated into microtiter wells containing 200 uL of S15 medium (ammonium sulfate, 10 mM; potassium phosphate buffer, pH 7.0, 1 mM; MOPS/KOH buffer,

pH 7.0, 50 mM; $MgCl_2$, 2 mM; $CaCl_2$, 0.7 mM; $MnCl_2$, 50 uM; $FeCl_3$, 1 uM; ZnCl, 1 uM; $CuSO_4$, 1.72 uM; $CoCl_2$, 2.53 uM; Na_2MoO_4, 2.42 uM; and thiamine hydrochloride, 2 uM) + 0.2% glycerol + 400 ng/mL of vitamin B_{12} + 0.001% yeast extract + 50 ug/mL ampicillin. In addition to the microtiter wells, a master plate containing LB-50 amp was also inoculated. After 96 h, 100 uL was withdrawn and centrifuged in a Rainin microfuge tube containing a 0.2 micron nylon membrane filter. Bacteria were retained and the filtrate was processed for HPLC analysis. Positive clones demonstrating 1,3-propanediol production were identified after screening approximately 240 colonies. Three positive clones were identified, two of which had grown on LB-50 amp and one of which had not. A single colony, isolated from one of the two positive clones grown on LB-50 amp and verified for the production of 1,3-propanediol, was designated as pKP4. Cosmid DNA was isolated from *E. coli* strains containing pKP4 and *E. coli* strain DH5a was transformed. An independent transformant, designated as DH5a-pKP4, was verified for the production of 1,3-propanediol.

ECL707:

E. coli strain ECL707 was transformed with cosmid *K. pneumoniae* DNA corresponding to one of pKP1, pKP2, pKP4 or the Supercos vector alone and named ECL707-pKP1, ECL707-pKP2, ECL707-pKP4, and ECL707-sc, respectively. ECL707 is defective in *glpK*, *gld*, and *ptsD* which encode the ATP-dependent glycerol kinase, NAD^+-linked glycerol dehydrogenase, and enzyme II for dihydroxyacetone of the phosphoenolpyruvate-dependent phosphotransferase system, respectively.

Twenty single colonies of each cosmid transformation and five of the Supercos vector alone (negative control) transformation, isolated from LB-50amp plates, were transferred to a master LB-50amp plate. These isolates were also tested for their ability to convert glycerol to 1,3-propanediol in order to determine if they contained dehydratase activity. The transformants were transferred with a sterile toothpick to microtiter plates containing 200 uL of Medium A supplemented with either 0.2% glycerol or 0.2% glycerol plus 0.2% D-glucose. After incubation for 48 hr at 30 °C, the contents of the microtiter plate wells were filtered through an 0.45 micron nylon filter and chromatographed by HPLC. The results of these tests are given in Table 1.

Table 1

Conversion of glycerol to 1,3-propanediol by transformed ECL707

Transformant	Glycerol*	Glycerol plus Glucose*
ECL707-pKP1	19/20	19/20
ECL707-pKP2	18/20	20/20
ECL707-pKP4	0/20	20/20
ECL707-sc	0/5	0/5

*(Number of positive isolates/number of isolates tested)

AA200:

E. coli strain AA200 was transformed with cosmid *K. pneumoniae* DNA corresponding to one of pKP1, pKP2, pKP4 and the Supercos vector alone and named AA200-pKP1, AA200-pKP2, AA200-pKP4, and AA200-sc, respectively. Strain AA200 is defective in triosephosphate isomerase (*tpi*).

Twenty single colonies of each cosmid transformation and five of the empty vector transformation were isolated and tested for their ability to convert glycerol to 1,3-propanediol as described for *E. coli* strain ECL707. The results of these tests are given in Table 2.

Table 2

Conversion of glycerol to 1,3-propanediol by transformed AA200

Transformant	Glycerol*	Glycerol plus Glucose*
AA200-pKP1	17/20	17/20
AA200-pKP2	17/20	17/20
AA200-pKP4	2/20	16/20
AA200-sc	0/5	0/5

*(Number of positive isolates/number of isolates tested)

EXAMPLE 2

CONVERSION OF D-GLUCOSE TO 1,3-PROPANEDIOL BY RECOMBINANT *E. coli* USING DAR1, GPP2, *dhaB*, and *dhaT*

Construction of general purpose expression plasmids for use in transformation of *Escherichia coli*

The expression vector pTacIQ

The *E. coli* expression vector, pTacIQ, contains the lacIq gene (Farabaugh, *Nature* 274, 5673 (1978)) and tac promoter (Amann et al., *Gene* 25, 167 (1983)) inserted into the EcoRI of pBR322 (Sutcliffe et al., *Cold Spring Harb. Symp. Quant. Biol.* 43, 77 (1979)). A multiple cloning site and terminator sequence (SEQ ID NO:20) replaces the pBR322 sequence from EcoRI to SphI.

Subcloning the glycerol dehydratase genes (*dhaB1, 2, 3*)

The open reading frame for *dhaB3* gene (incorporating an EcoRI site at the 5' end and a XbaI site at the 3' end) was amplified from pHK28-26 by PCR using primers (SEQ ID NOS:21 and 22). The product was subcloned into pLitmus29 (New England Biolab, Inc., Beverly, MA) to generate the plasmid pDHAB3 containing *dhaB3*.

The region containing the entire coding region for the four genes of the *dhaB* operon from pHK28-26 was cloned into pBluescriptII KS+ (Stratagene, La Jolla, CA) using the restriction enzymes KpnI and EcoRI to create the plasmid pM7.

The *dhaBX* gene was removed by digesting the plasmid pM7, which contains *dhaB(1,2,3,4),* with ApaI and XbaI (deleting part of *dhaB3* and all of *dhaBX*). The resulting 5.9 kb fragment was purified and ligated with the 325-bp ApaI-XbaI fragment from plasmid pDHAB3 (restoring the *dhaB3* gene) to create pM11, which contains *dhaB(1,2,3)*.

The open reading frame for the *dhaB1* gene (incorporating a HindIII site and a consensus RBS ribosome binding site at the 5' end and a XbaI site at the 3' end) was amplified from pHK28-26 by PCR using primers (SEQ ID NO:23 and SEQ ID NO:24). The product was subcloned into pLitmus28 (New England Biolab, Inc.) to generate the plasmid pDT1 containing *dhaB1.*

A NotI-XbaI fragment from pM11 containing part of the *dhaB1* gene, the *dhaB2* gene and the *dhaB3* gene was inserted into pDT1 to create the *dhaB* expression plasmid, pDT2. The HindIII-XbaI fragment containing the *dhaB(1,2,3)* genes from pDT2 was inserted into pTacIQ to create pDT3.

Subcloning the 1,3-propanediol dehydrogenase gene (*dhaT)*

The KpnI-SacI fragment of pHK28-26, containing the complete 1,3-propanediol dehydrogenase (*dhaT*) gene, was subcloned into pBluescriptII KS+ creating plasmid pAH1. The *dhaT* gene (incorporating an XbaI site at the 5' end and a BamHI site at the 3' end) was amplified by PCR from pAH1 as template DNA using synthetic primers (SEQ ID NO:25 with SEQ ID NO:26). The product was subcloned into pCR-Script (Stratagene) at the SrfI site to generate the plasmids pAH4 and pAH5 containing *dhaT*. The plasmid pAH4 contains the *dhaT* gene in the correct orientation for expression from the lac promoter in pCR-Script and pAH5 contains the *dhaT* gene in the opposite orientation. The XbaI-BamHI fragment from pAH4 containing the *dhaT* gene was inserted into pTacIQ to generate plasmid pAH8. The HindIII-BamHI fragment from pAH8 containing the RBS and *dhaT* gene was inserted into pBluescriptII KS+ to create pAH11. The HindIII-SalI fragment from pAH8 containing the RBS, *dhaT* gene and terminator was inserted into pBluescriptII SK+ to create pAH12.

Construction of an expression cassette for *dhaB(1,2,3)* and *dhaT*

An expression cassette for the *dhaB(1,2,3)* and *dhaT* was assembled from the individual *dhaB(1,2,3)* and *dhaT* subclones described above using standard molecular biology methods. The SpeI-KpnI fragment from pAH8 containing the RBS, *dhaT* gene and terminator was inserted into the XbaI-KpnI sites of pDT3 to create pAH23. The SmaI-EcoRI fragment between the *dhaB3* and *dhaT* gene of pAH23 was removed to create pAH26. The SpeI-NotI fragment containing an EcoRI site from pDT2 was used to replace the SpeI-NotI fragment of pAH26 to generate pAH27.

Construction of expression cassette for *dhaT* and *dhaB(1,2,3)*

An expression cassette for *dhaT* and *dhaB(1,2,3)* was assembled from the individual *dhaB(1,2,3)* and *dhaT* subclones described previously using standard molecular biology methods. A SpeI-SacI fragment containing the *dhaB(1,2,3)* genes from pDT3 was inserted into pAH11 at the SpeI-SacI sites to create pAH24.

Cloning and expression of glycerol 3-phosphatase for increased glycerol production in *E. coli*

The *Saccharomyces cerevisiae* chromosome V lamda clone 6592 (Gene Bank, accession # U18813x11) was obtained from ATCC. The glycerol 3- phosphate phosphatase (GPP2) gene (incorporating an BamHI-RBS-XbaI site at the 5' end and a SmaI site at the 3' end) was cloned by PCR cloning from the lamda clone as target DNA using synthetic primers (SEQ ID NO:27 with SEQ ID NO:28). The product was subcloned into pCR-Script (Stratagene) at the SrfI site to generate the plasmids pAH15 containing GPP2. The plasmid pAH15 contains the GPP2 gene in the inactive orientation for expression from the lac promoter in pCR-Script SK+. The BamHI-SmaI fragment from pAH15 containing the GPP2 gene was inserted into pBlueScriptII SK+ to generate plasmid pAH19. The pAH19 contains the GPP2 gene in the correct orientation for expression from the lac promoter. The XbaI-PstI fragment from pAH19 containing the GPP2 gene was inserted into pPHOX2 to create plasmid pAH21.

Plasmids for the expression of *dhaT, dhaB(1,2,3)* and GPP2 genes

A SalI-EcoRI-XbaI linker (SEQ ID NOS:29 and 30) was inserted into pAH5 which was digested with the restriction enzymes, SalI-XbaI to create pDT16. The linker destroys the XbaI site. The 1 kb SalI-MluI fragment from pDT16 was then inserted into pAH24 replacing the existing SalI-MluI fragment to create pDT18.

The 4.1 kb EcoRI-XbaI fragment containing the expression cassette for *dhaT* and *dhaB*(1,2,3) from pDT18 and the 1.0 kb XbaI-SalI fragment containing the GPP2 gene from pAH21 was inserted into the vector pMMB66EH (Füste et al., *GENE*, 48, 119 (1986)) digested with the restriction enzymes EcoRI and SalI to create pDT20.

Plasmids for the over-expression of DAR1 in *E. coli*

DAR1 was isolated by PCR cloning from genomic *S. cerevisiae* DNA using synthetic primers (SEQ ID NO:46 with SEQ ID NO:47). Successful PCR cloning places an *Nco*I site at the 5' end of DAR1 where the ATG within *Nco*I is the DAR1 initiator methionine. At the 3' end of DAR1 a *Bam*HI site is introduced following the translation terminator. The PCR fragments were digested with *Nco*I + *Bam*HI and cloned into the same sites within the expression plasmid pTrc99A (Pharmacia, Piscataway, New Jersey) to give pDAR1A.

In order to create a better ribosome binding site at the 5' end of DAR1, a SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:48 with SEQ ID NO:49) was inserted into the NcoI site of pDAR1A to create pAH40. Plasmid pAH40 contains the new RBS and DAR1

gene in the correct orientation for expression from the trc promoter of Trc99A (Pharmacia). The NcoI-BamHI fragment from pDAR1A and a second set of SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:31 with SEQ ID NO:32) was inserted into the SpeI-BamHI site of pBluescript II-SK+ (Stratagene) to create pAH41. The construct pAH41 contains an ampicillin resistance gene. The NcoI-BamHI fragment from pDAR1A and a second set of SpeI-RBS-NcoI linker obtained by annealing synthetic primers (SEQ ID NO:31 with SEQ ID NO:32) was inserted into the SpeI-BamHI site of pBC-SK+ (Stratagene) to create pAH42. The construct pAH42 contains a chloroamphenicol resistance gene.

Construction of an expression cassette for DAR1 and GPP2

An expression cassette for DAR1 and GPP2 was assembled from the individual DAR1 and GPP2 subclones described above using standard molecular biology methods. The BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was inserted into pAH40 to create pAH43. The BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was inserted into pAH41 to create pAH44. The same BamHI-PstI fragment from pAH19 containing the RBS and GPP2 gene was also inserted into pAH42 to create pAH45.

The ribosome binding site at the 5' end of GPP2 was modified as follows. A BamHI-RBS-SpeI linker, obtained by annealing synthetic primers GATCCAGGAAACAGA with CTAGTCTGTTTCCTG to the XbaI-PstI fragment from pAH19 containing the GPP2 gene, was inserted into the BamHI-PstI site of pAH40 to create pAH48. Plasmid pAH48 contains the DAR1 gene, the modified RBS, and the GPP2 gene in the correct orientation for expression from the trc promoter of pTrc99A (Pharmacia, Piscataway, N.J.).

E. coli strain construction

E. coli W1485 is a wild-type K-12 strain (ATCC 12435). This strain was transformed with the plasmids pDT20 and pAH42 and selected on LA (Luria Agar, Difco) plates supplemented with 50 mg/mL carbencillim and 10 mg/mL chloramphenicol.

Production of 1,3-propanediol from glucose

E. coli W1485/pDT20/pAH42 was transferred from a plate to 50 mL of a medium containing per liter: 22.5 g glucose, 6.85 g K_2HPO_4, 6.3 g $(NH_4)_2SO_4$, 0.5 g $NaHCO_3$, 2.5 g NaCl, 8 g yeast extract, 8 g tryptone, 2.5 mg vitamin B_{12}, 2.5 mL modified Balch's trace-element solution, 50 mg carbencillim and 10 mg chloramphenicol, final pH 6.8 (HCl), then filter sterilized. The composition of modified Balch's trace-element solution can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et al., eds, p. 158, American Society for Microbiology, Washington, DC (1994)). After incubating at 37 °C, 300 rpm for 6 h, 0.5 g glucose and IPTG (final concentration = 0.2 mM) were added and shaking was reduced to 100 rpm. Samples were analyzed by GC/MS. After 24 h, W1485/pDT20/pAH42 produced 1.1 g/L glycerol and 195 mg/L 1,3-propanediol.

EXAMPLE 3

CLONING AND EXPRESSION OF *dhaB* AND *dhaT*

IN *Saccharomyces cerevisiae*

Expression plasmids that could exist as replicating episomal elements were constructed for each of the four *dha* genes. For all expression plasmids a yeast ADH1 promoter was present and separated from a yeast ADH1 transcription terminator by fragments of DNA containing recognition sites for one or more restriction endonucleases. Each expression plasmid also contained the gene for b-lactamase for selection in *E. coli* on media containing ampicillin, an origin of replication for plasmid maintenance in *E. coli*, and a 2 micron origin of replication for maintenance in *S. cerevisiae*. The selectable nutritional markers used for yeast and present on the expression plasmids were one of the following: HIS3 gene encoding imidazoleglycerolphosphate dehydratase, URA3 gene encoding orotidine 5'-phosphate decarboxylase, TRP1 gene encoding N-(5'-phosphoribosyl)-anthranilate isomerase, and LEU2 encoding b-isopropylmalate dehydrogenase.

The open reading frames for *dhaT*, *dhaB3*, *dhaB2* and *dhaB1* were amplified from pHK28-26 (SEQ ID NO:19) by PCR using primers (SEQ ID NO:38 with SEQ ID NO:39, SEQ ID NO:40 with SEQ ID NO:41, SEQ ID NO:42 with SEQ ID NO:43, and SEQ ID NO:44 with SEQ ID NO:45 for *dhaT*, *dhaB3*, *dhaB2* and *dhaB1*, respectively) incorporating EcoR1 sites at the 5' ends (10 mM Tris pH 8.3, 50 mM KCl, 1.5 mM $MgCl_2$, 0.0001% gelatin, 200 mM dATP, 200 mM dCTP, 200 mM dGTP, 200 mM dTTP, 1 mM each primer, 1-10 ng target DNA, 25 units/mL Amplitaqä DNA polymerase (Perkin-Elmer Cetus, Norwalk CT)). PCR parameters were 1 min at 94 °C, 1 min at 55 °C, 1 min at 72 °C, 35 cycles. The products were subcloned into the EcoR1 site of pHIL-D4 (Phillips Petroleum, Bartlesville, OK) to generate the plasmids pMP13, pMP14, pMP20 and pMP15 containing *dhaT*, *dhaB3*, *dhaB2* and *dhaB1*, respectively.

Construction of *dhaB1* expression plasmid pMCK10

The 7.8 kb replicating plasmid pGADGH (Clontech, Palo Alto, CA) was digested with HindIII, dephosphorylated, and ligated to the *dhaB1* HindIII fragment from pMP15. The resulting plasmid (pMCK10) had *dhaB1* correctly oriented for transcription from the ADH1 promoter and contained a LEU2 marker.

Construction of *dhaB2* expression plasmid pMCK17

Plasmid pGADGH (Clontech, Palo Alto, CA) was digested with HindIII and the single-strand ends converted to EcoRI ends by ligation with HindIII-XmnI and EcoRI-XmnI adaptors (New England Biolabs, Beverly, MA). Selection for plasmids with correct EcoRI ends was achieved by ligation to a kanamycin resistance gene on an EcoRI fragment from plasmid pUC4K (Pharmacia Biotech, Uppsala), transformation into *E. coli* strain DH5a and selection on LB plates containing 25 mg/mL kanamycin. The resulting plasmid (pGAD/KAN2) was digested with SnaBI

and EcoRI and a 1.8 kb fragment with the ADH1 promoter was isolated. Plasmid pGBT9 (Clontech, Palo Alto, CA) was digested with SnaBI and EcoRI, and the 1.5 kb ADH1/GAL4 fragment replaced by the 1.8 kb ADH1 promoter fragment isolated from pGAD/KAN2 by digestion with SnaBI and EcoRI. The resulting vector (pMCK11) is a replicating plasmid in yeast with an ADH1 promoter and terminator and a TRP1 marker. Plasmid pMCK11 was digested with EcoRI, dephosphorylated, and ligated to the *dhaB2* EcoRI fragment from pMP20. The resulting plasmid (pMCK17) had *dhaB2* correctly oriented for transcription from the ADH1 promoter and contained a TRP1 marker.

Construction of *dhaB3* expression plasmid pMCK30

Plasmid pGBT9 (Clontech) was digested with NaeI and PvuII and the 1 kb TRP1 gene removed from this vector. The TRPI gene was replaced by a URA3 gene donated as a 1.7 kb AatII/NaeI fragment from plasmid pRS406 (Stratagene) to give the intermediary vector pMCK32. The truncated ADH1 promoter present on pMCK32 was removed on a 1.5 kb SnaBI/EcoRI fragment, and replaced with a full-length ADH1 promoter on a 1.8 kb SnaBI/EcoRI fragment from plasmid pGAD/KAN2 to yield the vector pMCK26. The unique EcoRI site on pMCK26 was used to insert an EcoRI fragment with *dhaB3* from plasmid pMP14 to yield pMCK30. The pMCK30 replicating expression plasmid has *dhaB3* orientated for expression from the ADH1 promoter, and has a URA3 marker.

Construction of *dhaT* expression plasmid pMCK35

Plasmid pGBT9 (Clontech) was digested with NaeI and PvuII and the 1 kb TRP1 gene removed from this vector. The TRPI gene was replaced by a HIS3 gene donated as an XmnI/NaeI fragment from plasmid pRS403 (Stratagene) to give the intermediary vector pMCK33. The truncated ADH1 promoter present on pMCK33 was removed on a 1.5 kb SnaBI/EcoRI fragment, and replaced with a full-length ADH1 promoter on a 1.8 kb SnaBI/EcoRI fragment from plasmid pGAD/KAN2 to yield the vector pMCK31. The unique EcoRI site on pMCK31 was used to insert an EcoRI fragment with *dhaT* from plasmid pMP13 to yield pMCK35. The pMCK35 replicating expression plasmid has *dhaT* orientated for expression from the ADH1 promoter, and has a HIS3 marker.

Transformation of *S. cerevisiae* with *dha* expression plasmids

S. cerevisiae strain YPH500 (*ura3-52 lys2-801 ade2-101 trp1-D63 his3-D200 leu2-D1*) (Sikorski R. S. and Hieter P., *Genetics* 122, 19-27, (1989)) purchased from Stratagene (La Jolla, CA) was transformed with 1-2 mg of plasmid DNA using a Frozen-EZ Yeast Transformation Kit (Catalog #T2001) (Zymo Research, Orange, CA). Colonies were grown on Supplemented Minimal Medium (SMM - 0.67% yeast nitrogen base without amino acids, 2% glucose) for 3-4 d at 29 °C with one or more of the following additions: adenine sulfate (20 mg/L), uracil (20 mg/L),

L-tryptophan (20 mg/L), L-histidine (20 mg/L), L-leucine (30 mg/L), L-lysine (30 mg/L). Colonies were streaked on selective plates and used to inoculate liquid media.

Screening of *S. cerevisiae* transformants for *dha* genes

Chromosomal DNA from URA^+, HIS^+, TRP^+, LEU^+ transformants was analyzed by PCR using primers specific for each gene (SEQ ID NOS:38-45). The presence of all four open reading frames was confirmed.

Expression of *dhaB* and *dhaT* activity in transformed *S. cerevisiae*

The presence of active glycerol dehydratase (*dhaB*) and 1,3-propanediol oxido-reductase (*dhaT*) was demonstrated using *in vitro* enzyme assays. Additionally, western blot analysis confirmed protein expression from all four open reading frames.

Strain YPH500, transformed with the group of plasmids pMCK10, pMCK17, pMCK30 and pMCK35, was grown on Supplemented Minimal Medium containing 0.67% yeast nitrogen base without amino acids 2% glucose 20 mg/L adenine sulfate, and 30 mg/L L-lysine. Cells were homogenized and extracts assayed for *dhaB* activity. A specific activity of 0.12 units per mg protein was obtained for glycerol dehydratase, and 0.024 units per mg protein for 1,3-propanediol oxido-reductase.

EXAMPLE 4

PRODUCTION OF 1,3-PROPANEDIOL FROM D-GLUCOSE USING RECOMBINANT *Saccharomyces cerevisiae*

S. cerevisiae YPH500, harboring the groups of plasmids pMCK10, pMCK17, pMCK30 and pMCK35, was grown in a BiostatB fermenter (B Braun Biotech, Inc.) in 1.0 L of minimal medium initially containing 20 g/L glucose, 6.7 g/L yeast nitrogen base without amino acids, 40 mg/L adenine sulfate and 60 mg/L L-lysine·HCl. During the course of the growth, an additional equivalent of yeast nitrogen base, adenine and lysine was added. The fermenter was controlled at pH 5.5 with addition of 10% phosphoric acid and 2 M NaOH, 30 °C, and 40% dissolved oxygen tension through agitation control. After 38 h, the cells (OD_{600} = 5.8 AU) were harvested by centrifugation and resuspended in base medium (6.7 g/L yeast nitrogen base without amino acids, 20 mg/L adenine sulfate, 30 mg/L L-lysine·HCl, and 50 mM potassium phosphate buffer, pH 7.0).

Reaction mixtures containing cells (OD_{600} = 20 AU) in a total volume of 4 mL of base media supplemented with 0.5% glucose, 5 ug/mL coenzyme B_{12} and 0, 10, 20, or 40 mM chloroquine were prepared, in the absence of light and oxygen (nitrogen sparging), in 10 mL crimp sealed serum bottles and incubated at 30 °C with shaking. After 30 h, aliquots were withdrawn and analyzed by HPLC. The results are shown in the Table 3.

Table 3

Production of 1,3-propanediol using recombinant *S. cerevisiae*

reaction	chloroquine (mM)	1,3-propanediol (mM)
1	0	0.2
2	10	0.2
3	20	0.3
4	40	0.7

EXAMPLE 5

USE OF A *S. cerevisiae* DOUBLE TRANSFORMANT FOR PRODUCTION OF 1,3-PROPANEDIOL FROM D-GLUCOSE WHERE *dhaB* AND *dhaT* ARE INTEGRATED INTO THE GENOME

Example 5 prophetically demonstrates the transformation of *S. cerevisiae* with *dhaB1*, *dhaB2*, *dhaB3*, and *dhaT* and the stable integration of the genes into the yeast genome for the production of 1,3-propanediol from glucose.

Construction of expression cassettes

Four expression cassettes (*dhaB1*, *dhaB2*, *dhaB3*, and *dhaT*) are constructed for glucose-induced and high-level constitutive expression of these genes in yeast, *Saccharomyces cerevisiae*. These cassettes consist of: (i) the phosphoglycerate kinase (PGK) promoter from *S. cerevisiae* strain S288C; (ii) one of the genes *dhaB1*, *dhaB2*, *dhaB3*, or *dhaT*; and (iii) the PGK terminator from *S. cerevisiae* strain S288C. The PCR-based technique of gene splicing by overlap extension (Horton et al., *BioTechniques*, 8:528-535, (1990)) is used to recombine DNA sequences to generate these cassettes with seamless joints for optimal expression of each gene. These cassettes are cloned individually into a suitable vector (pLITMUS 39) with restriction sites amenable to multi-cassette cloning in yeast expression plasmids.

Construction of yeast integration vectors

Vectors used to effect the integration of expression cassettes into the yeast genome are constructed. These vectors contain the following elements: (i) a polycloning region into which expression cassettes are subcloned; (ii) a unique marker used to select for stable yeast transformants; (iii) replication origin and selectable marker allowing gene manipulation in *E. coli* prior to transforming yeast. One integration vector contains the *URA3* auxotrophic marker (Ylp352b), and a second integration vector contains the *LYS2* auxotrophic marker (pKP7).

Construction of yeast expression plasmids

Expression cassettes for *dhaB1* and *dhaB2* are subcloned into the polycloning region of the Ylp352b (expression plasmid #1), and expression cassettes for *dhaB3* and *dhaT* are subcloned into the polycloning region of pKP7 (expression plasmid #2).

Transformation of yeast with expression plasmids

S. cerevisiae (*ura3*, *lys2*) is transformed with expression plasmid #1 using Frozen-EZ Yeast Transformation kit (Zymo Research, Orange, CA), and transformants selected on plates lacking uracil. Integration of expression cassettes for *dhaB1* and *dhaB2* is confirmed by PCR analysis of chromosomal DNA. Selected transformants are re-transformed with expression plasmid #2 using Frozen-EZ Yeast Transformation kit, and double transformants selected on plates lacking lysine. Integration of expression cassettes for *dhaB3* and *dhaT* is confirmed by PCR analysis of chromosomal DNA. The presence of all four expression cassettes (*dhaB1*, *dhaB2*, *dhaB3*, *dhaT*) in double transformants is confirmed by PCR analysis of chromosomal DNA.

Protein production from double-transformed yeast

Production of proteins encoded by *dhaB1*, *dhaB2*, *dhaB3* and *dhaT* from double-transformed yeast is confirmed by Western blot analysis.

Enzyme activity from double-transformed yeast

Active glycerol dehydratase and active 1,3-propanediol dehydrogenase from double-transformed yeast is confirmed by enzyme assay as described in General Methods above.

Production of 1,3-propanediol from double-transformed yeast

Production of 1,3-propanediol from glucose in double-transformed yeast is demonstrated essentially as described in Example 4.

EXAMPLE 6

CONSTRUCTION OF PLASMIDS CONTAINING DAR1/GPP2 OR *dhaT/dhaB1-3* AND TRANSFORMATION INTO *KLEBSIELLA* SPECIES

K. pneumoniae (ATCC 25955), *K. pneumoniae* (ECL2106), and *K. oxytoca* (ATCC 8724) are naturally resistant to ampicillin (up to 150 ug/mL) and kanamycin (up to 50 ug/mL), but sensitive to tetracycline (10 ug/mL) and chloramphenicol (25 ug/mL). Consequently, replicating plasmids which encode resistance to these latter two antibiotics are potentially useful as cloning vectors for these *Klebsiella* strains. The wild-type *K. pneumoniae* (ATCC 25955), the glucose-derepressed *K. pneumonia* (ECL2106), and *K. oxytoca* (ATCC 8724) were successfully transformed to tetracycline resistance by electroporation with the moderate-copy-number plasmid, pBR322 (New England Biolabs, Beverly, MA). This was accomplished by the following procedure: Ten mL of an overnight culture was inoculated into 1 L LB (1% (w/v) Bacto-tryptone (Difco, Detroit, MI), 0.5% (w/v) Bacto-yeast extract (Difco) and 0.5% (w/v) NaCl (Sigma, St. Louis,

MO) and the culture was incubated at 37 °C to an OD_{600} of 0.5-0.7. The cells were chilled on ice, harvested by centrifugation at 4000 x g for 15 min, and resuspended in 1 L ice-cold sterile 10% glycerol. The cells were repeatedly harvested by centrifugation and progressively resuspended in 500 mL, 20 mL and, finally, 2 mL ice-cold sterile 10% glycerol. For electroporation, 40 uL of cells were mixed with 1-2 uL DNA in a chilled 0.2 cm cuvette and were pulsed at 200 Ω, 2.5 kV for 4-5 msec using a BioRad Gene Pulser (BioRad, Richmond, CA). One mL of SOC medium (2% (w/v) Bacto-tryptone (Difco), 0.5% (w/v) Bacto-yeast extract (Difco), 10 mM NaCl, 10 mM $MgCl_2$, 10 mM $MgSO_4$, 2.5 mM KCl and 20 mM glucose) was added to the cells and, after the suspension was transferred to a 17 x 100 mm sterile polypropylene tube, the culture was incubated for 1 hr at 37 °C, 225 rpm. Aliquots were plated on selective medium, as indicated. Analyses of the plasmid DNA from independent tetracycline-resistant transformants showed the restriction endonuclease digestion patterns typical of pBR322, indicating that the vector was stably maintained after overnight culture at 37 °C in LB containing tetracycline (10 ug/mL). Thus, this vector, and derivatives such as pBR329 (ATCC 37264) which encodes resistance to ampicillin, tetracycline and chloramphenicol, may be used to introduce the *DAR1/GPP2* and *dhaT/dhaB1-3* expression cassettes into *K. pneumoniae* and *K. oxytoca*.

The *DAR1* and *GPP2* genes may be obtained by PCR-mediated amplification from the *Saccharomyces cerevisiae* genome, based on their known DNA sequence. The genes are then transformed into *K. pneumoniae* or *K. oxytoca* under the control of one or more promoters that may be used to direct their expression in media containing glucose. For convenience, the genes were obtained on a 2.4 kb DNA fragment obtained by digestion of plasmid pAH44 with the *PvuII* restriction endonuclease, whereby the genes are already arranged in an expression cassette under the control of the *E. coli lac* promoter. This DNA fragment was ligated to *PvuII*-digested pBR329, producing the insertional inactivation of its chloramphenicol resistance gene. The ligated DNA was used to transform *E. coli* DH5α (Gibco, Gaithersberg, MD). Transformants were selected by their resistance to tetracycline (10 ug/mL) and were screened for their sensitivity to chloramphenicol (25 ug/mL). Analysis of the plasmid DNA from tetracycline-resistant, chloramphenicol-sensitive transformants confirmed the presence of the expected plasmids, in which the P_{lac}-*dar1-gpp2* expression cassette was subcloned in either orientation into the pBR329 PvuII site. These plasmids, designated pJSP1A (clockwise orientation) and pJSP1B (counterclockwise orientation), were separately transformed by electroporation into *K. pneumonia* (ATCC 25955), *K. pneumonia* (ECL2106) and *K. oxytoca* (ATCC 8724) as described. Transformants were selected by their resistance to tetracycline (10 ug/mL) and were screened for their sensitivity to chloramphenicol (25 ug/mL). Restriction analysis of the plasmids isolated from independent transformants showed only the expected digestion patterns, and confirmed that they were stably maintained at 37 °C with antibiotic selection. The expression of the *DAR1* and *GPP2* genes may be enhanced by the addition of IPTG (0.2-2.0 mM) to the growth medium.

The four *K. pneumoniae dhaB(1-3)* and *dhaT* genes may be obtained by PCR-mediated amplification from the *K. pneumoniae* genome, based on their known DNA sequence. These genes are then transformed into *K. pneumoniae* under the control of one or more promoters that may be used to direct their expression in media containing glucose. For convenience, the genes were obtained on an approximately 4.0 kb DNA fragment obtained by digestion of plasmid pAH24 with the *KpnI/SacI* restriction endonucleases, whereby the genes are already arranged in an expression cassette under the control of the *E. coli lac* promoter. This DNA fragment was ligated to similarly digested pBC-KS+ (Stratagene, LaJolla, CA) and used to transform *E. coli* DH5α. Transformants were selected by their resistance to chloramphenicol (25 ug/mL) and were screened for a white colony phenotype on LB agar containing X-gal. Restriction analysis of the plasmid DNA from chloramphenicol-resistant transformants demonstrating the white colony phenotype confirmed the presence of the expected plasmid, designated pJSP2, in which the *dhaT-dhaB(1-3)* genes were subcloned under the control of the *E. coli lac* promoter.

To enhance the conversion of glucose to 1,3-propanediol, this plasmid was separately transformed by electroporation into *K. pneumoniae* (ATCC 25955) (pJSP1A), *K. pneumoniae* (ECL2106) (pJSP1A) and *K. oxytoca* (ATCC 8724) (pJSP1A) already containing the P_{lac}-*dar1-gpp2* expression cassette. Cotransformants were selected by their resistance to both tetracycline (10 ug/mL) and chloramphenicol (25 ug/mL). Restriction analysis of the plasmids isolated from independent cotransformants showed the digestion patterns expected for both pJSP1A and pJSP2. The expression of the *DAR1*, *GPP2*, *dhaB(1-3)*, and *dhaT* genes may be enhanced by the addition of IPTG (0.2-2.0 mM) to the medium.

EXAMPLE 7

Production of 1,3 propanediol from glucose by *K. pneumoniae*

Klebsiella pneumoniae strains ECL 2106 and 2106-47, both transformed with pJSP1A, and ATCC 25955, transformed with pJSP1A and pJSP2, were grown in a 5 L Applikon fermenter under various conditions (see Table 4) for the production of 1,3-propanediol from glucose. Strain 2104-47 is a fluoroacetate-tolerant derivative of ECL 2106 which was obtained from a fluoroacetate/lactate selection plate as described in Bauer et al., *Appl. Environ. Microbiol. 56*, 1296 (1990). In each case, the medium used contained 50-100 mM potassium phosphate buffer, pH 7.5, 40 mM $(NH_4)_2SO_4$, 0.1% (w/v) yeast extract, 10 μM $CoCl_2$, 6.5 μM $CuCl_2$, 100 μM $FeCl_3$, 18 μM $FeSO_4$, 5 μM H_3BO_3, 50 μM $MnCl_2$, 0.1 μM Na_2MoO_4, 25 μM $ZnCl_2$, 0.82 mM $MgSO_4$, 0.9 mM $CaCl_2$, and 10-20 g/L glucose. Additional glucose was fed, with residual glucose maintained in excess. Temperature was controlled at 37 °C and pH controlled at 7.5 with 5N KOH or NaOH. Appropriate antibiotics were included for plasmid maintenance; IPTG (isopropyl-b-D-thiogalactopyranoside) was added at the indicated concentrations as well. For anaerobic fermentations, 0.1 vvm nitrogen was sparged through the reactor; when the dO

setpoint was 5%, 1 vvm air was sparged through the reactor and the medium was supplemented with vitamin B12. Final concentrations and overall yields (g/g) are shown in Table 4.

Table 4

Production of 1,3 propanediol from glucose by *K. pneumoniae*

Organism	dO	IPTG, mM	vitamin B12, mg/L	Titer, g/L	Yield, g/g
25955[pJSP1A/pJSP2]	0	0.5	0	8.1	16%
25955[pJSP1A/pJSP2]	5%	0.2	0.5	5.2	4%
2106[pJSP1A]	0	0	0	4.9	17%
2106[pJSP1A]	5%	0	5	6.5	12%
2106-47[pJSP1A]	5%	0.2	0.5	10.9	12%

EXAMPLE 8

Conversion of carbon substrates to 1,3-propanediol by recombinant *K. pneumoniae* containing *dar*1, *qpp*2, *dha*B, and *dha*T

A. Conversion of D-fructose to 1,3-propanediol by various *K. pneumoniae* recombinant strains:

Single colonies of *K. pneumoniae* (ATCC 25955 pJSP1A), *K. pneumoniae* (ATCC 25955 pJSP1A/pJSP2), *K. pneumoniae* (ATCC 2106 pJSP1A), and *K. pneumoniae* (ATCC 2106 pJSP1A/pJSP2) were transferred from agar plates and in separate culture tubes were subcultured overnight in Luria-Bertani (LB) broth containing the appropriate antibiotic agent(s). A 50-mL flask containing 45 mL of a steri-filtered minimal medium defined as LLMM/F which contains per liter: 10 g fructose; 1 g yeast extract; 50 mmoles potassium phosphate, pH 7.5; 40 mmoles $(NH_4)_2SO_4$; 0.09 mmoles calcium chloride; 2.38 mg $CoCl_2 \cdot 6H_2O$; 0.88 mg $CuCl_2 \cdot 2H_2O$; 27 mg $FeCl_3 \cdot 6H_2O$; 5 mg $FeSO_4 \cdot 7H_2O$; 0.31 mg H_3BO_3; 10 mg $MnCl_2 \cdot 4H_2O$; 0.023 mg $Na_2MoO_4 \cdot 2H_2O$; 3.4 mg $ZnCl_2$; 0.2 g $MgSO4 \cdot 7H_2O$. Tetracycline at 10 ug/mL was added to medium for reactions using either of the single plasmid recombinants; 10 ug/mL tetracycline and 25 ug/mL chloramphenicol for reactions using either of the double plasmid recombinants. The medium was thoroughly sparged with nitrogen prior to inoculation with 2 mL of the subculture. IPTG (I) at final concentration of 0.5 mM was added to some flasks. The flasks were capped, then incubated at 37 °C, 100 rpm in a New Brunswick Series 25 incubator/shaker. Reactions were run for at least 24 hours or until most of the carbon substrate was converted into products. Samples were analyzed by HPLC. Table 5 describes the yields of 1,3-propanediol (3G) produced from fructose by the various *Klebsiella* recombinants.

Table 5

Production of 1,3-propanediol from D-fructose using recombinant *Klebsiella*

Klebsiella Strain	Medium	Conversion	[3G] (g/L)	Yield Carbon (%)
2106 pBR329	LLMM/F	100	0	0
2106 pJSP1A	LLMM/F	50	0.66	15.5
2106 pJSP1A	LLMM/F + I	100	0.11	1.4
2106 pJSP1A/pJSP2	LLMM/F	58	0.26	5
25955 pBR329	LLMM/F	100	0	0
25955 pJSP1A	LLMM/F	100	0.3	4
25955 pJSP1A	LLMM/F + I	100	0.15	2
25955 pJSP1A/pJSP2	LLMM/F	100	0.9	11
25955 pJSP1A/pJSP2	LLMM/F + I	62	1.0	20

B. Conversion of various carbon substrates to 1,3-propanediol *by K. pneumoniae* (ATCC 25955 pJSP1A/pJSP2):

An aliquot (0.1 mL) of frozen stock cultures of *K. pneumoniae* (ATCC 25955 pJSP1A/pJSP2) was transferred to 50 mL Seed medium in a 250 mL baffled flask. The Seed medium contained per liter: 0.1 molar NaK/PO_4 buffer, pH 7.0; 3 g $(NH_4)_2SO_4$; 5 g glucose, 0.15 g $MgSO_4 \cdot 7H_20$, 10 mL 100X Trace Element solution, 25 mg chloramphenicol, 10 mg tetracycline, and 1 g yeast extract. The 100X Trace Element contained per liter: 10 g citric acid, 1.5 g $CaCl_2 \cdot 2H_20$, 2.8 g $FeSO_4 \cdot 7H_20$, 0.39 g $ZnSO_4 \cdot 7H_20$, 0.38 g $CuSO_4 \cdot 5H_20$, 0.2 g $CoCl_2 \cdot 6H_20$, and 0.3 g $MnCl_2 \cdot 4H_20$. The resulting solution was titrated to pH 7.0 with either KOH or H_2SO_4. The glucose, trace elements, antibiotics and yeast extracts were sterilized separately. The seed inoculum was grown overnight at 35 °C and 250 rpm.

The reaction design was semi-aerobic. The system consisted of 130 mL Reaction medium in 125 mL seated flasks that were left partially open with aluminum foil strip. The Reaction Medium contained per liter: 3 g $(NH_4)_2SO_4$; 20 g carbon substrate; 0.15 molar NaK/PO_4 buffer, pH 7.5; 1 g yeast extract; 0.15 g $MgSO_4 \cdot 7H_20$; 0.5 mmoles IPTG; 10 mL 100X Trace Element solution; 25 mg chloramphenicol; and 10 mg tetracycline. The resulting solution was titrated to pH 7.5 with KOH or H_2SO_4. The carbon sources were: D-glucose (Glc); D-fructose (Frc); D-lactose (Lac); D-sucrose (Suc); D-maltose (Mal); and D-mannitol (Man). A few glass beads were included in the medium to improve mixing. The reactions were initiated by addition of seed inoculum so that the optical density of the cell suspension started at 0.1 AU as

measured at I_{600} nm. The flasks were incubated at 35 °C: 250 rpm. 3G production was measured by HPLC after 24 hr. Table 6 describes the yields of 1,3-propanediol produced from the various carbon substrates.

Table 6
Production of 1,3-propanediol from various carbon substrates using recombinant *Klebsiella* 25955 pJSP1A/pJSP2

	1,3-Propanediol (g/L)		
Carbon Substrate	Expt. 1	Expt. 2	Expt 3
Glc	0.89	1	1.6
Frc	0.19	0.23	0.24
Lac	0.15	0.58	0.56
Suc	0.88	0.62	
Mal	0.05	0.03	0.02
Man	0.03	0.05	0.04

EXAMPLE 9

IMPROVEMENT OF 1,3-PROPANEDIOL PRODUCTION USING *dhaBX* GENE

Example 9 demonstrates the improved production of 1,3-propanediol in E.coli when a gene encoding a protein X is introduced.

Construction of expression vector pTacIQ

The *E. coli* expression vector, pTacIQ containing the lacIq gene (Farabaugh, P.J. 1978, Nature 274 (5673) 765-769) and tac promoter (Amann et al, 1983, Gene 25, 167-178) was inserted into the restriction endonuclease site EcoRI of pBR322 (Sutcliffe, 1979, Cold Spring Harb. Symp. Quant. Biol. 43, 77-90). A multiple cloning site and terminator sequence (SEQ ID NO:50) replaces the pBR322 sequence from EcoRI to SphI.

Subcloning the glycerol dehydratase genes (*dhaB1 ,2,3, X*)

The region containing the entire coding region for Klebsiella dhaB1, dhaB2, dhaB3 and dhaBX of the *dhaB* operon from pHK28-26 was cloning into pBluescriptIIKS+(Stratagene) using the restriction enzymes KpnI and EcoRI to create the plasmid pM7.

The open reading frame for *dhaB3* gene was amplified from pHK 28-26 by PCR using primers (SEQ ID NO:51 and SEQ ID NO:52) incorporating an EcoRI site at the 5' end and a XbaI site at the 3' end. The product was subcloned into pLitmus29(NEB) to generate the plasmid pDHAB3 containing *dhaB3*.

The *dhaBX*gene was removed by digesting plasmid pM7 with ApaI and XbaI, purifying the 5.9 kb fragment and ligating it with the 325-bp ApaI-XbaI fragment from plasmid pDHAB3 to create pM11 containing dhaB1, dhaB2 and dhaB3.

The open reading frame for the *dhaB1* gene was amplified from pHK28-26 by PCR using primers (SEQ ID NO:53 and SEQ ID NO:54) incorporating HindIII site and a consensus ribosome binding site at the 5' end and a XbaI site at the 3' end. The product was subcloned into pLitmus28(NEB) to generate the plasmids pDT1 containing *dhaB1*.

A NotI-XbaI fragment from pM11 containing part of the dhaB1 gene, the *dhaB2* gene and the *dhaB3* gene with inserted into pDT1 to create the *dhaB* expression plasmid, pDT2. The HinDIII-XbaI fragment containing the *dhaB(1,2,3)* genes from pDT2 was inserted into pTacIQ to create pDT3.

Subcloning the TMG dehydrogenase gene (*dhaT)*

The KpnI-SacI fragment of pHK28-26, containing the TMG dehydrogenase (*dhaT*) gene, was subcloned into pBluescriptII KS+ creating plasmid pAH1. The *dhaT* gene was cloned by PCR from pAH1 as template DNA and synthetic primers (SEQ ID NO:55 with SEQ ID NO:56) incorporating an XbaI site at the 5' end and a BamHI site at the 3' end. The product was subcloned into pCR-Script(Stratagene) at the SrfI site to generate the plasmids pAH4 and pAH5 containing *dhaT*. The pAH4 contains the *dhaT* gene in the right orientation for expression from the lac promoter in pCR-Script and pAH5 contains *dhaT* gene in the opposite orientation. The XbaI-BamHI fragment from pHA4 containing the *dhaT* gene was inserted into pTacIQ to generate plasmid, pAH8. The HindII-BamHI fragment from pAH8 containing the RBS and *dhaT* gene was inserted into pBluescriptIIKS+ to create pAH11.

Construction of an expression cassette for *dhaT* and *dhaB(1,2,3)*

An expression cassette for *dhaT* and *dhaB(1,2,3)* was assembled from the individual *dhaB(1,2,3)* and *dhaT* subclones described previously using standard molecular biology methods. A SpeI-SacI fragment containing the *dhaB(1,2,3)* genes from pDT3 was inserted into pAH11 at the SpeI-SacI sites to create pAH24. A SalI-XbaI linker (SEQ ID NO 57and SEQ ID NO 58) was inserted into pAH5 which was digested with the restriction enzymes SalI-XbaI to create pDT16. The linker destroys the XbaI site. The 1 kb SalI-MluI fragment from pDT16 was then inserted into pAH24 replacing the existing SalI-MluI fragment to create pDT18.

Plasmid for the over-expression of *dhaT* and *dhaB(1, 2, 3, X)* in E. coli

The 4.4 kb NotI-XbaI fragment containing part of the dhaB1 gene, dhaB2, dhaB3 and dhaBX from plasmid pM7 was purified and ligated with the 4.1 Kb NotI-XbaI fragment from plasmid pDT18 (restoring dhaB1) to create pM33 containing the dhaB1, dhaB2, dhaB3 and dhaBX.

E. coli strain

E. coli DH5a was obtained from BRL (Difco). This strain was transformed with the plasmids pM7, pM11, pM33 or pDt18 and selected on LA plates containing 100 ug/ml carbenicillin.

Production of 1,3-propanediol

E. coli DH5a, containing plasmid pM7, pM11, pM33 or pDT18 was grown on LA plates plus 100 ug/ml carbenicillin overnight at 37°C. One colony from each was used to inoculate 25 ml of media (0.2 M KH_2PO4, citric acid 2.0 g/L, MgSO4*7H2O 2.0 g/L, H2SO4 (98%) 1.2 ml/L, Ferric ammonium citrate 0.3 g/L, CaCl2*2H2O 0.2 gram, yeast extract 5 g/L, glucose 10 g/L, glycerol 30 g/L,) plus Vitamine B12 0.005 g/L, 0.2 mM IPTG, 200 ug/ml carbenicillin and 5 ml modified Balch's trace-element solution (the composition of which can be found in Methods for General and Molecular Bacteriology (P. Gerhardt et el., eds, p 158, American Society for Microbiology, Washington,DC 1994), final pH 6.8 (NH4OH), then filter-sterilized in 250 ml erlenmeyers flasks. The shake flasks were incubated at 37°C with shaking (300 rpm) for several days, during which they were sampled for HPLC analysis by standard procedures. Final yields are shown in Table 4.

Overall, as shown in Table 7, the results indicate that the expression of dhaBX in plasmids expressing dhaB(1,2,3) or dhaT-dhaB(1,2,3) greatly enhances the production of 1,3-propanediol .

TABLE 7

Effect of *dhaBX* expression on the production of 1,3-propanediol by *E. coli*

Strain	Time (days)	1,3-propanediol (mg/L)*
DH5a/pM7 (dhaB1,2,3,X)	1	1500
	2	2700
DH5a/pM11 (dhaB1,2,3)	1	< 200 µg
	2	< 200 µg
DH5a/pM33 (dhaT-dhaB1,2,3,X)	2	1200
DH5a/pDT18 (dhaT-dhaB1,2,3)	2	88

* Expressed as an average from several experiments.

Primers:

SEQ ID NO: 50- MCS-TERMINATOR:

5 AGCTTAGGAGTCTAGAATATTGAGCTCGAATTCCCGGGCATGCGGTACCGGATCCAGAAAA AAGCCCGCACCTGACAGTGCGGGCTTTTTTTTT 3'

SEQ ID NO: 51 -dhaB3-5' end. EcoRI

GGAATTCAGATCTCAGCAATGAGCGAGAAAACCATGC

SEQ ID NO 52: dhaB3-3' end XbaI

GCTCTAGATTAGCTTCCTTTACGCAGC

SEQ ID NO 53: *dhaB*1 5' end-HindIII-SD
5' GGCCAAGCTTAAGGAGGTTAATTAAATGAAAAG 3'

SEQ ID NO 54: *dhaB*1 3' end-XbaI
5' GCTCTAGATTATTCAATGGTGTCGGG 3'

SEQ ID NO 55: *dhaT* 5' end-XbaI
5' GCGCCGTCTAGAATTATGAGCTATCGTATGTTTGATTATCTG 3'

SEQ ID NO 56: *dhaT* 3' end-BamHI
5' TCTGATACGGGATCCTCAGAATGCCTGGCGGAAAAT 3'

SEQ ID NO 57: pUSH Linker1:
5' TCGACGAATTCAGGAGGA 3'

SEQ ID NO 58: pUSH Linker2:
5' CTAGTCCTCCTGAATTCG 3'

EXAMPLE 10

Reactivation of the Glycerol Dehydratase Activity

Example 10 demonstrates the *in vivo* reactivation of the glycerol dehydratase activity in microorganisms containing at least one gene encoding protein X.

Plasmids pM7 and pM11 were constructed as described in Example 9 and transformed into E.coli DH5α cells. The transformed cells were cultured and assayed for the production of 1,3-propanediol according to the method of Honda et al. (1980, In Situ Reactivation of Glycerol-Inactivated Coenzyme B_{12}-Dependent Enzymes, Glycerol Dehydratase and Diol Dehydratase. Journal of Bacteriology 143:1458-1465).

Materials and methods

Toluenization of Cells

The cells were grown to mid-log phase and were harvested by centrifugation at room temperature early in growth, i.e. $0.2 > OD_{600} < 0.8$. The harvested cells were washed 2x in 50mM KPO_4 pH8.0 at room temperature. The cells were resuspended to OD_{600} 20-30 in 50mM KPO_4 pH8.0. The absolute OD is not critical. A lower cell mass is resuspend in less volume. If coenzyme B12 is added at this point, the remainder of the steps are performed in the dark.

Toluene is added to 1% final volume of cell suspension and the suspension is shaked vigorously for 5 minutes at room temperature. The suspension is centrifuged to pellet the cells. The cells are washed 2x in 50mM KPO_4 pH8.0 at room temperature (25mls each). The cell pellet is resuspended in the same volume as was used prior to toluene addition and transfer to fresh tubes. The OD_{600} for the toluenized cells was measured and recorded and stored at 4 degrees C..

Whole Cell Glycerol Dehydratase Assay

The toluene treated cells were assayed at 37 degrees C for the presence of dehydratase activity. Three sets of reactions were carried out as shown below: no ATP, ATP added at 0 time, and ATP added at 10 minutes.

No ATP:	100ul	2M Glycerol
	100ul	150uM CoB_{12}
	700ul	Buffer (0.03M KPO_4 / 0.5M KCl, pH8.0)
T=0 minute ATP	100ul	2M Glycerol
	100ul	150uM CoB_{12}
	600ul	Buffer (0.03M KPO_4 / 0.5M KCl, pH8.0)
	100ul	30mM ATP/ 30mM $MnCl_2$
T=10 minute ATP	100ul	2M Glycerol
	100ul	150uM CoB_{12}
	700ul	Buffer (0.03M KPO_4 / 0.5M KCl, pH8.0)

Controls were prepared for each of the above conditions by adding 100uls buffer instead of CoB_{12}. The tubes were mixed. 50uls MBTH (3-Methyl-2-Benzo-Thiazolinone Hydrazone) (6 mg/ml in 375mM Glycine / HCl pH2.7) was added to each of these tubes and continue incubation in ice water. The reaction tubes were placed in a 37 degree C water bath for a few minutes to equilibrate to 37 degree C. A tube containing enough toluenized cells for all assay tubes was placed into the 37 degree C water bath for a few minutes to equilibrate to 37 degree C. A tube containing 2.5 fold diluted (in assay buffer) 30mM ATP/ 30mM $MnCl_2$ (12mM each) was placed into the 37 degree C water bath for a few minutes to equilibrate to 37 degree C. A 100ul cell suspension was added to all tubes and samples were taken at 0,1,2,3,4,5,10,15,20 and 30 minutes. At every timepoint, 100uls of reaction was withdrawn and immediately added to 50uls ice cold MBTH, vortexed, and placed in an ice water bath. At T=10 minutes, a sample was withdrawn and added to MBTH, then 100uls of the 2.5 fold diluted ATP/Mn was added as fast as is possible. When all samples were collected, the sample tube rack was added to a boiling water bath and boiled for three minutes. The tubes were chilled in an ice water bath for 30 seconds.

500uls of freshly prepared 3.3 mg/ml FeCl3.6H2O, was added to the tubes and the tubes vortexed. The tubes were incubated at room temperature for 30 minutes, diluted 10x in H2O, and then centrifuged to collect the cells and particulates. The absorbance was measured at 670nM and the cells were diluted to keep OD under 1.0.

Example of Calculation of Activity

The observed OD670 was multiplied by the dilution factor to determine absorbance. The blank absorbance was substracted for that reaction series and the T0 A670nM was substracted. The absolute A670nM was divided by 53.4 (mM extinction coefficient for 3OH-propioaldehyde) and the mM concentration was multiplied by any dilution of reaction during timecourse. Because 1 ml reaction was used, the concentration (umoles/ml) of 3OH-propionaldehyde was divided by the mgs dry weight used in the assay (calculated via OD600 and 1OD 600 = 0.436 mgs dry weight) to get umoles aldehyde per mg dry weight cells.

Results

As shown in Figure 6, whole E.coli cells were assayed for reactivation of glycerol dehydratase in the absence and presence of added ATP and Mn++. The results indicate that cells containing a plasmid carrying dhaB 1, 2 and 3 as well as protein X have the ability to reactivate catalytically inactivated glycerol dehydrogenase. Cells containing protein 1, protein 2 and protein 3 have increased ability to reactivate the catalytically inactivated glycerol dehydratase.

As shown in Figure 7, whole E.coli cells were assayed for reactivation of glycerol-inactivated glycerol dehydratase in the absence and in the presence of added ATP and Mn++. The results show that cells containing dhaB subunits 1, 2 and 3 and X have the ability to reactivate catalytically inactivated glycerol dehydratase. Cell lacking the protein X gene do not have the ability to reactivate the catalytically inactivated glycerol dehydratase.

Figures 9 and 10 illustrate that host cells containing plasmid pHK 28-26 (Figure 1), when cultured under conditions suitable for the production of 1,3-propanediol, produced more 1,3-propanediol than host cells transformed with pDT24 and cultured under conditions suitable for the production of 1,3-propanediol. Plasmid pDT24 is a derivative of pDT18 (described in Example 9) and contains dhaT, dhaB 1, 2, 3 and protein X, but lacks proteins 1, 2 and 3.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: MARIA DIAZ-TORRES
NIGEL DUNN-COLEMAN
MATTHEW CHASE

(ii) TITLE OF INVENTION: METHOD FOR THE RECOMBINANT PRODUCTION OF 1,3 PROPANEDIOL

(iii) NUMBER OF SEQUENCES: 49

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: GENENCOR INTERNATIONAL, INC.
(B) STREET: 4 CAMBRIDGE PLACE
1870 SOUTH WINTON ROAD
(C) CITY: ROCHESTER
(D) STATE: NEW YORK
(E) COUNTRY: U.S.A.
(F) POSTAL CODE (ZIP): 14618

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.50 INCH DISKETTE
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: MICROSOFT WINDOWS 3.1
(D) SOFTWARE: MICROSOFT WORD 2.0C

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 11/13/97
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 60/030,601
(B) FILING DATE: 11/13/96
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: GLAISTER, DEBRA
(B) REGISTRATION NO.: 33,888
(C) REFERENCE/DOCKET NUMBER: GC 369-2
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 650-864-7620
(B) TELEFAX: 650-845-6504

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1668 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAAAAGAT CAAAACGATT TGCAGTACTG GCCCAGCGCC CCGTCAATCA GGACGGGCTG 60

ATTGGCGAGT GGCCTGAAGA GGGGCTGATC GCCATGGACA GCCCCTTTGA CCCGGTCTCT 120

TCAGTAAAAG TGGACAACGG TCTGATCGTC GAACTGGACG GCAAACGCCG GGACCAGTTT 180

GACATGATCG ACCGATTTAT CGCCGATTAC GCGATCAACG TTGAGCGCAC AGAGCAGGCA 240

ATGCGCCTGG AGGCGGTGGA AATAGCCCGT ATGCTGGTGG ATATTCACGT CAGCCGGGAG 300

GAGATCATTG CCATCACTAC CGCCATCACG CCGGCCAAAG CGGTCGAGGT GATGGCGCAG 360

ATGAACGTGG TGGAGATGAT GATGGCGCTG CAGAAGATGC GTGCCCGCCG GACCCCCTCC 420

AACCAGTGCC ACGTCACCAA TCTCAAAGAT AATCCGGTGC AGATTGCCGC TGACGCCGCC 480

GAGGCCGGGA TCCGCGGCTT CTCAGAACAG GAGACCACGG TCGGTATCGC GCGCTACGCG 540

CCGTTTAACG CCCTGGCGCT GTTGGTCGGT TCGCAGTGCG GCCGCCCCGG CGTGTTGACG 600

CAGTGCTCGG TGGAAGAGGC CACCGAGCTG GAGCTGGGCA TGCGTGGCTT AACCAGCTAC 660

GCCGAGACGG TGTCGGTCTA CGGCACCGAA GCGGTATTTA CCGACGGCGA TGATACGCCG 720

TGGTCAAAGG CGTTCCTCGC CTCGGCCTAC GCCTCCCGCG GGTTGAAAAT GCGCTACACC 780

TCCGGCACCG GATCCGAAGC GCTGATGGGC TATTCGGAGA GCAAGTCGAT GCTCTACCTC 840

GAATCGCGCT GCATCTTCAT TACTAAAGGC GCCGGGGTTC AGGGACTGCA AAACGGCGCG 900

GTGAGCTGTA TCGGCATGAC CGGCGCTGTG CCGTCGGGCA TTCGGGCGGT GCTGGCGGAA 960

AACCTGATCG CCTCTATGCT CGACCTCGAA GTGGCGTCCG CCAACGACCA GACTTTCTCC 1020

CACTCGGATA TTCGCCGCAC CGCGCGCACC CTGATGCAGA TGCTGCCGGG CACCGACTTT 1080

ATTTTCTCCG GCTACAGCGC GGTGCCGAAC TACGACAACA TGTTCGCCGG CTCGAACTTC 1140

GATGCGGAAG ATTTTGATGA TTACAACATC CTGCAGCGTG ACCTGATGGT TGACGGCGGC 1200

CTGCGTCCGG TGACCGAGGC GGAAACCATT GCCATTCGCC AGAAAGCGGC GCGGGCGATC 1260

CAGGCGGTTT TCCGCGAGCT GGGGCTGCCG CCAATCGCCG ACGAGGAGGT GGAGGCCGCC 1320

ACCTACGCGC ACGGCAGCAA CGAGATGCCG CCGCGTAACG TGGTGGAGGA TCTGAGTGCG 1380

GTGGAAGAGA TGATGAAGCG CAACATCACC GGCCTCGATA TTGTCGGCGC GCTGAGCCGC 1440

AGCGGCTTTG AGGATATCGC CAGCAATATT CTCAATATGC TGCGCCAGCG GGTCACCGGC 1500

GATTACCTGC AGACCTCGGC CATTCTCGAT CGGCAGTTCG AGGTGGTGAG TGCGGTCAAC 1560

GACATCAATG ACTATCAGGG GCCGGGCACC GGCTATCGCA TCTCTGCCGA ACGCTGGGCG 1620

GAGATCAAAA ATATTCCGGG CGTGGTTCAG CCCGACACCA TTGAATAA 1668

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 585 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTGCAACAGA CAACCCAAAT TCAGCCCTCT TTTACCCTGA AAACCCGCGA GGGCGGGGTA 60

GCTTCTGCCG ATGAACGCGC CGATGAAGTG GTGATCGGCG TCGGCCCTGC CTTCGATAAA 120

CACCAGCATC ACACTCTGAT CGATATGCCC CATGGCGCGA TCCTCAAAGA GCTGATTGCC 180

GGGGTGGAAG AAGAGGGGCT TCACGCCCGG GTGGTGCGCA TTCTGCGCAC GTCCGACGTC 240

TCCTTTATGG CCTGGGATGC GGCCAACCTG AGCGGCTCGG GGATCGGCAT CGGTATCCAG 300

TCGAAGGGGA CCACGGTCAT CCATCAGCGC GATCTGCTGC CGCTCAGCAA CCTGGAGCTG 360

TTCTCCCAGG CGCCGCTGCT GACGCTGGAG ACCTACCGGC AGATTGGCAA AAACGCTGCG 420

CGCTATGCGC GCAAAGAGTC ACCTTCGCCG GTGCCGGTGG TGAACGATCA GATGGTGCGG 480

CCGAAATTTA TGGCCAAAGC CGCGCTATTT CATATCAAAG AGACCAAACA TGTGGTGCAG 540

GACGCCGAGC CCGTCACCCT GCACATCGAC TTAGTAAGGG AGTGA 585

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 426 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGAGCGAGA AAACCATGCG CGTGCAGGAT TATCCGTTAG CCACCCGCTG CCCGGAGCAT 60

ATCCTGACGC CTACCGGCAA ACCATTGACC GATATTACCC TCGAGAAGGT GCTCTCTGGC 120

GAGGTGGGCC CGCAGGATGT GCGGATCTCC CGCCAGACCC TTGAGTACCA GGCGCAGATT 180

GCCGAGCAGA TGCAGCGCCA TGCGGTGGCG CGCAATTTCC GCCGCGCGGC GGAGCTTATC 240

GCCATTCCTG ACGAGCGCAT TCTGGCTATC TATAACGCGC TGCGCCCGTT CCGCTCCTCG 300

CAGGCGGAGC TGCTGGCGAT CGCCGACGAG CTGGAGCACA CCTGGCATGC GACAGTGAAT 360

GCCGCCTTTG TCCGGGAGTC GGCGGAAGTG TATCAGCAGC GGCATAAGCT GCGTAAAGGA 420

AGCTAA 426

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1164 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATGAGCTATC GTATGTTTGA TTATCTGGTG CCAAACGTTA ACTTTTTTGG CCCCAACGCC 60

ATTTCCGTAG TCGGCGAACG CTGCCAGCTG CTGGGGGGGA AAAAAGCCCT GCTGGTCACC 120

GACAAAGGCC TGCGGGCAAT TAAAGATGGC GCGGTGGACA AAACCCTGCA TTATCTGCGG 180

GAGGCCGGGA TCGAGGTGGC GATCTTTGAC GGCGTCGAGC CGAACCCGAA AGACACCAAC 240

GTGCGCGACG GCCTCGCCGT GTTTCGCCGC GAACAGTGCG ACATCATCGT CACCGTGGGC 300

GGCGGCAGCC CGCACGATTG CGGCAAAGGC ATCGGCATCG CCGCCACCCA TGAGGGCGAT 360

CTGTACCAGT ATGCCGGAAT CGAGACCCTG ACCAACCCGC TGCCGCCTAT CGTCGCGGTC 420

AATACCACCG CCGGCACCGC CAGCGAGGTC ACCCGCCACT GCGTCCTGAC CAACACCGAA 480

ACCAAAGTGA AGTTTGTGAT CGTCAGCTGG CGCAAACTGC CGTCGGTCTC TATCAACGAT 540

CCACTGCTGA TGATCGGTAA ACCGGCCGCC CTGACCGCGG CGACCGGGAT GGATGCCCTG 600

ACCCACGCCG TAGAGGCCTA TATCTCCAAA GACGCTAACC CGGTGACGGA CGCCGCCGCC 660

ATGCAGGCGA TCCGCCTCAT CGCCCGCAAC CTGCGCCAGG CCGTGGCCCT CGGCAGCAAT 720

CTGCAGGCGC GGGAAAACAT GGCCTATGCT TCTCTGCTGG CCGGGATGGC TTTCAATAAC 780

GCCAACCTCG GCTACGTGCA CGCCATGGCG CACCAGCTGG GCGGCCTGTA CGACATGCCG 840

CACGGCGTGG CCAACGCTGT CCTGCTGCCG CATGTGGCGC GCTACAACCT GATCGCCAAC 900

CCGGAGAAAT TCGCCGATAT CGCTGAACTG ATGGGCGAAA ATATCACCGG ACTGTCCACT 960

CTCGACGCGG CGGAAAAAGC CATCGCCGCT ATCACGCGTC TGTCGATGGA TATCGGTATT 1020

CCGCAGCATC TGCGCGATCT GGGGGTAAAA GAGGCCGACT TCCCCTACAT GGCGGAGATG 1080

GCTCTAAAAG ACGGCAATGC GTTCTCGAAC CCGCGTAAAG GCAACGAGCA GGAGATTGCC 1140

GCGATTTTCC GCCAGGCATT CTGA 1164

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1380 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPD1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTTTAATTTT CTTTTATCTT ACTCTCCTAC ATAAGACATC AAGAAACAAT TGTATATTGT 60

ACACCCCCCC CCTCCACAAA CACAAATATT GATAATATAA AGATGTCTGC TGCTGCTGAT 120

AGATTAAACT TAACTTCCGG CCACTTGAAT GCTGGTAGAA AGAGAAGTTC CTCTTCTGTT 180

TCTTTGAAGG CTGCCGAAAA GCCTTTCAAG GTTACTGTGA TTGGATCTGG TAACTGGGGT 240

ACTACTATTG CCAAGGTGGT TGCCGAAAAT TGTAAGGGAT ACCCAGAAGT TTTCGCTCCA 300

ATAGTACAAA TGTGGGTGTT CGAAGAAGAG ATCAATGGTG AAAAATTGAC TGAAATCATA 360

AATACTAGAC ATCAAAACGT GAAATACTTG CCTGGCATCA CTCTACCCGA CAATTTGGTT 420

GCTAATCCAG ACTTGATTGA TTCAGTCAAG GATGTCGACA TCATCGTTTT CAACATTCCA 480

CATCAATTTT TGCCCCGTAT CTGTAGCCAA TTGAAAGGTC ATGTTGATTC ACACGTCAGA 540

GCTATCTCCT GTCTAAAGGG TTTTGAAGTT GGTGCTAAAG GTGTCCAATT GCTATCCTCT 600

TACATCACTG AGGAACTAGG TATTCAATGT GGTGCTCTAT CTGGTGCTAA CATTGCCACC 660

GAAGTCGCTC AAGAACACTG GTCTGAAACA ACAGTTGCTT ACCACATTCC AAAGGATTTC 720

AGAGGCGAGG GCAAGGACGT CGACCATAAG GTTCTAAAGG CCTTGTTCCA CAGACCTTAC 780

TTCCACGTTA GTGTCATCGA AGATGTTGCT GGTATCTCCA TCTGTGGTGC TTTGAAGAAC 840

GTTGTTGCCT TAGGTTGTGG TTTCGTCGAA GGTCTAGGCT GGGGTAACAA CGCTTCTGCT 900

GCCATCCAAA GAGTCGGTTT GGGTGAGATC ATCAGATTCG GTCAAATGTT TTTCCCAGAA 960

TCTAGAGAAG AAACATACTA CCAAGAGTCT GCTGGTGTTG CTGATTTGAT CACCACCTGC 1020

GCTGGTGGTA GAAACGTCAA GGTTGCTAGG CTAATGGCTA CTTCTGGTAA GGACGCCTGG 1080

GAATGTGAAA AGGAGTTGTT GAATGGCCAA TCCGCTCAAG GTTTAATTAC CTGCAAAGAA 1140

GTTCACGAAT GGTTGGAAAC ATGTGGCTCT GTCGAAGACT TCCCATTATT TGAAGCCGTA 1200

TACCAAATCG TTTACAACAA CTACCCAATG AAGAACCTGC CGGACATGAT TGAAGAATTA 1260

GATCTACATG AAGATTAGAT TTATTGGAGA AAGATAACAT ATCATACTTC CCCCACTTTT 1320

TTCGAGGCTC TTCTATATCA TATTCATAAA TTAGCATTAT GTCATTTCTC ATAACTACTT 1380

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2946 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPD2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAATTCGAGC CTGAAGTGCT GATTACCTTC AGGTAGACTT CATCTTGACC CATCAACCCC 60

AGCGTCAATC CTGCAAATAC ACCACCCAGC AGCACTAGGA TGATAGAGAT AATATAGTAC 120

GTGGTAACGC TTGCCTCATC ACCTACGCTA TGGCCGGAAT CGGCAACATC CCTAGAATTG 180

AGTACGTGTG ATCCGGATAA CAACGGCAGT GAATATATCT TCGGTATCGT AAAGATGTGA 240

TATAAGATGA TGTATACCCA ATGAGGAGCG CCTGATCGTG ACCTAGACCT TAGTGGCAAA 300

AACGACATAT CTATTATAGT GGGGAGAGTT TCGTGCAAAT AACAGACGCA GCAGCAAGTA 360

ACTGTGACGA TATCAACTCT TTTTTTATTA TGTAATAAGC AAACAAGCAC GAATGGGGAA 420

AGCCTATGTG CAATCACCAA GGTCGTCCCT TTTTTCCCAT TTGCTAATTT AGAATTTAAA 480

GAAACCAAAA GAATGAAGAA AGAAAACAAA TACTAGCCCT AACCCTGACT TCGTTTCTAT 540

GATAATACCC TGCTTTAATG AACGGTATGC CCTAGGGTAT ATCTCACTCT GTACGTTACA 600

AACTCCGGTT ATTTTATCGG AACATCCGAG CACCCGCGCC TTCCTCAACC CAGGCACCGC 660

CCCAGGTAAC CGTGCGCGAT GAGCTAATCC TGAGCCATCA CCCACCCCAC CCGTTGATGA 720

CAGCAATTCG GGAGGGCGAA AATAAAACTG GAGCAAGGAA TTACCATCAC CGTCACCATC 780

ACCATCATAT CGCCTTAGCC TCTAGCCATA GCCATCATGC AAGCGTGTAT CTTCTAAGAT 840

TCAGTCATCA TCATTACCGA GTTTGTTTTC CTTCACATGA TGAAGAAGGT TTGAGTATGC 900

TCGAAACAAT AAGACGACGA TGGCTCTGCC ATTGGTTATA TTACGCTTTT GCGGCGAGGT 960

GCCGATGGGT TGCTGAGGGG AAGAGTGTTT AGCTTACGGA CCTATTGCCA TTGTTATTCC 1020

GATTAATCTA TTGTTCAGCA GCTCTTCTCT ACCCTGTCAT TCTAGTATTT TTTTTTTTTT 1080

TTTTTGGTTT TACTTTTTTT TCTTCTTGCC TTTTTTTCTT GTTACTTTTT TTCTAGTTTT 1140

TTTTCCTTCC ACTAAGCTTT TTCCTTGATT TATCCTTGGG TTCTTCTTTC TACTCCTTTA 1200

GATTTTTTTT TTATATATTA ATTTTTAAGT TTATGTATTT TGGTAGATTC AATTCTCTTT 1260

CCCTTTCCTT TTCCTTCGCT CCCCTTCCTT ATCAATGCTT GCTGTCAGAA GATTAACAAG 1320

ATACACATTC CTTAAGCGAA CGCATCCGGT GTTATATACT CGTCGTGCAT ATAAAATTTT 1380

GCCTTCAAGA TCTACTTTCC TAAGAAGATC ATTATTACAA ACACAACTGC ACTCAAAGAT 1440

GACTGCTCAT ACTAATATCA AACAGCACAA ACACTGTCAT GAGGACCATC CTATCAGAAG 1500

ATCGGACTCT GCCGTGTCAA TTGTACATTT GAAACGTGCG CCCTTCAAGG TTACAGTGAT 1560

TGGTTCTGGT AACTGGGGGA CCACCATCGC CAAAGTCATT GCGGAAAACA CAGAATTGCA 1620

TTCCCATATC TTCGAGCCAG AGGTGAGAAT GTGGGTTTTT GATGAAAAGA TCGGCGACGA 1680

AAATCTGACG GATATCATAA ATACAAGACA CCAGAACGTT AAATATCTAC CCAATATTGA 1740

CCTGCCCCAT AATCTAGTGG CCGATCCTGA TCTTTTACAC TCCATCAAGG GTGCTGACAT 1800

CCTTGTTTTC AACATCCCTC ATCAATTTTT ACCAAACATA GTCAAACAAT TGCAAGGCCA 1860

CGTGGCCCCT CATGTAAGGG CCATCTCGTG TCTAAAAGGG TTCGAGTTGG GCTCCAAGGG 1920

TGTGCAATTG CTATCCTCCT ATGTTACTGA TGAGTTAGGA ATCCAATGTG GCGCACTATC 1980

TGGTGCAAAC TTGGCACCGG AAGTGGCCAA GGAGCATTGG TCCGAAACCA CCGTGGCTTA 2040

CCAACTACCA AAGGATTATC AAGGTGATGG CAAGGATGTA GATCATAAGA TTTTGAAATT 2100

GCTGTTCCAC AGACCTTACT TCCACGTCAA TGTCATCGAT GATGTTGCTG GTATATCCAT 2160

TGCCGGTGCC TTGAAGAACG TCGTGGCACT TGCATGTGGT TTCGTAGAAG GTATGGGATG 2220

GGGTAACAAT GCCTCCGCAG CCATTCAAAG GCTGGGTTTA GGTGAAATTA TCAAGTTCGG 2280

TAGAATGTTT TTCCCAGAAT CCAAAGTCGA GACCTACTAT CAAGAATCCG CTGGTGTTGC 2340

AGATCTGATC ACCACCTGCT CAGGCGGTAG AAACGTCAAG GTTGCCACAT ACATGGCCAA 2400

GACCGGTAAG TCAGCCTTGG AAGCAGAAAA GGAATTGCTT AACGGTCAAT CCGCCCAAGG 2460

GATAATCACA TGCAGAGAAG TTCACGAGTG GCTACAAACA TGTGAGTTGA CCCAAGAATT 2520

CCCAATTATT CGAGGCAGTC TACCAGATAG TCTACAACAA CGTCCGCATG GAAGACCTAC 2580

CGGAGATGAT TGAAGAGCTA GACATCGATG ACGAATAGAC ACTCTCCCCC CCCCTCCCCC 2640

TCTGATCTTT CCTGTTGCCT CTTTTTCCCC CAACCAATTT ATCATTATAC ACAAGTTCTA 2700

CAACTACTAC TAGTAACATT ACTACAGTTA TTATAATTTT CTATTCTCTT TTTCTTTAAG 2760

AATCTATCAT TAACGTTAAT TTCTATATAT ACATAACTAC CATTATACAC GCTATTATCG 2820

TTTACATATC ACATCACCGT TAATGAAAGA TACGACACCC TGTACACTAA CACAATTAAA 2880

TAATCGCCAT AACCTTTTCT GTTATCTATA GCCCTTAAAG CTGTTTCTTC GAGCTTTTCA 2940

CTGCAG 2946

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3178 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GUT2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTGCAGAACT TCGTCTGCTC TGTGCCCATC CTCGCGGTTA GAAAGAAGCT GAATTGTTTC 60

ATGCGCAAGG GCATCAGCGA GTGACCAATA ATCACTGCAC TAATTCCTTT TTAGCAACAC 120

ATACTTATAT ACAGCACCAG ACCTTATGTC TTTTCTCTGC TCCGATACGT TATCCCACCC 180

AACTTTTATT TCAGTTTTGG CAGGGGAAAT TTCACAACCC CGCACGCTAA AAATCGTATT 240

TAAACTTAAA AGAGAACAGC CACAAATAGG GAACTTTGGT CTAAACGAAG GACTCTCCCT 300

CCCTTATCTT GACCGTGCTA TTGCCATCAC TGCTACAAGA CTAAATACGT ACTAATATAT 360

GTTTTCGGTA ACGAGAAGAA GAGCTGCCGG TGCAGCTGCT GCCATGGCCA CAGCCACGGG 420

GACGCTGTAC TGGATGACTA GCCAAGGTGA TAGGCCGTTA GTGCACAATG ACCCGAGCTA 480

CATGGTGCAA TTCCCCACCG CCGCTCCACC GGCAGGTCTC TAGACGAGAC CTGCTGGACC 540

GTCTGGACAA GACGCATCAA TTCGACGTGT TGATCATCGG TGGCGGGGCC ACGGGGACAG 600

GATGTGCCCT AGATGCTGCG ACCAGGGGAC TCAATGTGGC CCTTGTTGAA AAGGGGGATT 660

TTGCCTCGGG AACGTCGTCC AAATCTACCA AGATGATTCA CGGTGGGGTG CGGTACTTAG 720

AGAAGGCCTT CTGGGAGTTC TCCAAGGCAC AACTGGATCT GGTCATCGAG GCACTCAACG 780

AGCGTAAACA TCTTATCAAC ACTGCCCCTC ACCTGTGCAC GGTGCTACCA ATTCTGATCC 840

CCATCTACAG CACCTGGCAG GTCCCGTACA TCTATATGGG CTGTAAATTC TACGATTTCT 900

TTGGCGGTTC CCAAAACTTG AAAAAATCAT ACCTACTGTC CAAATCCGCC ACCGTGGAGA 960

AGGCTCCCAT GCTTACCACA GACAATTTAA AGGCCTCGCT TGTGTACCAT GATGGGTCCT 1020

TTAACGACTC GCGTTTGAAC GCCACTTTAG CCATCACGGG TGTGGAGAAC GGCGCTACCG 1080

TCTTGATCTA TGTCGAGGTA CAAAAATTGA TCAAAGACCC AACTTCTGGT AAGGTTATCG 1140

GTGCCGAGGC CCGGGACGTT GAGACTAATG AGCTTGTCAG AATCAACGCT AAATGTGTGG 1200

TCAATGCCAC GGGCCCATAC AGTGACGCCA TTTTGCAAAT GGACCGCAAC CCATCCGGTC 1260

TGCCGGACTC CCCGCTAAAC GACAACTCCA AGATCAAGTC GACTTTCAAT CAAATCTCCG 1320

TCATGGACCC GAAAATGGTC ATCCCATCTA TTGGCGTTCA CATCGTATTG CCCTCTTTTT 1380

ACTCCCCGAA GGATATGGGT TTGTTGGACG TCAGAACCTC TGATGGCAGA GTGATGTTCT 1440

TTTTACCTTG GCAGGGCAAA GTCCTTGCCG GCACCACAGA CATCCCACTA AAGCAAGTCC 1500

CAGAAAACCC TATGCCTACA GAGGCTGATA TTCAAGATAT CTTGAAAGAA CTACAGCACT 1560

ATATCGAATT CCCCGTGAAA AGAGAAGACG TGCTAAGTGC ATGGGCTGGT GTCAGACCTT 1620

TGGTCAGAGA TCCACGTACA ATCCCCGCAG ACGGGAAGAA GGGCTCTGCC ACTCAGGGCG 1680

TGGTAAGATC CCACTTCTTG TTCACTTCGG ATAATGGCCT AATTACTATT GCAGGTGGTA 1740

AATGGACTAC TTACAGACAA ATGGCTGAGG AAACAGTCGA CAAAGTTGTC GAAGTTGGCG 1800

GATTCCACAA CCTGAAACCT TGTCACACAA GAGATATTAA GCTTGCTGGT GCAGAAGAAT 1860

GGACGCAAAA CTATGTGGCT TTATTGGCTC AAAACTACCA TTTATCATCA AAAATGTCCA 1920

ACTACTTGGT TCAAAACTAC GGAACCCGTT CCTCTATCAT TTGCGAATTT TTCAAAGAAT 1980

CCATGGAAAA TAAACTGCCT TTGTCCTTAG CCGACAAGGA AAATAACGTA ATCTACTCTA 2040

GCGAGGAGAA CAACTTGGTC AATTTTGATA CTTTCAGATA TCCATTCACA ATCGGTGAGT 2100

TAAAGTATTC CATGCAGTAC GAATATTGTA GAACTCCCTT GGACTTCCTT TTAAGAAGAA 2160

CAAGATTCGC CTTCTTGGAC GCCAAGGAAG CTTTGAATGC CGTGCATGCC ACCGTCAAAG 2220

TTATGGGTGA TGAGTTCAAT TGGTCGGAGA AAAAGAGGCA GTGGGAACTT GAAAAAACTG 2280

TGAACTTCAT CCAAGGACGT TTCGGTGTCT AAATCGATCA TGATAGTTAA GGGTGACAAA 2340

GATAACATTC ACAAGAGTAA TAATAATGGT AATGATGATA ATAATAATAA TGATAGTAAT 2400

AACAATAATA ATAATGGTGG TAATGGCAAT GAAATCGCTA TTATTACCTA TTTTCCTTAA 2460

TGGAAGAGTT AAAGTAAACT AAAAAAACTA CAAAAATATA TGAAGAAAAA AAAAAAAAGA 2520

GGTAATAGAC TCTACTACTA CAATTGATCT TCAAATTATG ACCTTCCTAG TGTTTATATT 2580

CTATTTCCAA TACATAATAT AATCTATATA ATCATTGCTG GTAGACTTCC GTTTTAATAT 2640

CGTTTTAATT ATCCCCTTTA TCTCTAGTCT AGTTTTATCA TAAAATATAG AAACACTAAA 2700

TAATATTCTT CAAACGGTCC TGGTGCATAC GCAATACATA TTTATGGTGC AAAAAAAAAA 2760

ATGGAAAATT TTGCTAGTCA TAAACCCTTT CATAAAACAA TACGTAGACA TCGCTACTTG 2820

AAATTTTCAA GTTTTTATCA GATCCATGTT TCCTATCTGC CTTGACAACC TCATCGTCGA 2880

AATAGTACCA TTTAGAACGC CCAATATTCA CATTGTGTTC AAGGTCTTTA TTCACCAGTG 2940

ACGTGTAATG GCCATGATTA ATGTGCCTGT ATGGTTAACC ACTCCAAATA GCTTATATTT 3000

CATAGTGTCA TTGTTTTTCA ATATAATGTT TAGTATCAAT GGATATGTTA CGACGGTGTT 3060

ATTTTTCTTG GTCAAATCGT AATAAAATCT CGATAAATGG ATGACTAAGA TTTTTGGTAA 3120

AGTTACAAAA TTTATCGTTT TCACTGTTGT CAATTTTTTG TTCTTGTAAT CACTCGAG 3178

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 816 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATGAAACGTT TCAATGTTTT AAAATATATC AGAACAACAA AAGCAAATAT ACAAACCATC 60

GCAATGCCTT TGACCACAAA ACCTTTATCT TTGAAAATCA ACGCCGCTCT ATTCGATGTT 120

GACGGTACCA TCATCATCTC TCAACCAGCC ATTGCTGCTT TCTGGAGAGA TTTCGGTAAA 180

GACAAGCCTT ACTTCGATGC CGAACACGTT ATTCACATCT CTCACGGTTG GAGAACTTAC 240

GATGCCATTG CCAAGTTCGC TCCAGACTTT GCTGATGAAG AATACGTTAA CAAGCTAGAA 300

GGTGAAATCC CAGAAAAGTA CGGTGAACAC TCCATCGAAG TTCCAGGTGC TGTCAAGTTG 360

TGTAATGCTT TGAACGCCTT GCCAAAGGAA AAATGGGCTG TCGCCACCTC TGGTACCCGT 420

GACATGGCCA AGAAATGGTT CGACATTTTG AAGATCAAGA GACCAGAATA CTTCATCACC 480

GCCAATGATG TCAAGCAAGG TAAGCCTCAC CCAGAACCAT ACTTAAAGGG TAGAAACGGT 540

TTGGGTTTCC CAATTAATGA ACAAGACCCA TCCAAATCTA AGGTTGTTGT CTTTGAAGAC 600

GCACCAGCTG GTATTGCTGC TGGTAAGGCT GCTGGCTGTA AAATCGTTGG TATTGCTACC 660

ACTTTCGATT TGGACTTCTT GAAGGAAAAG GGTTGTGACA TCATTGTCAA GAACCACGAA 720

TCTATCAGAG TCGGTGAATA CAACGCTGAA ACCGATGAAG TCGAATTGAT CTTTGATGAC 780

TACTTATACG CTAAGGATGA CTTGTTGAAA TGGTAA 816

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 753 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPP2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGGGATTGA CTACTAAACC TCTATCTTTG AAAGTTAACG CCGCTTTGTT CGACGTCGAC 60

GGTACCATTA TCATCTCTCA ACCAGCCATT GCTGCATTCT GGAGGGATTT CGGTAAGGAC 120

AAACCTTATT TCGATGCTGA ACACGTTATC CAAGTCTCGC ATGGTTGGAG AACGTTTGAT 180

GCCATTGCTA AGTTCGCTCC AGACTTTGCC AATGAAGAGT ATGTTAACAA ATTAGAAGCT 240

GAAATTCCGG TCAAGTACGG TGAAAAATCC ATTGAAGTCC CAGGTGCAGT TAAGCTGTGC 300

AACGCTTTGA ACGCTCTACC AAAAGAGAAA TGGGCTGTGG CAACTTCCGG TACCCGTGAT 360

ATGGCACAAA AATGGTTCGA GCATCTGGGA ATCAGGAGAC CAAAGTACTT CATTACCGCT 420

AATGATGTCA AACAGGGTAA GCCTCATCCA GAACCATATC TGAAGGGCAG GAATGGCTTA 480

GGATATCCGA TCAATGAGCA AGACCCTTCC AAATCTAAGG TAGTAGTATT TGAAGACGCT 540

CCAGCAGGTA TTGCCGCCGG AAAAGCCGCC GGTTGTAAGA TCATTGGTAT TGCCACTACT 600

TTCGACTTGG ACTTCCTAAA GGAAAAAGGC TGTGACATCA TTGTCAAAAA CCACGAATCC 660

ATCAGAGTTG GCGGCTACAA TGCCGAAACA GACGAAGTTG AATTCATTTT TGACGACTAC 720

TTATATGCTA AGGACGATCT GTTGAAATGG TAA 753

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2520 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GUT1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TGTATTGGCC ACGATAACCA CCCTTTGTAT ACTGTTTTTG TTTTTCACAT GGTAAATAAC 60

GACTTTTATT AAACAACGTA TGTAAAAACA TAACAAGAAT CTACCCATAC AGGCCATTTC 120

GTAATTCTTC TCTTCTAATT GGAGTAAAAC CATCAATTAA AGGGTGTGGA GTAGCATAGT 180

GAGGGGCTGA CTGCATTGAC AAAAAAATTG AAAAAAAAAA AGGAAAAGGA AAGGAAAAAA 240

AGACAGCCAA GACTTTTAGA ACGGATAAGG TGTAATAAAA TGTGGGGGGA TGCCTGTTCT 300

CGAACCATAT AAAATATACC ATGTGGTTTG AGTTGTGGCC GGAACTATAC AAATAGTTAT 360

ATGTTTCCCT CTCTCTTCCG ACTTGTAGTA TTCTCCAAAC GTTACATATT CCGATCAAGC 420

CAGCGCCTTT ACACTAGTTT AAAACAAGAA CAGAGCCGTA TGTCCAAAAT AATGGAAGAT 480

TTACGAAGTG ACTACGTCCC GCTTATCGCC AGTATTGATG TAGGAACGAC CTCATCCAGA 540

TGCATTCTGT TCAACAGATG GGGCCAGGAC GTTTCAAAAC ACCAAATTGA ATATTCAACT 600

TCAGCATCGA AGGGCAAGAT TGGGGTGTCT GGCCTAAGGA GACCCTCTAC AGCCCCAGCT 660

CGTGAAACAC CAAACGCCGG TGACATCAAA ACCAGCGGAA AGCCCATCTT TTCTGCAGAA 720

GGCTATGCCA TTCAAGAAAC CAAATTCCTA AAAATCGAGG AATTGGACTT GGACTTCCAT 780

AACGAACCCA CGTTGAAGTT CCCCAAACCG GGTTGGGTTG AGTGCCATCC GCAGAAATTA 840

CTGGTGAACG TCGTCCAATG CCTTGCCTCA AGTTTGCTCT CTCTGCAGAC TATCAACAGC 900

GAACGTGTAG CAAACGGTCT CCCACCTTAC AAGGTAATAT GCATGGGTAT AGCAAACATG 960

AGAGAAACCA CAATTCTGTG GTCCCGCCGC ACAGGAAAAC CAATTGTTAA CTACGGTATT 1020

GTTTGGAACG ACACCAGAAC GATCAAAATC GTTAGAGACA AATGGCAAAA CACTAGCGTC 1080

GATAGGCAAC TGCAGCTTAG ACAGAAGACT GGATTGCCAT TGCTCTCCAC GTATTTCTCC 1140

TGTTCCAAGC TGCGCTGGTT CCTCGACAAT GAGCCTCTGT GTACCAAGGC GTATGAGGAG 1200

AACGACCTGA TGTTCGGCAC TGTGGACACA TGGCTGATTT ACCAATTAAC TAAACAAAAG 1260

GCGTTCGTTT CTGACGTAAC CAACGCTTCC AGAACTGGAT TTATGAACCT CTCCACTTTA 1320

AAGTACGACA ACGAGTTGCT GGAATTTTGG GGTATTGACA AGAACCTGAT TCACATGCCC 1380

GAAATTGTGT CCTCATCTCA ATACTACGGT GACTTTGGCA TTCCTGATTG GATAATGGAA 1440

AAGCTACACG ATTCGCCAAA AACAGTACTG CGAGATCTAG TCAAGAGAAA CCTGCCCATA 1500

CAGGGCTGTC TGGGCGACCA AAGCGCATCC ATGGTGGGGC AACTCGCTTA CAAACCCGGT 1560

GCTGCAAAAT GTACTTATGG TACCGGTTGC TTTTTACTGT ACAATACGGG GACCAAAAAA 1620

TTGATCTCCC AACATGGCGC ACTGACGACT CTAGCATTTT GGTTCCCACA TTTGCAAGAG 1680

TACGGTGGCC AAAAACCAGA ATTGAGCAAG CCACATTTTG CATTAGAGGG TTCCGTCGCT 1740

GTGGCTGGTG CTGTGGTCCA ATGGCTACGT GATAATTTAC GATTGATCGA TAAATCAGAG 1800

GATGTCGGAC CGATTGCATC TACGGTTCCT GATTCTGGTG GCGTAGTTTT CGTCCCCGCA 1860

TTTAGTGGCC TATTCGCTCC CTATTGGGAC CCAGATGCCA GAGCCACCAT AATGGGGATG 1920

TCTCAATTCA CTACTGCCTC CCACATCGCC AGAGCTGCCG TGGAAGGTGT TTGCTTTCAA 1980

GCCAGGGCTA TCTTGAAGGC AATGAGTTCT GACGCGTTTG GTGAAGGTTC CAAAGACAGG 2040

GACTTTTTAG AGGAAATTTC CGACGTCACA TATGAAAAGT CGCCCCTGTC GGTTCTGGCA 2100

GTGGATGGCG GGATGTCGAG GTCTAATGAA GTCATGCAAA TTCAAGCCGA TATCCTAGGT 2160

CCCTGTGTCA AAGTCAGAAG GTCTCCGACA GCGGAATGTA CCGCATTGGG GGCAGCCATT 2220

GCAGCCAATA TGGCTTTCAA GGATGTGAAC GAGCGCCCAT TATGGAAGGA CCTACACGAT 2280

GTTAAGAAAT GGGTCTTTTA CAATGGAATG GAGAAAAACG AACAAATATC ACCAGAGGCT 2340

CATCCAAACC TTAAGATATT CAGAAGTGAA TCCGACGATG CTGAAAGGAG AAAGCATTGG 2400

AAGTATTGGG AAGTTGCCGT GGAAAGATCC AAAGGTTGGC TGAAGGACAT AGAAGGTGAA 2460

CACGAACAGG TTCTAGAAAA CTTCCAATAA CAACATAAAT AATTTCTATT AACAATGTAA 2520

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 391 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPD1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
Met Ser Ala Ala Ala Asp Arg Leu Asn Leu Thr Ser Gly His Leu Asn
1               5                  10                  15

Ala Gly Arg Lys Arg Ser Ser Ser Ser Val Ser Leu Lys Ala Ala Glu
            20                  25                  30

Lys Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr Thr
        35                  40                  45

Ile Ala Lys Val Val Ala Glu Asn Cys Lys Gly Tyr Pro Glu Val Phe
    50                  55                  60

Ala Pro Ile Val Gln Met Trp Val Phe Glu Glu Glu Ile Asn Gly Glu
65                  70                  75                  80

Lys Leu Thr Glu Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr Leu
                85                  90                  95

Pro Gly Ile Thr Leu Pro Asp Asn Leu Val Ala Asn Pro Asp Leu Ile
            100                 105                 110

Asp Ser Val Lys Asp Val Asp Ile Ile Val Phe Asn Ile Pro His Gln
        115                 120                 125

Phe Leu Pro Arg Ile Cys Ser Gln Leu Lys Gly His Val Asp Ser His
    130                 135                 140

Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Val Gly Ala Lys Gly
145                 150                 155                 160

Val Gln Leu Leu Ser Ser Tyr Ile Thr Glu Glu Leu Gly Ile Gln Cys
                165                 170                 175

Gly Ala Leu Ser Gly Ala Asn Ile Ala Thr Glu Val Ala Gln Glu His
            180                 185                 190

Trp Ser Glu Thr Thr Val Ala Tyr His Ile Pro Lys Asp Phe Arg Gly
        195                 200                 205

Glu Gly Lys Asp Val Asp His Lys Val Leu Lys Ala Leu Phe His Arg
```

```
    210                 215                 220

Pro Tyr Phe His Val Ser Val Ile Glu Asp Val Ala Gly Ile Ser Ile
225                 230                 235                 240

Cys Gly Ala Leu Lys Asn Val Val Ala Leu Gly Cys Gly Phe Val Glu
                245                 250                 255

Gly Leu Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Val Gly
            260                 265                 270

Leu Gly Glu Ile Ile Arg Phe Gly Gln Met Phe Phe Pro Glu Ser Arg
        275                 280                 285

Glu Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile Thr
    290                 295                 300

Thr Cys Ala Gly Gly Arg Asn Val Lys Val Ala Arg Leu Met Ala Thr
305                 310                 315                 320

Ser Gly Lys Asp Ala Trp Glu Cys Glu Lys Glu Leu Leu Asn Gly Gln
                325                 330                 335

Ser Ala Gln Gly Leu Ile Thr Cys Lys Glu Val His Glu Trp Leu Glu
            340                 345                 350

Thr Cys Gly Ser Val Glu Asp Phe Pro Leu Phe Glu Ala Val Tyr Gln
        355                 360                 365

Ile Val Tyr Asn Asn Tyr Pro Met Lys Asn Leu Pro Asp Met Ile Glu
    370                 375                 380

Glu Leu Asp Leu His Glu Asp
385                 390
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 384 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPD2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Met Thr Ala His Thr Asn Ile Lys Gln His Lys His Cys His Glu Asp
1               5                   10                  15

His Pro Ile Arg Arg Ser Asp Ser Ala Val Ser Ile Val His Leu Lys
            20                  25                  30
```

```
Arg Ala Pro Phe Lys Val Thr Val Ile Gly Ser Gly Asn Trp Gly Thr
        35                  40                  45

Thr Ile Ala Lys Val Ile Ala Glu Asn Thr Glu Leu His Ser His Ile
    50                  55                  60

Phe Glu Pro Glu Val Arg Met Trp Val Phe Asp Glu Lys Ile Gly Asp
65                  70                  75                  80

Glu Asn Leu Thr Asp Ile Ile Asn Thr Arg His Gln Asn Val Lys Tyr
                85                  90                  95

Leu Pro Asn Ile Asp Leu Pro His Asn Leu Val Ala Asp Pro Asp Leu
            100                 105                 110

Leu His Ser Ile Lys Gly Ala Asp Ile Leu Val Phe Asn Ile Pro His
        115                 120                 125

Gln Phe Leu Pro Asn Ile Val Lys Gln Leu Gln Gly His Val Ala Pro
    130                 135                 140

His Val Arg Ala Ile Ser Cys Leu Lys Gly Phe Glu Leu Gly Ser Lys
145                 150                 155                 160

Gly Val Gln Leu Leu Ser Ser Tyr Val Thr Asp Glu Leu Gly Ile Gln
                165                 170                 175

Cys Gly Ala Leu Ser Gly Ala Asn Leu Ala Pro Glu Val Ala Lys Glu
            180                 185                 190

His Trp Ser Glu Thr Thr Val Ala Tyr Gln Leu Pro Lys Asp Tyr Gln
        195                 200                 205

Gly Asp Gly Lys Asp Val Asp His Lys Ile Leu Lys Leu Leu Phe His
    210                 215                 220

Arg Pro Tyr Phe His Val Asn Val Ile Asp Asp Val Ala Gly Ile Ser
225                 230                 235                 240

Ile Ala Gly Ala Leu Lys Asn Val Val Ala Leu Ala Cys Gly Phe Val
                245                 250                 255

Glu Gly Met Gly Trp Gly Asn Asn Ala Ser Ala Ala Ile Gln Arg Leu
            260                 265                 270

Gly Leu Gly Glu Ile Ile Lys Phe Gly Arg Met Phe Phe Pro Glu Ser
        275                 280                 285

Lys Val Glu Thr Tyr Tyr Gln Glu Ser Ala Gly Val Ala Asp Leu Ile
    290                 295                 300

Thr Thr Cys Ser Gly Gly Arg Asn Val Lys Val Ala Thr Tyr Met Ala
305                 310                 315                 320

Lys Thr Gly Lys Ser Ala Leu Glu Ala Glu Lys Glu Leu Leu Asn Gly
                325                 330                 335
```

```
Gln Ser Ala Gln Gly Ile Ile Thr Cys Arg Glu Val His Glu Trp Leu
            340                 345                 350

Gln Thr Cys Glu Leu Thr Gln Glu Phe Pro Ile Ile Arg Gly Ser Leu
        355                 360                 365

Pro Asp Ser Leu Gln Gln Arg Pro His Gly Arg Pro Thr Gly Asp Asp
    370                 375                 380
```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 614 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GUT2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
Met Thr Arg Ala Thr Trp Cys Asn Ser Pro Pro Pro Leu His Arg Gln
1               5                   10                  15

Val Ser Arg Arg Asp Leu Leu Asp Arg Leu Asp Lys Thr His Gln Phe
            20                  25                  30

Asp Val Leu Ile Ile Gly Gly Gly Ala Thr Gly Thr Gly Cys Ala Leu
        35                  40                  45

Asp Ala Ala Thr Arg Gly Leu Asn Val Ala Leu Val Glu Lys Gly Asp
    50                  55                  60

Phe Ala Ser Gly Thr Ser Ser Lys Ser Thr Lys Met Ile His Gly Gly
65                  70                  75                  80

Val Arg Tyr Leu Glu Lys Ala Phe Trp Glu Phe Ser Lys Ala Gln Leu
                85                  90                  95

Asp Leu Val Ile Glu Ala Leu Asn Glu Arg Lys His Leu Ile Asn Thr
            100                 105                 110

Ala Pro His Leu Cys Thr Val Leu Pro Ile Leu Ile Pro Ile Tyr Ser
        115                 120                 125

Thr Trp Gln Val Pro Tyr Ile Tyr Met Gly Cys Lys Phe Tyr Asp Phe
    130                 135                 140

Phe Gly Gly Ser Gln Asn Leu Lys Lys Ser Tyr Leu Leu Ser Lys Ser
145                 150                 155                 160

Ala Thr Val Glu Lys Ala Pro Met Leu Thr Thr Asp Asn Leu Lys Ala
```

```
                  165                 170                 175

Ser Leu Val Tyr His Asp Gly Ser Phe Asn Asp Ser Arg Leu Asn Ala
            180                 185                 190

Thr Leu Ala Ile Thr Gly Val Glu Asn Gly Ala Thr Val Leu Ile Tyr
        195                 200                 205

Val Glu Val Gln Lys Leu Ile Lys Asp Pro Thr Ser Gly Lys Val Ile
    210                 215                 220

Gly Ala Glu Ala Arg Asp Val Glu Thr Asn Glu Leu Val Arg Ile Asn
225                 230                 235                 240

Ala Lys Cys Val Val Asn Ala Thr Gly Pro Tyr Ser Asp Ala Ile Leu
                245                 250                 255

Gln Met Asp Arg Asn Pro Ser Gly Leu Pro Asp Ser Pro Leu Asn Asp
            260                 265                 270

Asn Ser Lys Ile Lys Ser Thr Phe Asn Gln Ile Ser Val Met Asp Pro
        275                 280                 285

Lys Met Val Ile Pro Ser Ile Gly Val His Ile Val Leu Pro Ser Phe
    290                 295                 300

Tyr Ser Pro Lys Asp Met Gly Leu Leu Asp Val Arg Thr Ser Asp Gly
305                 310                 315                 320

Arg Val Met Phe Phe Leu Pro Trp Gln Gly Lys Val Leu Ala Gly Thr
                325                 330                 335

Thr Asp Ile Pro Leu Lys Gln Val Pro Glu Asn Pro Met Pro Thr Glu
            340                 345                 350

Ala Asp Ile Gln Asp Ile Leu Lys Glu Leu Gln His Tyr Ile Glu Phe
        355                 360                 365

Pro Val Lys Arg Glu Asp Val Leu Ser Ala Trp Ala Gly Val Arg Pro
    370                 375                 380

Leu Val Arg Asp Pro Arg Thr Ile Pro Ala Asp Gly Lys Lys Gly Ser
385                 390                 395                 400

Ala Thr Gln Gly Val Val Arg Ser His Phe Leu Phe Thr Ser Asp Asn
                405                 410                 415

Gly Leu Ile Thr Ile Ala Gly Gly Lys Trp Thr Thr Tyr Arg Gln Met
            420                 425                 430

Ala Glu Glu Thr Val Asp Lys Val Val Glu Val Gly Gly Phe His Asn
        435                 440                 445

Leu Lys Pro Cys His Thr Arg Asp Ile Lys Leu Ala Gly Ala Glu Glu
    450                 455                 460
```

```
Trp Thr Gln Asn Tyr Val Ala Leu Leu Ala Gln Asn Tyr His Leu Ser
465                 470                 475                 480

Ser Lys Met Ser Asn Tyr Leu Val Gln Asn Tyr Gly Thr Arg Ser Ser
                485                 490                 495

Ile Ile Cys Glu Phe Phe Lys Glu Ser Met Glu Asn Lys Leu Pro Leu
            500                 505                 510

Ser Leu Ala Asp Lys Glu Asn Asn Val Ile Tyr Ser Ser Glu Glu Asn
        515                 520                 525

Asn Leu Val Asn Phe Asp Thr Phe Arg Tyr Pro Phe Thr Ile Gly Glu
    530                 535                 540

Leu Lys Tyr Ser Met Gln Tyr Glu Tyr Cys Arg Thr Pro Leu Asp Phe
545                 550                 555                 560

Leu Leu Arg Arg Thr Arg Phe Ala Phe Leu Asp Ala Lys Glu Ala Leu
                565                 570                 575

Asn Ala Val His Ala Thr Val Lys Val Met Gly Asp Glu Phe Asn Trp
            580                 585                 590

Ser Glu Lys Lys Arg Gln Trp Glu Leu Glu Lys Thr Val Asn Phe Ile
        595                 600                 605

Gln Gly Arg Phe Gly Val
    610
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 339 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPSA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```
Met Asn Gln Arg Asn Ala Ser Met Thr Val Ile Gly Ala Gly Ser Tyr
1               5                   10                  15

Gly Thr Ala Leu Ala Ile Thr Leu Ala Arg Asn Gly His Glu Val Val
            20                  25                  30

Leu Trp Gly His Asp Pro Glu His Ile Ala Thr Leu Glu Arg Asp Arg
        35                  40                  45

Cys Asn Ala Ala Phe Leu Pro Asp Val Pro Phe Pro Asp Thr Leu His
    50                  55                  60
```

```
Leu Glu Ser Asp Leu Ala Thr Ala Leu Ala Ala Ser Arg Asn Ile Leu
65                  70                  75                  80

Val Val Val Pro Ser His Val Phe Gly Glu Val Leu Arg Gln Ile Lys
                85                  90                  95

Pro Leu Met Arg Pro Asp Ala Arg Leu Val Trp Ala Thr Lys Gly Leu
            100                 105                 110

Glu Ala Glu Thr Gly Arg Leu Leu Gln Asp Val Ala Arg Glu Ala Leu
        115                 120                 125

Gly Asp Gln Ile Pro Leu Ala Val Ile Ser Gly Pro Thr Phe Ala Lys
    130                 135                 140

Glu Leu Ala Ala Gly Leu Pro Thr Ala Ile Ser Leu Ala Ser Thr Asp
145                 150                 155                 160

Gln Thr Phe Ala Asp Asp Leu Gln Gln Leu Leu His Cys Gly Lys Ser
                165                 170                 175

Phe Arg Val Tyr Ser Asn Pro Asp Phe Ile Gly Val Gln Leu Gly Gly
            180                 185                 190

Ala Val Lys Asn Val Ile Ala Ile Gly Ala Gly Met Ser Asp Gly Ile
        195                 200                 205

Gly Phe Gly Ala Asn Ala Arg Thr Ala Leu Ile Thr Arg Gly Leu Ala
    210                 215                 220

Glu Met Ser Arg Leu Gly Ala Ala Leu Gly Ala Asp Pro Ala Thr Phe
225                 230                 235                 240

Met Gly Met Ala Gly Leu Gly Asp Leu Val Leu Thr Cys Thr Asp Asn
                245                 250                 255

Gln Ser Arg Asn Arg Arg Phe Gly Met Met Leu Gly Gln Gly Met Asp
            260                 265                 270

Val Gln Ser Ala Gln Glu Lys Ile Gly Gln Val Val Glu Gly Tyr Arg
        275                 280                 285

Asn Thr Lys Glu Val Arg Glu Leu Ala His Arg Phe Gly Val Glu Met
    290                 295                 300

Pro Ile Thr Glu Glu Ile Tyr Gln Val Leu Tyr Cys Gly Lys Asn Ala
305                 310                 315                 320

Arg Glu Ala Ala Leu Thr Leu Leu Gly Arg Ala Arg Lys Asp Glu Arg
                325                 330                 335

Ser Ser His
```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 501 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GLPD

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```
Met Glu Thr Lys Asp Leu Ile Val Ile Gly Gly Gly Ile Asn Gly Ala
1               5                  10                  15

Gly Ile Ala Ala Asp Ala Ala Gly Arg Gly Leu Ser Val Leu Met Leu
            20                  25                  30

Glu Ala Gln Asp Leu Ala Cys Ala Thr Ser Ser Ala Ser Ser Lys Leu
        35                  40                  45

Ile His Gly Gly Leu Arg Tyr Leu Glu His Tyr Glu Phe Arg Leu Val
    50                  55                  60

Ser Glu Ala Leu Ala Glu Arg Glu Val Leu Leu Lys Met Ala Pro His
65                  70                  75                  80

Ile Ala Phe Pro Met Arg Phe Arg Leu Pro His Arg Pro His Leu Arg
                85                  90                  95

Pro Ala Trp Met Ile Arg Ile Gly Leu Phe Met Tyr Asp His Leu Gly
            100                 105                 110

Lys Arg Thr Ser Leu Pro Gly Ser Thr Gly Leu Arg Phe Gly Ala Asn
        115                 120                 125

Ser Val Leu Lys Pro Glu Ile Lys Arg Gly Phe Glu Tyr Ser Asp Cys
    130                 135                 140

Trp Val Asp Asp Ala Arg Leu Val Leu Ala Asn Ala Gln Met Val Val
145                 150                 155                 160

Arg Lys Gly Gly Glu Val Leu Thr Arg Thr Arg Ala Thr Ser Ala Arg
                165                 170                 175

Arg Glu Asn Gly Leu Trp Ile Val Glu Ala Glu Asp Ile Asp Thr Gly
            180                 185                 190

Lys Lys Tyr Ser Trp Gln Ala Arg Gly Leu Val Asn Ala Thr Gly Pro
        195                 200                 205

Trp Val Lys Gln Phe Phe Asp Asp Gly Met His Leu Pro Ser Pro Tyr
    210                 215                 220
```

```
Gly Ile Arg Leu Ile Lys Gly Ser His Ile Val Val Pro Arg Val His
225                 230                 235                 240

Thr Gln Lys Gln Ala Tyr Ile Leu Gln Asn Glu Asp Lys Arg Ile Val
                245                 250                 255

Phe Val Ile Pro Trp Met Asp Glu Phe Ser Ile Ile Gly Thr Thr Asp
            260                 265                 270

Val Glu Tyr Lys Gly Asp Pro Lys Ala Val Lys Ile Glu Glu Ser Glu
        275                 280                 285

Ile Asn Tyr Leu Leu Asn Val Tyr Asn Thr His Phe Lys Lys Gln Leu
    290                 295                 300

Ser Arg Asp Asp Ile Val Trp Thr Tyr Ser Gly Val Arg Pro Leu Cys
305                 310                 315                 320

Asp Asp Glu Ser Asp Ser Pro Gln Ala Ile Thr Arg Asp Tyr Thr Leu
                325                 330                 335

Asp Ile His Asp Glu Asn Gly Lys Ala Pro Leu Leu Ser Val Phe Gly
            340                 345                 350

Gly Lys Leu Thr Thr Tyr Arg Lys Leu Ala Glu His Ala Leu Glu Lys
        355                 360                 365

Leu Thr Pro Tyr Tyr Gln Gly Ile Gly Pro Ala Trp Thr Lys Glu Ser
    370                 375                 380

Val Leu Pro Gly Gly Ala Ile Glu Gly Asp Arg Asp Asp Tyr Ala Ala
385                 390                 395                 400

Arg Leu Arg Arg Arg Tyr Pro Phe Leu Thr Glu Ser Leu Ala Arg His
                405                 410                 415

Tyr Ala Arg Thr Tyr Gly Ser Asn Ser Glu Leu Leu Leu Gly Asn Ala
            420                 425                 430

Gly Thr Val Ser Asp Leu Gly Glu Asp Phe Gly His Glu Phe Tyr Glu
        435                 440                 445

Ala Glu Leu Lys Tyr Leu Val Asp His Glu Trp Val Arg Arg Ala Asp
    450                 455                 460

Asp Ala Leu Trp Arg Arg Thr Lys Gln Gly Met Trp Leu Asn Ala Asp
465                 470                 475                 480

Gln Gln Ser Arg Val Ser Gln Trp Leu Val Glu Tyr Thr Gln Gln Arg
                485                 490                 495

Leu Ser Leu Ala Ser
            500
```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 542 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GLPABC

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```
Met Lys Thr Arg Asp Ser Gln Ser Ser Asp Val Ile Ile Ile Gly Gly
1               5                  10                  15

Gly Ala Thr Gly Ala Gly Ile Ala Arg Asp Cys Ala Leu Arg Gly Leu
            20                  25                  30

Arg Val Ile Leu Val Glu Arg His Asp Ile Ala Thr Gly Ala Thr Gly
        35                  40                  45

Arg Asn His Gly Leu Leu His Ser Gly Ala Arg Tyr Ala Val Thr Asp
    50                  55                  60

Ala Glu Ser Ala Arg Glu Cys Ile Ser Glu Asn Gln Ile Leu Lys Arg
65                  70                  75                  80

Ile Ala Arg His Cys Val Glu Pro Thr Asn Gly Leu Phe Ile Thr Leu
                85                  90                  95

Pro Glu Asp Asp Leu Ser Phe Gln Ala Thr Phe Ile Arg Ala Cys Glu
            100                 105                 110

Glu Ala Gly Ile Ser Ala Glu Ala Ile Asp Pro Gln Gln Ala Arg Ile
        115                 120                 125

Ile Glu Pro Ala Val Asn Pro Ala Leu Ile Gly Ala Val Lys Val Pro
    130                 135                 140

Asp Gly Thr Val Asp Pro Phe Arg Leu Thr Ala Ala Asn Met Leu Asp
145                 150                 155                 160

Ala Lys Glu His Gly Ala Val Ile Leu Thr Ala His Glu Val Thr Gly
                165                 170                 175

Leu Ile Arg Glu Gly Ala Thr Val Cys Gly Val Arg Val Arg Asn His
            180                 185                 190

Leu Thr Gly Glu Thr Gln Ala Leu His Ala Pro Val Val Val Asn Ala
        195                 200                 205

Ala Gly Ile Trp Gly Gln His Ile Ala Glu Tyr Ala Asp Leu Arg Ile
    210                 215                 220

Arg Met Phe Pro Ala Lys Gly Ser Leu Leu Ile Met Asp His Arg Ile
```

```
225                 230                 235                 240

Asn Gln His Val Ile Asn Arg Cys Arg Lys Pro Ser Asp Ala Asp Ile
                245                 250                 255

Leu Val Pro Gly Asp Thr Ile Ser Leu Ile Gly Thr Thr Ser Leu Arg
            260                 265                 270

Ile Asp Tyr Asn Glu Ile Asp Asp Asn Arg Val Thr Ala Glu Glu Val
        275                 280                 285

Asp Ile Leu Leu Arg Glu Gly Glu Lys Leu Ala Pro Val Met Ala Lys
    290                 295                 300

Thr Arg Ile Leu Arg Ala Tyr Ser Gly Val Arg Pro Leu Val Ala Ser
305                 310                 315                 320

Asp Asp Asp Pro Ser Gly Arg Asn Leu Ser Arg Gly Ile Val Leu Leu
                325                 330                 335

Asp His Ala Glu Arg Asp Gly Leu Asp Gly Phe Ile Thr Ile Thr Gly
            340                 345                 350

Gly Lys Leu Met Thr Tyr Arg Leu Met Ala Glu Trp Ala Thr Asp Ala
        355                 360                 365

Val Cys Arg Lys Leu Gly Asn Thr Arg Pro Cys Thr Thr Ala Asp Leu
    370                 375                 380

Ala Leu Pro Gly Ser Gln Glu Pro Ala Glu Val Thr Leu Arg Lys Val
385                 390                 395                 400

Ile Ser Leu Pro Ala Pro Leu Arg Gly Ser Ala Val Tyr Arg His Gly
                405                 410                 415

Asp Arg Thr Pro Ala Trp Leu Ser Glu Gly Arg Leu His Arg Ser Leu
            420                 425                 430

Val Cys Glu Cys Glu Ala Val Thr Ala Gly Glu Val Gln Tyr Ala Val
        435                 440                 445

Glu Asn Leu Asn Val Asn Ser Leu Leu Asp Leu Arg Arg Arg Thr Arg
    450                 455                 460

Val Gly Met Gly Thr Cys Gln Gly Glu Leu Cys Ala Cys Arg Ala Ala
465                 470                 475                 480

Gly Leu Leu Gln Arg Phe Asn Val Thr Thr Ser Ala Gln Ser Ile Glu
                485                 490                 495

Gln Leu Ser Thr Phe Leu Asn Glu Arg Trp Lys Gly Val Gln Pro Ile
            500                 505                 510

Ala Trp Gly Asp Ala Leu Arg Glu Ser Glu Phe Thr Arg Trp Val Tyr
        515                 520                 525
```

```
Gln Gly Leu Cys Gly Leu Glu Lys Glu Gln Lys Asp Ala Leu
    530                 535                 540
```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 250 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPP2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```
Met Gly Leu Thr Thr Lys Pro Leu Ser Leu Lys Val Asn Ala Ala Leu
1               5                  10                  15

Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln Pro Ala Ile Ala Ala
            20                  25                  30

Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr Phe Asp Ala Glu His
        35                  40                  45

Val Ile Gln Val Ser His Gly Trp Arg Thr Phe Asp Ala Ile Ala Lys
    50                  55                  60

Phe Ala Pro Asp Phe Ala Asn Glu Glu Tyr Val Asn Lys Leu Glu Ala
65                  70                  75                  80

Glu Ile Pro Val Lys Tyr Gly Glu Lys Ser Ile Glu Val Pro Gly Ala
                85                  90                  95

Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro Lys Glu Lys Trp Ala
            100                 105                 110

Val Ala Thr Ser Gly Thr Arg Asp Met Ala Gln Lys Trp Phe Glu His
        115                 120                 125

Leu Gly Ile Arg Arg Pro Lys Tyr Phe Ile Thr Ala Asn Asp Val Lys
    130                 135                 140

Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys Gly Arg Asn Gly Leu
145                 150                 155                 160

Gly Tyr Pro Ile Asn Glu Gln Asp Pro Ser Lys Ser Lys Val Val Val
                165                 170                 175

Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly Lys Ala Ala Gly Cys
            180                 185                 190

Lys Ile Ile Gly Ile Ala Thr Thr Phe Asp Leu Asp Phe Leu Lys Glu
        195                 200                 205
```

```
Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu Ser Ile Arg Val Gly
    210                 215                 220

Gly Tyr Asn Ala Glu Thr Asp Glu Val Glu Phe Ile Phe Asp Asp Tyr
225                 230                 235                 240

Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
                245                 250
```

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 709 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GUT1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
Met Phe Pro Ser Leu Phe Arg Leu Val Val Phe Ser Lys Arg Tyr Ile
1               5                   10                  15

Phe Arg Ser Ser Gln Arg Leu Tyr Thr Ser Leu Lys Gln Glu Gln Ser
            20                  25                  30

Arg Met Ser Lys Ile Met Glu Asp Leu Arg Ser Asp Tyr Val Pro Leu
        35                  40                  45

Ile Ala Ser Ile Asp Val Gly Thr Thr Ser Ser Arg Cys Ile Leu Phe
    50                  55                  60

Asn Arg Trp Gly Gln Asp Val Ser Lys His Gln Ile Glu Tyr Ser Thr
65                  70                  75                  80

Ser Ala Ser Lys Gly Lys Ile Gly Val Ser Gly Leu Arg Arg Pro Ser
                85                  90                  95

Thr Ala Pro Ala Arg Glu Thr Pro Asn Ala Gly Asp Ile Lys Thr Ser
            100                 105                 110

Gly Lys Pro Ile Phe Ser Ala Glu Gly Tyr Ala Ile Gln Glu Thr Lys
        115                 120                 125

Phe Leu Lys Ile Glu Glu Leu Asp Leu Asp Phe His Asn Glu Pro Thr
    130                 135                 140

Leu Lys Phe Pro Lys Pro Gly Trp Val Glu Cys His Pro Gln Lys Leu
145                 150                 155                 160

Leu Val Asn Val Val Gln Cys Leu Ala Ser Ser Leu Leu Ser Leu Gln
```

```
                165                 170                 175

Thr Ile Asn Ser Glu Arg Val Ala Asn Gly Leu Pro Pro Tyr Lys Val
            180                 185                 190

Ile Cys Met Gly Ile Ala Asn Met Arg Glu Thr Thr Ile Leu Trp Ser
        195                 200                 205

Arg Arg Thr Gly Lys Pro Ile Val Asn Tyr Gly Ile Val Trp Asn Asp
    210                 215                 220

Thr Arg Thr Ile Lys Ile Val Arg Asp Lys Trp Gln Asn Thr Ser Val
225                 230                 235                 240

Asp Arg Gln Leu Gln Leu Arg Gln Lys Thr Gly Leu Pro Leu Leu Ser
                245                 250                 255

Thr Tyr Phe Ser Cys Ser Lys Leu Arg Trp Phe Leu Asp Asn Glu Pro
            260                 265                 270

Leu Cys Thr Lys Ala Tyr Glu Glu Asn Asp Leu Met Phe Gly Thr Val
        275                 280                 285

Asp Thr Trp Leu Ile Tyr Gln Leu Thr Lys Gln Lys Ala Phe Val Ser
    290                 295                 300

Asp Val Thr Asn Ala Ser Arg Thr Gly Phe Met Asn Leu Ser Thr Leu
305                 310                 315                 320

Lys Tyr Asp Asn Glu Leu Leu Glu Phe Trp Gly Ile Asp Lys Asn Leu
                325                 330                 335

Ile His Met Pro Glu Ile Val Ser Ser Ser Gln Tyr Tyr Gly Asp Phe
            340                 345                 350

Gly Ile Pro Asp Trp Ile Met Glu Lys Leu His Asp Ser Pro Lys Thr
        355                 360                 365

Val Leu Arg Asp Leu Val Lys Arg Asn Leu Pro Ile Gln Gly Cys Leu
    370                 375                 380

Gly Asp Gln Ser Ala Ser Met Val Gly Gln Leu Ala Tyr Lys Pro Gly
385                 390                 395                 400

Ala Ala Lys Cys Thr Tyr Gly Thr Gly Cys Phe Leu Leu Tyr Asn Thr
                405                 410                 415

Gly Thr Lys Lys Leu Ile Ser Gln His Gly Ala Leu Thr Thr Leu Ala
            420                 425                 430

Phe Trp Phe Pro His Leu Gln Glu Tyr Gly Gly Gln Lys Pro Glu Leu
        435                 440                 445

Ser Lys Pro His Phe Ala Leu Glu Gly Ser Val Ala Val Ala Gly Ala
    450                 455                 460
```

```
Val Val Gln Trp Leu Arg Asp Asn Leu Arg Leu Ile Asp Lys Ser Glu
465                 470                 475                 480

Asp Val Gly Pro Ile Ala Ser Thr Val Pro Asp Ser Gly Gly Val Val
                485                 490                 495

Phe Val Pro Ala Phe Ser Gly Leu Phe Ala Pro Tyr Trp Asp Pro Asp
            500                 505                 510

Ala Arg Ala Thr Ile Met Gly Met Ser Gln Phe Thr Thr Ala Ser His
        515                 520                 525

Ile Ala Arg Ala Ala Val Glu Gly Val Cys Phe Gln Ala Arg Ala Ile
    530                 535                 540

Leu Lys Ala Met Ser Ser Asp Ala Phe Gly Glu Gly Ser Lys Asp Arg
545                 550                 555                 560

Asp Phe Leu Glu Glu Ile Ser Asp Val Thr Tyr Glu Lys Ser Pro Leu
                565                 570                 575

Ser Val Leu Ala Val Asp Gly Gly Met Ser Arg Ser Asn Glu Val Met
            580                 585                 590

Gln Ile Gln Ala Asp Ile Leu Gly Pro Cys Val Lys Val Arg Arg Ser
        595                 600                 605

Pro Thr Ala Glu Cys Thr Ala Leu Gly Ala Ala Ile Ala Ala Asn Met
    610                 615                 620

Ala Phe Lys Asp Val Asn Glu Arg Pro Leu Trp Lys Asp Leu His Asp
625                 630                 635                 640

Val Lys Lys Trp Val Phe Tyr Asn Gly Met Glu Lys Asn Glu Gln Ile
                645                 650                 655

Ser Pro Glu Ala His Pro Asn Leu Lys Ile Phe Arg Ser Glu Ser Asp
            660                 665                 670

Asp Ala Glu Arg Arg Lys His Trp Lys Tyr Trp Glu Val Ala Val Glu
        675                 680                 685

Arg Ser Lys Gly Trp Leu Lys Asp Ile Glu Gly Glu His Glu Gln Val
    690                 695                 700

Leu Glu Asn Phe Gln
705
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12145 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: PHK28-26

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GTCGACCACC ACGGTGGTGA CTTTAATGCC GCTCTCATGC AGCAGCTCGG TGGCGGTCTC 60

AAAATTCAGG ATGTCGCCGG TATAGTTTTT GATAATCAGC AAGACGCCTT CGCCGCCGTC 120

AATTTGCATC GCGCATTCAA ACATTTTGTC CGGCGTCGGC GAGGTGAATA TTTCCCCCGG 180

ACAGGCGCCG GAGAGCATGC CCTGGCCGAT ATAGCCGCAG TGCATCGGTT CATGTCCGCT 240

GCCGCCGCCG GAGAGCAGGG CCACCTTGCC AGCCACCGGC GCGTCGGTGC GGGTCACATA 300

CAGCGGGTCC TGATGCAGGG TCAGCTGCGG ATGGGCTTTA GCCAGCCCCT GTAATTGTTC 360

ATTCAGTACA TCTTCAACAC GGTTAATCAG CTTTTTCATT ATTCAGTGCT CCGTTGGAGA 420

AGGTTCGATG CCGCCTCTCT GCTGGCGGAG GCGGTCATCG CGTAGGGGTA TCGTCTGACG 480

GTGGAGCGTG CCTGGCGATA TGATGATTCT GGCTGAGCGG ACGAAAAAAA GAATGCCCCG 540

ACGATCGGGT TTCATTACGA AACATTGCTT CCTGATTTTG TTTCTTTATG GAACGTTTTT 600

GCTGAGGATA TGGTGAAAAT GCGAGCTGGC GCGCTTTTTT TCTTCTGCCA TAAGCGGCGG 660

TCAGGATAGC CGGCGAAGCG GGTGGGAAAA AATTTTTTGC TGATTTTCTG CCGACTGCGG 720

GAGAAAAGGC GGTCAAACAC GGAGGATTGT AAGGGCATTA TGCGGCAAAG GAGCGGATCG 780

GGATCGCAAT CCTGACAGAG ACTAGGGTTT TTTGTTCCAA TATGGAACGT AAAAAATTAA 840

CCTGTGTTTC ATATCAGAAC AAAAAGGCGA AAGATTTTTT TGTTCCCTGC CGGCCCTACA 900

GTGATCGCAC TGCTCCGGTA CGCTCCGTTC AGGCCGCGCT TCACTGGCCG GCGCGGATAA 960

CGCCAGGGCT CATCATGTCT ACATGCGCAC TTATTTGAGG GTGAAAGGAA TGCTAAAAGT 1020

TATTCAATCT CCAGCCAAAT ATCTTCAGGG TCCTGATGCT GCTGTTCTGT TCGGTCAATA 1080

TGCCAAAAAC CTGGCGGAGA GCTTCTTCGT CATCGCTGAC GATTTCGTAA TGAAGCTGGC 1140

GGGAGAGAAA GTGGTGAATG GCCTGCAGAG CCACGATATT CGCTGCCATG CGGAACGGTT 1200

TAACGGCGAA TGCAGCCATG CGGAAATCAA CCGTCTGATG GCGATTTTGC AAAAACAGGG 1260

CTGCCGCGGC GTGGTCGGGA TCGGCGGTGG TAAAACCCTC GATACCGCGA AGGCGATCGG 1320

TTACTACCAG AAGCTGCCGG TGGTGGTGAT CCCGACCATC GCCTCGACCG ATGCGCCAAC 1380

CAGCGCGCTG TCGGTGATCT ACACCGAAGC GGGCGAGTTT GAAGAGTATC TGATCTATCC 1440

GAAAAACCCG GATATGGTGG TGATGGACAC GGCGATTATC GCCAAAGCGC CGGTACGCCT 1500

GCTGGTCTCC GGCATGGGCG ATGCGCTCTC CACCTGGTTC GAGGCCAAAG CTTGCTACGA 1560

TGCGCGCGCC ACCAGCATGG CCGGAGGACA GTCCACCGAG GCGGCGCTGA GCCTCGCCCG 1620

CCTGTGCTAT GATACGCTGC TGGCGGAGGG CGAAAAGGCC CGTCTGGCGG CGCAGGCCGG 1680

GGTAGTGACC GAAGCGCTGG AGCGCATCAT CGAGGCGAAC ACTTACCTCA GCGGCATTGG 1740

CTTTGAAAGC AGTGGCCTGG CCGCTGCCCA TGCAATCCAC AACGGTTTCA CCATTCTTGA 1800

AGAGTGCCAT CACCTGTATC ACGGTGAGAA AGTGGCCTTC GGTACCCTGG CGCAGCTGGT 1860

GCTGCAGAAC AGCCCGATGG ACGAGATTGA AACGGTGCAG GGCTTCTGCC AGCGCGTCGG 1920

CCTGCCGGTG ACGCTCGCGC AGATGGGCGT CAAAGAGGGG ATCGACGAGA AAATCGCCGC 1980

GGTGGCGAAA GCTACCTGCG CGGAAGGGGA AACCATCCAT AATATGCCGT TTGCGGTGAC 2040

CCCGGAGAGC GTCCATGCCG CTATCCTCAC CGCCGATCTG TTAGGCCAGC AGTGGCTGGC 2100

GCGTTAATTC GCGGTGGCTA AACCGCTGGC CCAGGTCAGC GGTTTTTCTT TCTCCCCTCC 2160

GGCAGTCGCT GCCGGAGGGG TTCTCTATGG TACAACGCGG AAAAGGATAT GACTGTTCAG 2220

ACTCAGGATA CCGGGAAGGC GGTCTCTTCC GTCATTGCCC AGTCATGGCA CCGCTGCAGC 2280

AAGTTTATGC AGCGCGAAAC CTGGCAAACG CCGCACCAGG CCCAGGGCCT GACCTTCGAC 2340

TCCATCTGTC GGCGTAAAAC CGCGCTGCTC ACCATCGGCC AGGCGGCGCT GGAAGACGCC 2400

TGGGAGTTTA TGGACGGCCG CCCCTGCGCG CTGTTTATTC TTGATGAGTC CGCCTGCATC 2460

CTGAGCCGTT GCGGCGAGCC GCAAACCCTG GCCCAGCTGG CTGCCCTGGG ATTTCGCGAC 2520

GGCAGCTATT GTGCGGAGAG CATTATCGGC ACCTGCGCGC TGTCGCTGGC CGCGATGCAG 2580

GGCCAGCCGA TCAACACCGC CGGCGATCGG CATTTTAAGC AGGCGCTACA GCCATGGAGT 2640

TTTTGCTCGA CGCCGGTGTT TGATAACCAC GGGCGGCTGT TCGGCTCTAT CTCGCTTTGC 2700

TGTCTGGTCG AGCACCAGTC CAGCGCCGAC CTCTCCCTGA CGCTGGCCAT CGCCCGCGAG 2760

GTGGGTAACT CCCTGCTTAC CGACAGCCTG CTGGCGGAAT CCAACCGTCA CCTCAATCAG 2820

ATGTACGGCC TGCTGGAGAG CATGGACGAT GGGGTGATGG CGTGGAACGA ACAGGGCGTG 2880

CTGCAGTTTC TCAATGTTCA GGCGGCGAGA CTGCTGCATC TTGATGCTCA GGCCAGCCAG 2940

GGGAAAAATA TCGCCGATCT GGTGACCCTC CCGGCGCTGC TGCGCCGCGC CATCAAACAC 3000

GCCCGCGGCC TGAATCACGT CGAAGTCACC TTTGAAAGTC AGCATCAGTT TGTCGATGCG 3060

GTGATCACCT TAAAACCGAT TGTCGAGGCG CAAGGCAACA GTTTTATTCT GCTGCTGCAT 3120

CCGGTGGAGC AGATGCGGCA GCTGATGACC AGCCAGCTCG GTAAAGTCAG CCACACCTTT 3180

GAGCAGATGT CTGCCGACGA TCCGGAAACC CGACGCCTGA TCCACTTTGG CCGCCAGGCG 3240

GCGCGCGGCG GCTTCCCGGT GCTACTGTGC GGCGAAGAGG GGGTCGGGAA AGAGCTGCTG 3300

AGCCAGGCTA TTCACAATGA AAGCGAACGG GCGGGCGGCC CCTACATCTC CGTCAACTGC 3360

CAGCTATATG CCGACAGCGT GCTGGGCCAG GACTTTATGG GCAGCGCCCC TACCGACGAT 3420

GAAAATGGTC GCCTGAGCCG CCTTGAGCTG GCCAACGGCG GCACCCTGTT TCTGGAAAAG 3480

ATCGAGTATC TGGCGCCGGA GCTGCAGTCG GCTCTGCTGC AGGTGATTAA GCAGGGCGTG 3540

CTCACCCGCC TCGACGCCCG GCGCCTGATC CCGGTGGATG TGAAGGTGAT TGCCACCACC 3600

ACCGTCGATC TGGCCAATCT GGTGGAACAG AACCGCTTTA GCCGCCAGCT GTACTATGCG 3660

CTGCACTCCT TTGAGATCGT CATCCCGCCG CTGCGCGCCC GACGCAACAG TATTCCGTCG 3720

CTGGTGCATA ACCGGTTGAA GAGCCTGGAG AAGCGTTTCT CTTCGCGACT GAAAGTGGAC 3780

GATGACGCGC TGGCACAGCT GGTGGCCTAC TCGTGGCCGG GGAATGATTT TGAGCTCAAC 3840

AGCGTCATTG AGAATATCGC CATCAGCAGC GACAACGGCC ACATTCGCCT GAGTAATCTG 3900

CCGGAATATC TCTTTTCCGA GCGGCCGGGC GGGGATAGCG CGTCATCGCT GCTGCCGGCC 3960

AGCCTGACTT TTAGCGCCAT CGAAAAGGAA GCTATTATTC ACGCCGCCCG GGTGACCAGC 4020

GGGCGGGTGC AGGAGATGTC GCAGCTGCTC AATATCGGCC GCACCACCCT GTGGCGCAAA 4080

ATGAAGCAGT ACGATATTGA CGCCAGCCAG TTCAAGCGCA AGCATCAGGC CTAGTCTCTT 4140

CGATTCGCGC CATGGAGAAC AGGGCATCCG ACAGGCGATT GCTGTAGCGT TTGAGCGCGT 4200

CGCGCAGCGG ATGCGCGCGG TCCATGGCCG TCAGCAGGCG TTCGAGCCGA CGGGACTGGG 4260

TGCGCGCCAC GTGCAGCTGG GCAGAGGCGA GATTCCTCCC CGGGATCACG AACTGTTTTA 4320

ACGGGCCGCT CTCGGCCATA TTGCGGTCGA TAAGCCGCTC CAGGGCGGTG ATCTCCTCTT 4380

CGCCGATCGT CTGGCTCAGG CGGGTCAGGC CCCGCGCATC GCTGGCCAGT TCAGCCCCCA 4440

GCACGAACAG CGTCTGCTGA ATATGGTGCA GGCTTTCCCG CAGCCCGGCG TCGCGGGTCG 4500

TGGCGTAGCA GACGCCCAGC TGGGATATCA GTTCATCGAC GGTGCCGTAG GCCTCGACGC 4560

GAATATGGTC TTTCTCGATG CGGCTGCCGC CGTACAGGGC GGTGGTGCCT TTATCCCCGG 4620

TGCGGGTATA GATACGATAC ATTCAGTTTC TCTCACTTAA CGGCAGGACT TTAACCAGCT 4680

GCCCGGCGTT GGCGCCGAGC GTACGCAGTT GATCGTCGCT ATCGGTGACG TGTCCGGTAG 4740

CCAGCGGCGC GTCCGCCGGC AGCTGGGCAT GAGTGAGGGC TATCTCGCCG GACGCGCTGA 4800

GCCCGATACC CACCCGCAGG GGCGAGCTTC TGGCCGCCAG GGCGCCCAGC GCAGCGGCGT 4860

CACCGCCTCC GTCATAGGTT ATGGTCTGGC AGGGGACCCC CTGCTCCTCC AGCCCCCAGC 4920

ACAGCTCATT GATGGCGCCG GCATGGTGCC CGCGCGGATC GTAAAACAGG CGTACGCCTG 4980

GCGGTGAAAG CGACATGACG GTCCCCTCGT TAACACTCAG AATGCCTGGC GGAAAATCGC 5040

GGCAATCTCC TGCTCGTTGC CTTTACGCGG GTTCGAGAAC GCATTGCCGT CTTTTAGAGC 5100

CATCTCCGCC ATGTAGGGGA AGTCGGCCTC TTTTACCCCC AGATCGCGCA GATGCTGCGG 5160

AATACCGATA TCCATCGACA GACGCGTGAT AGCGGCGATG GCTTTTTCCG CCGCGTCGAG 5220

AGTGGACAGT CCGGTGATAT TTTCGCCCAT CAGTTCAGCG ATATCGGCGA ATTTCTCCGG 5280

GTTGGCGATC AGGTTGTAGC GCGCCACATG CGGCAGCAGG ACAGCGTTGG CCACGCCGTG 5340

CGGCATGTCG TACAGGCCGC CCAGCTGGTG CGCCATGGCG TGCACGTAGC CGAGGTTGGC 5400

GTTATTGAAA GCCATCCCGG CCAGCAGAGA AGCATAGGCC ATGTTTTCCC GCGCCTGCAG 5460

ATTGCTGCCG AGGGCCACGG CCTGGCGCAG GTTGCGGGCG ATGAGGCGGA TCGCCTGCAT 5520

GGCGGCGGCG TCCGTCACCG GGTTAGCGTC TTTGGAGATA TAGGCCTCTA CGGCGTGGGT 5580

CAGGGCATCC ATCCCGGTCG CCGCGGTCAG GGCGGCCGGT TTACCGATCA TCAGCAGTGG 5640

ATCGTTGATA GAGACCGACG GCAGTTTGCG CCAGCTGACG ATCACAAACT TCACTTTGGT 5700

TTCGGTGTTG GTCAGGACGC AGTGGCGGGT GACCTCGCTG GCGGTGCCGG CGGTGGTATT 5760

GACCGCGACG ATAGGCGGCA GCGGGTTGGT CAGGGTCTCG ATTCCGGCAT ACTGGTACAG 5820

ATCGCCCTCA TGGGTGGCGG CGATGCCGAT GCCTTTGCCG CAATCGTGCG GGCTGCCGCC 5880

GCCCACGGTG ACGATGATGT CGCACTGTTC GCGGCGAAAC ACGGCGAGGC CGTCGCGCAC 5940

GTTGGTGTCT TTCGGGTTCG GCTCGACGCC GTCAAAGATC GCCACCTCGA TCCCGGCCTC 6000

CCGCAGATAA TGCAGGGTTT TGTCCACCGC GCCATCTTTA ATTGCCCGCA GGCCTTTGTC 6060

GGTGACCAGC AGGGCTTTTT TCCCCCCCAG CAGCTGGCAG CGTTCGCCGA CTACGGAAAT 6120

GGCGTTGGGG CCAAAAAAGT TAACGTTTGG CACCAGATAA TCAAACATAC GATAGCTCAT 6180

AATATACCTT CTCGCTTCAG GTTATAATGC GGAAAAACAA TCCAGGGCGC ACTGGGCTAA 6240

TAATTGATCC TGCTCGACCG TACCGCCGCT AACGCCGACG GCGCCAATTA CCTGCTCATT 6300

AAAAATAACT GGCAGGCCGC CGCCAAAAAT AATAATTCGC TGTTGGTTGG TTAGCTGCAG 6360

ACCGTACAGA GATTGTCCTG GCTGGACCGC TGACGTAATT TCATGGGTAC CTTGCTTCAG 6420

GCTGCAGGCG CTCCAGGCTT TATTCAGGGA AATATCGCAG CTGGAGACGA AGGCCTCGTC 6480

CATCCGCTGG ATAAGCAGCG TGTTGCCTCC GCGGTCAACT ACGGAAAACA CCACCGCCAC 6540

GTTGATCTCA GTGGCTTTTT TTTCCACCGC CGCCGCCATT TGCTGGGCGG CGGCCAGGGT 6600

GATTGTCTGA ACTTGTTGGC TCTTGTTCAT CATTCTCTCC CGCACCAGGA TAACGCTGGC 6660

GCGAATAGTC AGTAGGGGGC GATAGTAAAA AACTATTACC ATTCGGTTGG CTTGCTTTAT 6720

TTTTGTCAGC GTTATTTTGT CGCCCGCCAT GATTTAGTCA ATAGGGTTAA AATAGCGTCG 6780

GAAAAACGTA ATTAAGGGCG TTTTTTATTA ATTGATTTAT ATCATTGCGG GCGATCACAT 6840

TTTTTATTTT TGCCGCCGGA GTAAAGTTTC ATAGTGAAAC TGTCGGTAGA TTTCGTGTGC 6900

CAAATTGAAA CGAAATTAAA TTTATTTTTT TCACCACTGG CTCATTTAAA GTTCCGCTAT 6960

TGCCGGTAAT GGCCGGGCGG CAACGACGCT GGCCCGGCGT ATTCGCTACC GTCTGCGGAT 7020

TTCACCTTTT GAGCCGATGA ACAATGAAAA GATCAAAACG ATTTGCAGTA CTGGCCCAGC 7080

GCCCCGTCAA TCAGGACGGG CTGATTGGCG AGTGGCCTGA AGAGGGGCTG ATCGCCATGG 7140

ACAGCCCCTT TGACCCGGTC TCTTCAGTAA AAGTGGACAA CGGTCTGATC GTCGAACTGG 7200

ACGGCAAACG CCGGGACCAG TTTGACATGA TCGACCGATT TATCGCCGAT TACGCGATCA 7260

ACGTTGAGCG CACAGAGCAG GCAATGCGCC TGGAGGCGGT GGAAATAGCC CGTATGCTGG 7320

TGGATATTCA CGTCAGCCGG GAGGAGATCA TTGCCATCAC TACCGCCATC ACGCCGGCCA 7380

AAGCGGTCGA GGTGATGGCG CAGATGAACG TGGTGGAGAT GATGATGGCG CTGCAGAAGA 7440

TGCGTGCCCG CCGGACCCCC TCCAACCAGT GCCACGTCAC CAATCTCAAA GATAATCCGG 7500

TGCAGATTGC CGCTGACGCC GCCGAGGCCG GGATCCGCGG CTTCTCAGAA CAGGAGACCA 7560

CGGTCGGTAT CGCGCGCTAC GCGCCGTTTA ACGCCCTGGC GCTGTTGGTC GGTTCGCAGT 7620

GCGGCCGCCC CGGCGTGTTG ACGCAGTGCT CGGTGGAAGA GGCCACCGAG CTGGAGCTGG 7680

GCATGCGTGG CTTAACCAGC TACGCCGAGA CGGTGTCGGT CTACGGCACC GAAGCGGTAT 7740

TTACCGACGG CGATGATACG CCGTGGTCAA AGGCGTTCCT CGCCTCGGCC TACGCCTCCC 7800

GCGGGTTGAA AATGCGCTAC ACCTCCGGCA CCGGATCCGA AGCGCTGATG GGCTATTCGG 7860

AGAGCAAGTC GATGCTCTAC CTCGAATCGC GCTGCATCTT CATTACTAAA GGCGCCGGGG 7920

TTCAGGGACT GCAAAACGGC GCGGTGAGCT GTATCGGCAT GACCGGCGCT GTGCCGTCGG 7980

GCATTCGGGC GGTGCTGGCG GAAAACCTGA TCGCCTCTAT GCTCGACCTC GAAGTGGCGT 8040

CCGCCAACGA CCAGACTTTC TCCCACTCGG ATATTCGCCG CACCGCGCGC ACCCTGATGC 8100

AGATGCTGCC GGGCACCGAC TTTATTTTCT CCGGCTACAG CGCGGTGCCG AACTACGACA 8160

ACATGTTCGC CGGCTCGAAC TTCGATGCGG AAGATTTTGA TGATTACAAC ATCCTGCAGC 8220

GTGACCTGAT GGTTGACGGC GGCCTGCGTC CGGTGACCGA GGCGGAAACC ATTGCCATTC 8280

GCCAGAAAGC GGCGCGGGCG ATCCAGGCGG TTTTCCGCGA GCTGGGGCTG CCGCCAATCG 8340

CCGACGAGGA GGTGGAGGCC GCCACCTACG CGCACGGCAG CAACGAGATG CCGCCGCGTA 8400

ACGTGGTGGA GGATCTGAGT GCGGTGGAAG AGATGATGAA GCGCAACATC ACCGGCCTCG 8460

ATATTGTCGG CGCGCTGAGC CGCAGCGGCT TTGAGGATAT CGCCAGCAAT ATTCTCAATA 8520

TGCTGCGCCA GCGGGTCACC GGCGATTACC TGCAGACCTC GGCCATTCTC GATCGGCAGT 8580

TCGAGGTGGT GAGTGCGGTC AACGACATCA ATGACTATCA GGGGCCGGGC ACCGGCTATC 8640

GCATCTCTGC CGAACGCTGG GCGGAGATCA AAAATATTCC GGGCGTGGTT CAGCCCGACA 8700

CCATTGAATA AGGCGGTATT CCTGTGCAAC AGACAACCCA AATTCAGCCC TCTTTTACCC 8760

TGAAAACCCG CGAGGGCGGG GTAGCTTCTG CCGATGAACG CGCCGATGAA GTGGTGATCG 8820

GCGTCGGCCC TGCCTTCGAT AAACACCAGC ATCACACTCT GATCGATATG CCCCATGGCG 8880

CGATCCTCAA AGAGCTGATT GCCGGGGTGG AAGAAGAGGG GCTTCACGCC CGGGTGGTGC 8940

GCATTCTGCG CACGTCCGAC GTCTCCTTTA TGGCCTGGGA TGCGGCCAAC CTGAGCGGCT 9000

CGGGGATCGG CATCGGTATC CAGTCGAAGG GGACCACGGT CATCCATCAG CGCGATCTGC 9060

TGCCGCTCAG CAACCTGGAG CTGTTCTCCC AGGCGCCGCT GCTGACGCTG GAGACCTACC 9120

GGCAGATTGG CAAAAACGCT GCGCGCTATG CGCGCAAAGA GTCACCTTCG CCGGTGCCGG 9180

TGGTGAACGA TCAGATGGTG CGGCCGAAAT TTATGGCCAA AGCCGCGCTA TTTCATATCA 9240

AAGAGACCAA ACATGTGGTG CAGGACGCCG AGCCCGTCAC CCTGCACATC GACTTAGTAA 9300

GGGAGTGACC ATGAGCGAGA AAACCATGCG CGTGCAGGAT TATCCGTTAG CCACCCGCTG 9360

CCCGGAGCAT ATCCTGACGC CTACCGGCAA ACCATTGACC GATATTACCC TCGAGAAGGT 9420

GCTCTCTGGC GAGGTGGGCC CGCAGGATGT GCGGATCTCC CGCCAGACCC TTGAGTACCA 9480

GGCGCAGATT GCCGAGCAGA TGCAGCGCCA TGCGGTGGCG CGCAATTTCC GCCGCGCGGC 9540

GGAGCTTATC GCCATTCCTG ACGAGCGCAT TCTGGCTATC TATAACGCGC TGCGCCCGTT 9600

CCGCTCCTCG CAGGCGGAGC TGCTGGCGAT CGCCGACGAG CTGGAGCACA CCTGGCATGC 9660

GACAGTGAAT GCCGCCTTTG TCCGGGAGTC GGCGGAAGTG TATCAGCAGC GGCATAAGCT 9720

GCGTAAAGGA AGCTAAGCGG AGGTCAGCAT GCCGTTAATA GCCGGGATTG ATATCGGCAA 9780

CGCCACCACC GAGGTGGCGC TGGCGTCCGA CTACCCGCAG GCGAGGGCGT TTGTTGCCAG 9840

CGGGATCGTC GCGACGACGG GCATGAAAGG GACGCGGGAC AATATCGCCG GGACCCTCGC 9900

CGCGCTGGAG CAGGCCCTGG CGAAAACACC GTGGTCGATG AGCGATGTCT CTCGCATCTA 9960

TCTTAACGAA GCCGCGCCGG TGATTGGCGA TGTGGCGATG GAGACCATCA CCGAGACCAT 10020

TATCACCGAA TCGACCATGA TCGGTCATAA CCCGCAGACG CCGGGCGGGG TGGGCGTTGG 10080

CGTGGGGACG ACTATCGCCC TCGGGCGGCT GGCGACGCTG CCGGCGGCGC AGTATGCCGA 10140

GGGGTGGATC GTACTGATTG ACGACGCCGT CGATTTCCTT GACGCCGTGT GGTGGCTCAA 10200

TGAGGCGCTC GACCGGGGGA TCAACGTGGT GGCGGCGATC CTCAAAAAGG ACGACGGCGT 10260

GCTGGTGAAC AACCGCCTGC GTAAAACCCT GCCGGTGGTG GATGAAGTGA CGCTGCTGGA 10320

GCAGGTCCCC GAGGGGGTAA TGGCGGCGGT GGAAGTGGCC GCGCCGGGCC AGGTGGTGCG 10380

GATCCTGTCG AATCCCTACG GGATCGCCAC CTTCTTCGGG CTAAGCCCGG AAGAGACCCA 10440

GGCCATCGTC CCCATCGCCC GCGCCCTGAT TGGCAACCGT TCCGCGGTGG TGCTCAAGAC 10500

CCCGCAGGGG GATGTGCAGT CGCGGGTGAT CCCGGCGGGC AACCTCTACA TTAGCGGCGA 10560

AAAGCGCCGC GGAGAGGCCG ATGTCGCCGA GGGCGCGGAA GCCATCATGC AGGCGATGAG 10620

CGCCTGCGCT CCGGTACGCG ACATCCGCGG CGAACCGGGC ACCCACGCCG GCGGCATGCT 10680

TGAGCGGGTG CGCAAGGTAA TGGCGTCCCT GACCGGCCAT GAGATGAGCG CGATATACAT 10740

CCAGGATCTG CTGGCGGTGG ATACGTTTAT TCCGCGCAAG GTGCAGGGCG GGATGGCCGG 10800

CGAGTGCGCC ATGGAGAATG CCGTCGGGAT GGCGGCGATG GTGAAAGCGG ATCGTCTGCA 10860

AATGCAGGTT ATCGCCCGCG AACTGAGCGC CCGACTGCAG ACCGAGGTGG TGGTGGGCGG 10920

CGTGGAGGCC AACATGGCCA TCGCCGGGGC GTTAACCACT CCCGGCTGTG CGGCGCCGCT 10980

GGCGATCCTC GACCTCGGCG CCGGCTCGAC GGATGCGGCG ATCGTCAACG CGGAGGGGCA 11040

GATAACGGCG GTCCATCTCG CCGGGGCGGG GAATATGGTC AGCCTGTTGA TTAAAACCGA 11100

GCTGGGCCTC GAGGATCTTT CGCTGGCGGA AGCGATAAAA AAATACCCGC TGGCCAAAGT 11160

GGAAAGCCTG TTCAGTATTC GTCACGAGAA TGGCGCGGTG GAGTTCTTTC GGGAAGCCCT 11220

CAGCCCGGCG GTGTTCGCCA AAGTGGTGTA CATCAAGGAG GGCGAACTGG TGCCGATCGA 11280

TAACGCCAGC CCGCTGGAAA AAATTCGTCT CGTGCGCCGG CAGGCGAAAG AGAAAGTGTT 11340

TGTCACCAAC TGCCTGCGCG CGCTGCGCCA GGTCTCACCC GGCGGTTCCA TTCGCGATAT 11400

CGCCTTTGTG GTGCTGGTGG GCGGCTCATC GCTGGACTTT GAGATCCCGC AGCTTATCAC 11460

GGAAGCCTTG TCGCACTATG GCGTGGTCGC CGGGCAGGGC AATATTCGGG GAACAGAAGG 11520

GCCGCGCAAT GCGGTCGCCA CCGGGCTGCT ACTGGCCGGT CAGGCGAATT AAACGGGCGC 11580

TCGCGCCAGC CTCTCTCTTT AACGTGCTAT TTCAGGATGC CGATAATGAA CCAGACTTCT 11640

ACCTTAACCG GGCAGTGCGT GGCCGAGTTT CTTGGCACCG GATTGCTCAT TTTCTTCGGC 11700

GCGGGCTGCG TCGCTGCGCT GCGGGTCGCC GGGGCCAGCT TTGGTCAGTG GGAGATCAGT 11760

ATTATCTGGG GCCTTGGCGT CGCCATGGCC ATCTACCTGA CGGCCGGTGT CTCCGGCGCG 11820

CACCTAAATC CGGCGGTGAC CATTGCCCTG TGGCTGTTCG CCTGTTTTGA ACGCCGCAAG 11880

GTGCTGCCGT TTATTGTTGC CCAGACGGCC GGGGCCTTCT GCGCCGCCGC GCTGGTGTAT 11940

GGGCTCTATC GCCAGCTGTT TCTCGATCTT GAACAGAGTC AGCATATCGT GCGCGGCACT 12000

GCCGCCAGTC TTAACCTGGC CGGGGTCTTT TCCACGTACC CGCATCCACA TATCACTTTT 12060

ATACAAGCGT TTGCCGTGGA GACCACCATC ACGGCAATCC TGATGGCGAT GATCATGGCC 12120

CTGACCGACG ACGGCAACGG AATTC 12145

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGCTTAGGAG TCTAGAATAT TGAGCTCGAA TTCCCGGGCA TGCGGTACCG GATCCAGAAA 60

AAAGCCCGCA CCTGACAGTG CGGGCTTTTT TTTT 94

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GGAATTCAGA TCTCAGCAAT GAGCGAGAAA ACCATGC 37

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCTCTAGATT AGCTTCCTTT ACGCAGC 27

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGCCAAGCTT AAGGAGGTTA ATTAAATGAA AAG 33

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GCTCTAGATT ATTCAATGGT GTCGGG 26

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCGCCGTCTA GAATTATGAG CTATCGTATG TTTGATTATC TG 42

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TCTGATACGG GATCCTCAGA ATGCCTGGCG GAAAAT 36

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GCGCGGATCC AGGAGTCTAG AATTATGGGA TTGACTACTA AACCTCTATC T 51

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GATACGCCCG GGTTACCATT TCAACAGATC GTCCTT 36

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TCGACGAATT CAGGAGGA 18

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CTAGTCCTCC TGAATTCG 18

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CTAGTAAGGA GGACAATTC 19

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CATGGAATTG TCCTCCTTA 19

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 271 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: GPP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Lys Arg Phe Asn Val Leu Lys Tyr Ile Arg Thr Thr Lys Ala Asn
1 5 10 15

Ile Gln Thr Ile Ala Met Pro Leu Thr Thr Lys Pro Leu Ser Leu Lys

```
            20                  25                  30

Ile Asn Ala Ala Leu Phe Asp Val Asp Gly Thr Ile Ile Ile Ser Gln
        35                  40                  45

Pro Ala Ile Ala Ala Phe Trp Arg Asp Phe Gly Lys Asp Lys Pro Tyr
    50                  55                  60

Phe Asp Ala Glu His Val Ile His Ile Ser His Gly Trp Arg Thr Tyr
65                  70                  75                  80

Asp Ala Ile Ala Lys Phe Ala Pro Asp Phe Ala Asp Glu Glu Tyr Val
                85                  90                  95

Asn Lys Leu Glu Gly Glu Ile Pro Glu Lys Tyr Gly Glu His Ser Ile
            100                 105                 110

Glu Val Pro Gly Ala Val Lys Leu Cys Asn Ala Leu Asn Ala Leu Pro
        115                 120                 125

Lys Glu Lys Trp Ala Val Ala Thr Ser Gly Thr Arg Asp Met Ala Lys
    130                 135                 140

Lys Trp Phe Asp Ile Leu Lys Ile Lys Arg Pro Glu Tyr Phe Ile Thr
145                 150                 155                 160

Ala Asn Asp Val Lys Gln Gly Lys Pro His Pro Glu Pro Tyr Leu Lys
                165                 170                 175

Gly Arg Asn Gly Leu Gly Phe Pro Ile Asn Glu Gln Asp Pro Ser Lys
            180                 185                 190

Ser Lys Val Val Val Phe Glu Asp Ala Pro Ala Gly Ile Ala Ala Gly
        195                 200                 205

Lys Ala Ala Gly Cys Lys Ile Val Gly Ile Ala Thr Thr Phe Asp Leu
    210                 215                 220

Asp Phe Leu Lys Glu Lys Gly Cys Asp Ile Ile Val Lys Asn His Glu
225                 230                 235                 240

Ser Ile Arg Val Gly Glu Tyr Asn Ala Glu Thr Asp Glu Val Glu Leu
                245                 250                 255

Ile Phe Asp Asp Tyr Leu Tyr Ala Lys Asp Asp Leu Leu Lys Trp
            260                 265                 270
```

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 555 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```
Met Lys Arg Ser Lys Arg Phe Ala Val Leu Ala Gln Arg Pro Val Asn
1               5                  10                  15

Gln Asp Gly Leu Ile Gly Glu Trp Pro Glu Glu Gly Leu Ile Ala Met
            20                  25                  30

Asp Ser Pro Phe Asp Pro Val Ser Ser Val Lys Val Asp Asn Gly Leu
        35                  40                  45

Ile Val Glu Leu Asp Gly Lys Arg Arg Asp Gln Phe Asp Met Ile Asp
    50                  55                  60

Arg Phe Ile Ala Asp Tyr Ala Ile Asn Val Glu Arg Thr Glu Gln Ala
65                  70                  75                  80

Met Arg Leu Glu Ala Val Glu Ile Ala Arg Met Leu Val Asp Ile His
                85                  90                  95

Val Ser Arg Glu Glu Ile Ile Ala Ile Thr Thr Ala Ile Thr Pro Ala
            100                 105                 110

Lys Ala Val Glu Val Met Ala Gln Met Asn Val Val Glu Met Met Met
        115                 120                 125

Ala Leu Gln Lys Met Arg Ala Arg Arg Thr Pro Ser Asn Gln Cys His
    130                 135                 140

Val Thr Asn Leu Lys Asp Asn Pro Val Gln Ile Ala Ala Asp Ala Ala
145                 150                 155                 160

Glu Ala Gly Ile Arg Gly Phe Ser Glu Gln Glu Thr Thr Val Gly Ile
                165                 170                 175

Ala Arg Tyr Ala Pro Phe Asn Ala Leu Ala Leu Leu Val Gly Ser Gln
            180                 185                 190

Cys Gly Arg Pro Gly Val Leu Thr Gln Cys Ser Val Glu Glu Ala Thr
        195                 200                 205

Glu Leu Glu Leu Gly Met Arg Gly Leu Thr Ser Tyr Ala Glu Thr Val
    210                 215                 220

Ser Val Tyr Gly Thr Glu Ala Val Phe Thr Asp Gly Asp Asp Thr Pro
225                 230                 235                 240

Trp Ser Lys Ala Phe Leu Ala Ser Ala Tyr Ala Ser Arg Gly Leu Lys
                245                 250                 255

Met Arg Tyr Thr Ser Gly Thr Gly Ser Glu Ala Leu Met Gly Tyr Ser
            260                 265                 270
```

```
Glu Ser Lys Ser Met Leu Tyr Leu Glu Ser Arg Cys Ile Phe Ile Thr
        275                 280                 285

Lys Gly Ala Gly Val Gln Gly Leu Gln Asn Gly Ala Val Ser Cys Ile
    290                 295                 300

Gly Met Thr Gly Ala Val Pro Ser Gly Ile Arg Ala Val Leu Ala Glu
305                 310                 315                 320

Asn Leu Ile Ala Ser Met Leu Asp Leu Glu Val Ala Ser Ala Asn Asp
                325                 330                 335

Gln Thr Phe Ser His Ser Asp Ile Arg Arg Thr Ala Arg Thr Leu Met
            340                 345                 350

Gln Met Leu Pro Gly Thr Asp Phe Ile Phe Ser Gly Tyr Ser Ala Val
        355                 360                 365

Pro Asn Tyr Asp Asn Met Phe Ala Gly Ser Asn Phe Asp Ala Glu Asp
    370                 375                 380

Phe Asp Asp Tyr Asn Ile Leu Gln Arg Asp Leu Met Val Asp Gly Gly
385                 390                 395                 400

Leu Arg Pro Val Thr Glu Ala Glu Thr Ile Ala Ile Arg Gln Lys Ala
                405                 410                 415

Ala Arg Ala Ile Gln Ala Val Phe Arg Glu Leu Gly Leu Pro Pro Ile
            420                 425                 430

Ala Asp Glu Glu Val Glu Ala Ala Thr Tyr Ala His Gly Ser Asn Glu
        435                 440                 445

Met Pro Pro Arg Asn Val Val Glu Asp Leu Ser Ala Val Glu Glu Met
    450                 455                 460

Met Lys Arg Asn Ile Thr Gly Leu Asp Ile Val Gly Ala Leu Ser Arg
465                 470                 475                 480

Ser Gly Phe Glu Asp Ile Ala Ser Asn Ile Leu Asn Met Leu Arg Gln
                485                 490                 495

Arg Val Thr Gly Asp Tyr Leu Gln Thr Ser Ala Ile Leu Asp Arg Gln
            500                 505                 510

Phe Glu Val Val Ser Ala Val Asn Asp Ile Asn Asp Tyr Gln Gly Pro
        515                 520                 525

Gly Thr Gly Tyr Arg Ile Ser Ala Glu Arg Trp Ala Glu Ile Lys Asn
    530                 535                 540

Ile Pro Gly Val Val Gln Pro Asp Thr Ile Glu
545                 550                 555
```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 194 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```
Met Gln Gln Thr Thr Gln Ile Gln Pro Ser Phe Thr Leu Lys Thr Arg
1               5                  10                  15

Glu Gly Gly Val Ala Ser Ala Asp Glu Arg Ala Asp Glu Val Val Ile
            20                  25                  30

Gly Val Gly Pro Ala Phe Asp Lys His Gln His His Thr Leu Ile Asp
        35                  40                  45

Met Pro His Gly Ala Ile Leu Lys Glu Leu Ile Ala Gly Val Glu Glu
    50                  55                  60

Glu Gly Leu His Ala Arg Val Val Arg Ile Leu Arg Thr Ser Asp Val
65                  70                  75                  80

Ser Phe Met Ala Trp Asp Ala Ala Asn Leu Ser Gly Ser Gly Ile Gly
                85                  90                  95

Ile Gly Ile Gln Ser Lys Gly Thr Thr Val Ile His Gln Arg Asp Leu
            100                 105                 110

Leu Pro Leu Ser Asn Leu Glu Leu Phe Ser Gln Ala Pro Leu Leu Thr
        115                 120                 125

Leu Glu Thr Tyr Arg Gln Ile Gly Lys Asn Ala Ala Arg Tyr Ala Arg
    130                 135                 140

Lys Glu Ser Pro Ser Pro Val Pro Val Val Asn Asp Gln Met Val Arg
145                 150                 155                 160

Pro Lys Phe Met Ala Lys Ala Ala Leu Phe His Ile Lys Glu Thr Lys
                165                 170                 175

His Val Val Gln Asp Ala Glu Pro Val Thr Leu His Ile Asp Leu Val
            180                 185                 190

Arg Glu
```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 140 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAB3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```
Met Ser Glu Lys Thr Met Arg Val Gln Asp Tyr Pro Leu Ala Thr Arg
1               5                  10                  15

Cys Pro Glu His Ile Leu Thr Pro Thr Gly Lys Pro Leu Thr Asp Ile
            20                  25                  30

Thr Leu Glu Lys Val Leu Ser Gly Glu Val Gly Pro Gln Asp Val Arg
        35                  40                  45

Ile Ser Arg Gln Thr Leu Glu Tyr Gln Ala Gln Ile Ala Glu Gln Met
    50                  55                  60

Gln His Ala Val Ala Arg Asn Phe Arg Arg Ala Ala Glu Leu Ile Ala
65                  70                  75                  80

Ile Pro Asp Glu Arg Ile Leu Ala Ile Tyr Asn Ala Leu Arg Pro Phe
                85                  90                  95

Arg Ser Ser Gln Ala Glu Leu Leu Ala Ile Ala Asp Glu Leu Glu His
            100                 105                 110

Thr Trp His Ala Thr Val Asn Ala Ala Phe Val Arg Glu Ser Ala Glu
        115                 120                 125

Val Tyr Gln Gln Arg His Lys Leu Arg Lys Gly Ser
    130                 135                 140
```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 387 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
(A) ORGANISM: DHAT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

```
Met Ser Tyr Arg Met Phe Asp Tyr Leu Val Pro Asn Val Asn Phe Phe
1               5                  10                  15

Gly Pro Asn Ala Ile Ser Val Val Gly Glu Arg Cys Gln Leu Leu Gly
            20                  25                  30

Gly Lys Lys Ala Leu Leu Val Thr Asp Lys Gly Leu Arg Ala Ile Lys
        35                  40                  45

Asp Gly Ala Val Asp Lys Thr Leu His Tyr Leu Arg Glu Ala Gly Ile
    50                  55                  60

Glu Val Ala Ile Phe Asp Gly Val Glu Pro Asn Pro Lys Asp Thr Asn
65                  70                  75                  80

Val Arg Asp Gly Leu Ala Val Phe Arg Arg Glu Gln Cys Asp Ile Ile
                85                  90                  95

Val Thr Val Gly Gly Gly Ser Pro His Asp Cys Gly Lys Gly Ile Gly
            100                 105                 110

Ile Ala Ala Thr His Glu Gly Asp Leu Tyr Gln Tyr Ala Gly Ile Glu
        115                 120                 125

Thr Leu Thr Asn Pro Leu Pro Pro Ile Val Ala Val Asn Thr Thr Ala
    130                 135                 140

Gly Thr Ala Ser Glu Val Thr Arg His Cys Val Leu Thr Asn Thr Glu
145                 150                 155                 160

Thr Lys Val Lys Phe Val Ile Val Ser Trp Arg Lys Leu Pro Ser Val
                165                 170                 175

Ser Ile Asn Asp Pro Leu Leu Met Ile Gly Lys Pro Ala Ala Leu Thr
            180                 185                 190

Ala Ala Thr Gly Met Asp Ala Leu Thr His Ala Val Glu Ala Tyr Ile
        195                 200                 205

Ser Lys Asp Ala Asn Pro Val Thr Asp Ala Ala Ala Met Gln Ala Ile
    210                 215                 220

Arg Leu Ile Ala Arg Asn Leu Arg Gln Ala Val Ala Leu Gly Ser Asn
225                 230                 235                 240

Leu Gln Ala Arg Glu Asn Met Ala Tyr Ala Ser Leu Leu Ala Gly Met
                245                 250                 255

Ala Phe Asn Asn Ala Asn Leu Gly Tyr Val His Ala Met Ala His Gln
            260                 265                 270

Leu Gly Gly Leu Tyr Asp Met Pro His Gly Val Ala Asn Ala Val Leu
        275                 280                 285
```

```
Leu Pro His Val Ala Arg Tyr Asn Leu Ile Ala Asn Pro Glu Lys Phe
    290                 295                 300

Ala Asp Ile Ala Glu Leu Met Gly Glu Asn Ile Thr Gly Leu Ser Thr
305                 310                 315                 320

Leu Asp Ala Ala Glu Lys Ala Ile Ala Ala Ile Thr Arg Leu Ser Met
                325                 330                 335

Asp Ile Gly Ile Pro Gln His Leu Arg Asp Leu Gly Val Lys Glu Ala
            340                 345                 350

Asp Phe Pro Tyr Met Ala Glu Met Ala Leu Lys Asp Gly Asn Ala Phe
        355                 360                 365

Ser Asn Pro Arg Lys Gly Asn Glu Gln Glu Ile Ala Ala Ile Phe Arg
    370                 375                 380

Gln Ala Phe
385
```

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GCGAATTCAT GAGCTATCGT ATGTTTG 27

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GCGAATTCAG AATGCCTGGC GGAAAATC 28

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GGGAATTCAT GAGCGAGAAA ACCATGCG 28

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GCGAATTCTT AGCTTCCTTT ACGCAGC 27

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GCGAATTCAT GCAACAGACA ACCCAAATTC 30

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GCGAATTCAC TCCCTTACTA AGTCG 25

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GGGAATTCAT GAAAAGATCA AAACGATTTG 30

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GCGAATTCTT ATTCAATGGT GTCGGGCTG 29

(2) INFORMATION FOR SEQ ID NO:46

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TTGATAATAT AACCATGGCT GCTGCTGCTG ATAG 34

(2) INFORMATION FOR SEQ ID NO:47

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GTATGATATG TTATCTTGGA TCCAATAAAT CTAATCTTC 39

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

CATGACTAGT AAGGAGGACA ATTC 24

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

CATGGAATTG TCCTCCTTAC TAGT 24

WHAT IS CLAIMED IS:

1. An improved method for the production of 1,3-propanediol from a microorganism comprising the steps of:

a) obtaining a recombinant microorganism capable of producing 1,3-propanediol, said microorganism comprising at least one nucleic acid encoding a dehydratase activity and a nucleic acid encoding protein X; and

b) culturing the recombinant microorganism in the presence of at least one carbon source capable of being converted to 1,3 propanediol in said transformed microorganism and under conditions suitable for the production of 1,3 propanediol wherein the carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and a one carbon substrate.

2. The method of Claim 1 wherein said recombinant microorganism comprises at least one nucleic acid encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3.

3. The method of Claim 1 further comprising the step of recovering the 1,3 propanediol.

4. The method of Claim 1 wherein the nucleic acid encoding protein X is isolated from a glycerol dehydratase gene cluster.

5. The method of Claim 1 wherein the nucleic acid encoding protein X is isolated from a diol dehydratase gene cluster.

6. The method of Claim 4 wherein the glycerol dehydratase gene cluster is from an organism selected from the genera consisting of Klebsiella and Citrobactor.

7. The method of Claim 5 wherein the diol dehydratase gene cluster is from an organism selected from the genera consisting of Klebsiella, Clostridium and Salmonella.

8. The method of Claim 1 wherein the nucleic acid encoding a dehydratase activity is heterologous to the organism.

9. The method of Claim 1 wherein the nucleic acid encoding a dehydratase activity is homologous to the organism.

10. The method of Claim 1 wherein the recombinant microorganism is selected from the group of genera consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*.

11. The method of Claim 10 wherein the microorganism is selected from the group consisting of *E.coli* and *Klebsiella spp.*

12. The method of Claim 1 wherein the nucleic acid encoding protein X is stably maintained in the host genome.

13. The method of Claim 2 wherein at least one nucleic acid encoding a protein selected from protein 1, protein 2 and protein 3 is stably maintained in the host genome.

14. The method of Claim 1 wherein the carbon source is glucose.

15. The method of Claim 1 wherein the nucleic acid encoding protein X has the sequence as shown in SEQ ID NO: 59.

16. The method of Claim 2 wherein protein 1 has the sequence as shown in SEQ ID NO: 60 or SEQ ID NO: 61.

17. The method of Claim 2 wherein protein 2 has the sequence as shown in SEQ ID NO: 62 or SEQ ID NO: 63.

18. The method of Claim 2 wherein protein 3 has the sequence as shown in SEQ ID NO:64 or SEQ ID NO: 65.

19. A recombinant microorganism capable of producing 1,3-propanediol from a carbon source said recombinant microorganism comprising a) at least one nucleic acid encoding a dehydratase activity; b) at least one nucleic acid encoding a glycerol-3-phosphatase; and c) at least one nucleic acid encoding protein X.

20. The recombinant microorganism of Claim 19 further comprising d) at least one nucleic acid encoding a protein selected from the group consisting of protein 1, protein 2 and protein 3.

21. The recombinant microorganism of Claim 19 selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*.

22. The recombinant microorganism of Claim 19 wherein the nucleic acid encoding protein X is isolated from a glycerol dehydratase gene cluster.

23. The recombinant microorganism of Claim 19 wherein the nucleic acid encoding protein X is isolated from a diol dehydratase gene cluster.

24. The recombinant microorganism of Claim 22 wherein the glycerol dehydratase gene cluster is from an organism selected from the genera consisting of *Klebsiella* and *Citrobactor*.

25. The recombinant microorganism of Claim 23 wherein the diol dehydratase gene cluster is from an organism selected from the genera consisting of Klebsiella, Clostridium and Salmonella.

26. The recombinant microorganism of Claim 19 wherein said dehydratase activity is heterologous to said microorganism.

27. The recombinant microorganism of Claim 19 wherein said dehydratase activity is homologous to said microorganism.

28. The recombinant microorganism of Claim 19 wherein the nucleic acid encoding protein X has the sequence as shown in SEQ ID NO: 59.

29. The recombinant microorganism of Claim 20 wherein protein 1 has the sequence as shown in SEQ ID NO: 60 or SEQ ID NO: 61.

30. The recombinant microorganism of Claim 20 wherein protein 2 has the sequence as shown in SEQ ID NO: 62 or SEQ ID NO: 63.

31. The recombinant of Claim 20 wherein protein 3 has the sequence as shown in SEQ ID: 64 or SEQ ID NO: 65.

32. A method for extending the half-life of dehydratase activity in a transformed microorganism capable of producing 1,3-propanediol and containing at least one nucleic acid encoding a dehydratase activity, comprising the step of introducing a nucleic acid encoding protein X into said microorganism and culturing under conditions suitable for production of 1,3-propanediol.

33. The method of Claim 32 wherein the nucleic acid encoding the dehydratase activity is heterologous to said microorganism.

34. The method of Claim 32 wherein the nucleic acid encoding the dehydratase activity is homologous to said microorganism.

35. The method of Claim 32 wherein the nucleic acid encoding protein X is isolated from a glycerol dehydratase gene cluster.

36. The method of Claim 32 wherein the nucleic acid encoding protein X is isolated from a diol dehydratase gene cluster.

37. The method of Claim 35 wherein the glycerol dehydratase gene cluster is from an organism selected from the genera consisting of Klebsiella and Citrobactor.

38. The method of Claim 34 wherein the diol dehydratase gene cluster is from an organism selected from the genera consisting of Klebsiella, Clostridium and Salmonella.

39. The method of Claim 32 wherein the microorganism is selected from the group consisting of *Citrobacter*, *Enterobacter*, *Clostridium*, *Klebsiella*, *Aerobacter*, *Lactobacillus*, *Aspergillus*, *Saccharomyces*, *Schizosaccharomyces*, *Zygosaccharomyces*, *Pichia*, *Kluyveromyces*, *Candida*, *Hansenula*, *Debaryomyces*, *Mucor*, *Torulopsis*, *Methylobacter*, *Escherichia*, *Salmonella*, *Bacillus*, *Streptomyces* and *Pseudomonas*.

40. The method of Claim 32 further comprising the step of introducing at least one nucleic acid encoding protein 1, protein 2 or protein 3 into said microorganism.

FIG._1

```
MSLSSPGVHLFYDSRGQGAGALDELCWGLEEQGVPCQAIT  Majority
         10        20        30        40

1  MSLSSPGVHLFYHSRWQGTRVLDELCWGLEEQGVPCRAIC  cfu_orfX.aa
1  MSLSPPGVRLFYDPRGHHAGAINELCWGLEEQGVPCQTIT  kpn_orfX.aa

YDGGGDAAALGALAAKSSTLRVGLGLSASGDIALTHAQLP  Majority
         50        60        70        80

41 CDDHDCALALGKLAAKSSTLRVGLGLNATGDIALTHAQLP  cfu_orfX.aa
41 YDGGGDAAALGALAARSSPLRVGIGLSASGEIALTHAQLP  kpn_orfX.aa

ADAALATGHVTAGTAQLRTLGANAGQLVKVLPLSERIK  Majority
         90       100       110

81 EDRALVCGHTRAGTAQIRTLGANAGQLVKVLPFSE-IK  cfu_orfX.aa
81 ADAPLATGHVTDSDDQLRTLGANAGQLVKVLPLSERN.  kpn_orfX.aa
```

FIG._4

FIG._2A-1

ATGAACGTGGTGGAGATGATGGCGCTGCAGAAGATGCGTGCCCGCCGGACCCCCTCCAACCAGTGCCACGTCACCAATCTCAAAGAT
TACTTGCACCACCTCTACTACTACCGCGACGTCTTCTACGCACGGGCGGCCTGGGGGAGGTTGGTCACGGTGCAGTGGTTAGAGTTTCTA
M N V V E M M M A L Q K M R A R R T P S N Q C H V T N L K D
dhaB1
AATCCGGTGCAGATTGCCGCTGACGCCGCCGAGGCCGGGATCCGCGGCTTCTCAGAACAGGAGACCACGGTCGGTATCGCGCGCTACGCG
TTAGGCCACGTCTAACGGCGACTGCGGCGGCTCCGGCCCTAGGCGCCGAAGAGTCTTGTCCTCTGGTGCCAGCCATAGCGCGCGATGCGC
N P V Q I A A D A A E A G I R G F S E Q E T T V G I A R Y A
dhaB1
CciNI
Not I
Bsb I
CCGTTTAACGCCCTGGCGCTGTTGGTCGGTTCGCAGTGCGGCGCCCCGGCGTGTTGACGCAGTGCTCGGTGGAAGAGGCCACCGAGCTG
GGCAAATTGCGGGACCGCGACAACCAGCCAAGCGTCACGCCGGCGGGGCCGCACAACTGCGTCACGAGCCACCTTCTCCGGTGGCTCGAC
P F N A L A L L V G S Q C G R P G V L T Q C S V E E A T E L
dhaB1
Dsa VI
Acc I
FbiI
GAGCTGGGCATGCGTGGCTTAACCAGCTACGCCGAGACGGTGTCGCTCTACGGCACCGAAGCGGTATTTACCGACGGCGATGATACGCCG
CTCGACCCGTACGCACCGAATTGGTCGATGCGGCTCTGCCACACGGCCAGATGCCGTGGCTTCGCCATAAATGGCTGCCGCTACTATGCGGC
E L G M R G L T S Y A E T V S V Y G T E A V F T D G D D T P
dhaB1

FIG._2A-2

FIG._2B-1

PfI1108 I
ATTTTCTCCGGCTACAGCGCGGTGCCGAACTACGACAACATGTTCGCCGGCTCGAACTTCGATGCGGAAGATTTTGATGATTACAACATC
TAAAAGAGGCCGATGTCGCGCCACGGCTTGATGCTGTTGTACAAGCCGGCCGAGCTTGAAGCTACGCCTTCTAAAACTACTAATGTTGTAG
I F S G Y S A V P N Y D N M F A G S N F D A E D F D D Y N I
dhaB1
1170
CTGCAGCGTGACCTGATGGTTGACGGCGGCCTGCGTCCGGTGACCGAGGCGGAAACCATTGCCATTCGCCAGAAAGCGGCGCGGGCGATC
GACGTCGCACTGGACTACCAACTGCCGCCGGACGCAGGCCACTGGCTCCGCCTTTGGTAACGGTAAGCGGTCTTTCGCCGCGCCCGCTAG
L Q R D L M V D G G L R P V T E A E T I A I R Q K A A R A I
dhaB1
1260
CAGGCGGTTTTCCCCGAGCTGGGGCTGCCGCCAATCGCCGACGAGGTGGAGGCCGCCACCTACGCGCACGGCAGCAACGAGATGCCG
GTCCGCCAAAAGGCGCTCGACCCCGACGGCGGTTAGCGGCTGCTCCTCCACCTCCGCGGCGGTGGATGCGCGTGCCGTCGTTGCTCTACGGC
Q A V F R E L G L P P I A D E E V E A A T Y A H G S N E M P
dhaB1
1350
CCGCGTAACGTGGTGGAGGATCTGAGTGCGGTGGAAGAGATGATGAAGCGCAACATCACCGGCCTCGATATTGTCGGCGCGCTGAGCCGC
GGCGCATTGCACCACCTCCTAGACTCACGCCACCTTCTCTACTACTTCGCGTTGTAGTGGCCGGAGCTATAACAGCCGCGCGACTCGGCG
P R N V V E D L S A V E E M M K R N I T G L D I V G A L S R
dhaB1
1440

FIG._2B-2

AGCGGCTTTGAGGATATCGCCAGCAATATTCTCAATATGCTGCGCCAGCGGGTCACCGGCGATTACCTGCAGACCTGGCCATTCTCGAT 1530
TCGCCGAAACTCCTATAGCGGTCGTTATAAGAGTTATACGACGCGGTCCCCCAGTGGCCGCTAATGGACGTCTGGAGCCGGTAAGAGCTA
S G F E D I A S N I L N M L R Q R V T G D Y L Q T S A I L D
dhaB1
FIG._2B-3
CGGCAGTTCGAGGTGGTGAGTGCGGTCAACGACATCAATGACTATCAGGGCCGGGCACCGGCTATCCCATCTCTGCCGAACGCTGGGCG 1620
GCCGTCAAGCTCCACCACTCACGCCAGTTGCTGTAGTTACTGATAGTCCCCGGCCCGTGGCCGATAGCGTAGAGACGGCTTGCGACCCGC
R Q F E V V S A V N D I N D Y Q G P G T G Y R I S A E R W A
dhaB1
PrdII
GAGATCAAAAATATTCCGGGCGTGGTTCAGCCCGACACCATTGAATAAGGCGGTATTCCTGTGCAACAGACAACCCAAATTCAGCCCTCT 1710
CTCTAGTTTTTATAAGGCCCGCACCAAGTCGGGCTGTGGTAACTTATTCCGCCATAAGGACACGTTGTCTGTTGGGTTTAAGTCGGGAGA
E I K N I P G V V Q P D T I E
dhaB1
H
dhaB2
V Q Q T T Q I Q P S
TTTACCCTGAAAACCCGCGAGGGCGGGTAGCTTCTGCCGATGAACGCGCCCATGAAGTGGTGATCGGCGTCGGCCCTGCCTTCGATAAA 1800
AAATGGGACTTTTGGGCGCTCCCGCCCATCGAAGACGGCTACTTGCGCGGCTACTTCACCACTAGCCGCAGCCGGGACGGAAAGCTATTT
F T L K T R E G G V A S A D E R A D E V V I G V G P A F D K
dhaB2
FIG._2C-1

Uba1220 I
Cfr9I
PspAI
Xma I
CfrJ4I
Sma I
CACCAGCATCACACTCTGATCGATATGCCCCATGGCGCGATCCTCTAAAGAGCTGATTGCCGGGGTGGAAGAAGAGGGGCTTCACGCCCGG 1890
GTGGTCGTAGTGTGAGACTAGCTATACGGGGTACCGCGCTAGGAGTTTCTCGACTAACGGCCCCACCTTCTTCTCCCCGAAGTGCGGGCC
H Q H H T L I D M P H G A I L K E L I A G V E E E G L H A R
dhaB2
Ppu1253 I
Aat II
GTGGTGCGCATTCTGCGCACGTCCGACGTCTCCTTTATGGCCTGGGATGCGGCCAACCTGAGCGGCTCGGGGATCGGCATCGGTATCCAG 1980
CACCACGCGTAAGACGCGTGCAGGCTGCAGAGGAAATACCGGACCCTACGCCGGTTGGACTCGCCGAGCCCCTAGCCGTAGCCATAGGTC
V V R I L R T S D V S F M A W D A A N L S G S G I G I Q
dhaB2
TCGAAGGGGACCACGGTCATCCATCAGCGCGATCTGCTGCCGCTCAGCAACCTGGAGCTGTTCTCCCAGGGCGCCGCTGCTGACGCTGGAG 2070
AGCTTCCCCTGGTGCCAGTAGGTAGTCGCGCTAGACGACGGCGAGTCGTTGGACCTCGACAAGAGGGTCCGCGGCGACGACTGCGACCTC
S K G T T V I H Q R D L L P L S N L E L F S Q A P L L T L E
dhaB2

FIG._2C-2

```
ACCTACCGGCAGATTGGCAAAAACGCTGCGCGCTATGCGCGCAAAGAGTCACCTTCGCCGGTGCCGGTGGTGAACGATCAGATGGTGCGG 2160
TGGATGGCCGTCTAACCGTTTTTGCGACGCGCGATACGCGCGTTTCTCAGTGGAAGCGGCCACGGCCACCACTTGCTAGTCTACCACGCC

T  Y  R  Q  I  G  K  N  A  A  R  Y  A  R  K  E  S  P  S  P  V  P  V  V  N  D  Q  M  V  R
                              dhaB2
```

FIG._2C-3

```
CCGAAATTTATGGCCAAAGCCGCGCTATTTCATATCAAAGAGACCAAACATGTGGTGCAGGACGCCGAGCCCGTCACCCTGCACATCGAC 2250
GGCTTTAAATACCGGTTTCGGCGCGATAAAGTATAGTTTCTCTGGTTTGTACACCACGTCCTGCGGCTCGGGCAGTGGGACGTGTAGCTG

P  K  F  M  A  K  A  A  L  F  H  I  K  E  T  K  H  V  V  Q  D  A  E  P  V  T  L  H  I  D
                              dhaB2

TTAGTAAGGGAGTGACCATGAGCGAGAAAACCATGCGCGTGCAGGATTATCCGTTAGCCACCCGCTGCCCGGAGCATATCCTGACGCCTA 2340
AATCATTCCCTCACTGGTACTCGCTCTTTTGGTACGCGCACGTCCTAATAGGCAATCGGTGGGCGACGGGCCTCGTATAGGACTGCGGAT

                  M  S  E  K  T  M  R  V  Q  D  Y  P  L  A  T  R  C  P  E  H  I  L  T  P
                                          dhaB3
L  V  R  E  .
   dhaB2
```

FIG._2D-1

EciE I
Bsp120 I
Apa I
Ppel
CCGGCAAACCATTGACCGATATTACCCTCGAGAAGGTGCTCTCTGGCGCAGGTGGGCCCGCAGGATGTGCGGATCTCCCGCCAGACCCTTG
GGCCGTTTGGTAACTGGCTATAATGGGAGCTCTTCCACGAGACCGCTCCACCCGGGCGTCCTACACGCCTAGAGGGCGGTCTGGGAAC
T G K P L T D I T L E K V L S G E V G P O O D V R I S R O T L
dhaB3
Van91 I
AGTACCAGGCGCAGATTGCCGAGCAGATGCAGCGCCATGCGGTGGCGCGCAATTTCCGCCGCGGCGGAGCTTATCGCCATTCCTGACG
TCATGGTCCGCGTCTAACGGCTCGTCTACGTCGGGTACGCCACCGCGCGTTAAAGGCGGCGCCGCCTCGAATAGCGGTAAGGACTGC
E Y O A O I A E O M O R H A V A R N F R R A A E L I A I P D
dhaB3
Sgf I
AGCGCATTCTGGCTATCTATAACGCGCTGCGCCCGTTCCGCTCCTCGCAGGCGGAGCTGCTGGCGATCGCCGACGAGCTGGAGCACACCT
TCGCGTAAGACCGATAGATATTGCGCGACGCGGGCAAGGCGAGGAGCGTCCGCCTCGACGACCGCTAGCGGCTGCTCGACCTCGTGTGGA
E R I L A I Y N A L R P F R S S O A E L L A I A D E L E H T
dhaB3

FIG._2D-2

GGCATGCGACAGTGAATGCCGCCTTTGTCCGGCGAAGTGGTATCAGCAGCGGCATAAGCTGCGTAAAGGAAGCTAAGCGGAAGG 2700
CCGTACGCTGTCACTTACGGCGGAAACAGGCCCTCAGCCGCCTTCACATAGTCGTCGCCGTATTCGACGCATTTCCTTCGATTCGCCTCC
W H A T V N A A F V R E S A E V Y Q Q R H K L R K G S
dhaB3
Xcm I
TCAGCATGCCGTTAATAGCCGGGATTGATATCGGCAACGCCACCACCGAGGTGGCGCTGGCGTCCGACTACCCGCAGGCGAGGGCGTTTG 2790
AGTCGTACGGCAATTATCGGCCCTAACTATAGCCGTTGCGGTGGTGGCTCCACCGCGACCGCAGGCTGATGGGCGTCCGCTCCCGCAAAC
M P L I A G I D I G N A T T E V A L A S D Y P Q A R A F
dhaB4
FIG._2D-3
SanD I
TTGCCAGCGGGATCGTCGCGACGACGGGCATGAAAGGGACGCGGGACAATATCGCCGGGACCCTCGCCGCGCTGGAGCAGGCCCTGGCGA 2880
AACGGTCGCCCTAGCAGCGCTGCTGCCCGTACTTTCCCTGCGCCCTGTTATAGCGGCCCTGGGAAGCGGCGCGACCTCGTCCGGACCGCT
V A S G I V A T T G M K G T R D N I A G T L A A L E Q A L A
dhaB4
AAACACCGTGGTCGATGAGCGATGTCTCTCGCATCTATCTTAACGAACCCCGCCGGTGATTGGCGATGTGGCGATGGAGACCATCACCG 2970'
TTTGTGGCACCAGCTACTCGCTACAGAGAGCGTAGATAGAATTGCTTCGGCCGGCCACTAACCGCTACACCGCTACCTCTGGTAGTGGC
K T P W S M S D V S R I Y L N E A A P V I G D V A M E T I T
dhaB4
FIG._2E-1

FIG._2E-2

```
TGGTGCGGATCCTGTCGAATCCCTACGGGATCGCCACCTTCTTCGGGCTAAGCCCGGAAGAGACCCAGGCCATCGTCCCCATCGCCCGCG 3420
ACCACGCCTAGGACAGCTTAGGGATGCCCTAGCGGTGGAAGAAGCCCGATTCGGGCCTTCTCTGGGTCCGGTAGCAGGGGTAGCGGGCGC

 V  V  R  I  L  S  N  P  Y  G  I  A  T  F  F  G  L  S  P  E  E  T  Q  A  I  V  P  I  A  R
                                      dhaB4

CCCTGATTGGCAACCGTTCCGCGGTGGTGCTCAAGACCCCGCAGGGGGATGTGCAGTCGCGGGTGATCCCGGCGGGCAACCTCTACATTA 3510
GGGACTAACCGTTGGCAAGGCGCCACCACGAGTTCTGGGGCGTCCCCCTACACGTCAGCGCCCACTAGGGCCGCCCGTTGGAGATGTAAT

 A  L  I  G  N  R  S  A  V  V  L  K  T  P  Q  G  D  V  Q  S  R  V  I  P  A  G  N  L  Y  I
                                      dhaB4

GCGGCGAAAAGCGCCGCGGAGAGGCCGATGTCGCCGAGGGCGCGGAAGCCATCATGCAGGCGATGAGCGCCTGCGCTCCGGTACGCGACA 3600
CGCCGCTTTTCGCGGCGCCTCTCCGGCTACAGCGGCTCCCGCGCCTTCGGTAGTACGTCCGCTACTCGCGGACGCGAGGCCATGCGCTGT

 S  G  E  K  R  R  G  E  A  D  V  A  E  G  A  E  A  I  M  Q  A  M  S  A  C  A  P  V  R  D
                                      dhaB4
```

FIG._2E-3

```
                           Taq II'
TCCGCGGCGAACCGGGCACCCACGCCGGCGGCATGCTTGAGCGGGTGCGCAAGGTAATGGCGTCCCTGACCGGCCATGAGATGAGCGCGA 3690
AGGCGCCGCTTGGCCCGTGGGTGCGGCCGCCGTACGAACTCGCCCACGCGTTCCATTACCGCAGGGACTGGCCGGTACTCTACTCGCGCT

 I  R  G  E  P  G  T  H  A  G  G  M  L  E  R  V  R  K  V  M  A  S  L  T  G  H  E  M  S  A
                                      dhaB4
```

FIG._2F-1

TATACATCCAGGATCTGCTGGCGGTGGATACGTTTATTCCGCGCAAGGTGCAGGGCGGGATGGCCGGCGAGTGCGCCATGGAGAATGCCG 3780
ATATGTAGGTCCTAGACGACCGCCACCTATGCAAATAAGGCGCGTTCCACGTCCCGCCCTACCGGCCGCTCACGCGGTACCTCTTACGGC
I Y I Q D L L A V D T F I P R K V Q G G M A G E C A M E N A
dhaB4
TCGGGATGGCGGCGATGGTGAAAGCGGATCGTCTGCAAAATGCAGGTTATCGCCCGCGAACTGAGCGCCGCAGACCGAGGTGGTGG 3870
AGCCCTACCGCCGCTACCACTTTCGCCTAGCAGACGTTTACGTCCAATAGCGGGCGCTTGACTCGCGGGCTGACGTCTGGCTCCACCACC
V G M A A M V K A D R L Q M Q V I A R E L S A R L Q T E V V
dhaB4
BsaK I
BstHPI
Hpa I
SdiI
Sfi I
TGGGCGGCGTGGAGGCCAACATGGCCATCGCCGGGGGCGTTAACCACTCCCGGCTGTGCGGCGCGCTGGCGATCCTCGACCTCGGCGCCG 3960
ACCCGCCGCACCTCCGGTTGTACCGGTAGCGGCCCCGCAATTGGTGAGGGCCGACACGCCGCGGCGACCGCTAGGAGCTGGAGCCGCGGC
V G G V E A N M A I A G A L T T P G C A A P L A I L D L G A
dhaB4
GCTCGACGGATGCGGCGATCGTCAACGCGGAGGGGCAGATAACGGCGGTCCATCTCGCCGGGGCGGGGAATATGGTCAGCCTGTTGATTA 4050
CGAGCTGCCTACGCCGCTAGCAGTTGCGCCTCCCCGTCTATTGCCGCCAGGTAGAGCGGCCCCGCCCCTTATACCAGTCGGACAACTAAT
G S T D A A I V N A E G Q I T A V H L A G A G N M V S L L I
dhaB4

FIG._2F-2

UbaD I
4140
AAACCGAGCTCGGCCTCGAGGATCTTTCGCTGGCGGAAGCGATAAAAAAATACCCGCTGGCCAAAGTGGAAAAGCCTGTTCAGTATTCGTC
TTTGGCTCGACCCGGAGCTCCTAGAAAGCGACCGCCTTCGCTATTTTTTTATGGGCGACCGGTTTCACCTTTCGGACAAGTCATAAGCAG
K T E L G L L E D L S L A E A I K K Y P L A K V E S L F S I R
dhaB4
BsmG I
BsrG I
4230
ACGAGAATGGCGCGGTGGAGTTCTTTCGGGAAGCCCTCAGCCCGGCGGTGTTCGCCAAAGTGGTGTACATCAAGGAGGGCGAACTGGTGC
TGCTCTTACCGCGCCACCTCAAGAAAGCCCTTCGGGAGTCGGGCCGCCACAAGCGGTTTCACCACATGTAGTTCCTCCCGCTTGACCACG
H E N G A V E F F R E A L S P A V F A K V V Y I K E G E L V
dhaB4
Syn II Xmn I
4320
CGATCGATAACGCCAGCCCGCTGGAAAAAATTCGTCTCGTGCGCCGGCAGGCGAAAGAGAAAGTGTTTGTCACCAACTGCCTGCGCGCGC
GCTAGCTATTGCGGTCGGGCGACCTTTTTTAAGCAGAGCACGCGGCCCGTCCGCTTTCTCTTTCACAAACAGTGGTTGACGGACGCGCGCG
P I D N A S P L E K I R L V R R Q A K E K V F V T N C L R A
dhaB4

FIG._2F-3

TGCGCCAGGTCTCACCCGGCGGTTCCATTCGCGATATCGCCTTTGTGGTGCTGGTGGGCGGCTCATCGCTGGACTTTGAGATCCCGCAGC
ACGCGGTCCAGAGTGGGCCGCCAAGGTAAGCGCTATAGCGGAAACACCACGACCACCCGCCGAGTAGCGACCTGAAACTCTAGGGCGTCG
4410
L R Q V S P G G G S I R D I A F V V L V G G S S L D F E I P Q
dhaB4
Ecoprr I
Bcg I'
TTATCACGGAAGCCTTGTCGCACTATGGCGTGGTCGCCGGGCAGGGCAATATTCGGGGAACAGAAGGGCCGCGCAATGCGGTCGCCACCG
AATAGTGCCTTCGGAACAGCGTGATACCGCACCAGCGGCCCGTCCCGTTATAAGCCCCTTGTCTTCCCGGCGCGTTACGCCAGCGGTGGC
4500
L I T E A L S H Y G V V A G Q G N I R G T E G P R N A V A T
dhaB4
Bcg I
GGCTGCTACTGGCCGGTCAGGCGAATTAA
CCGACGATGACCGGCCAGTCCGCTTAATT
4529
G L L L A G Q A N
dhaB4

FIG._2G

```
        MMNKSQQVATITLAAAQQMAAAVEAKALEINVAVVFSVVD  Majority
                 10        20        30        40
  1     M-NKSQQIATITLAAAKKMAQAVEAKALEINVPVVFSVVD  cfu_orfY.aa
  1     MMNKSQQVQTITLAAAQQMAAAVEKKATEINVAVVFSVVD  Kpn_orfY.aa

        HGGNTLLIQRMDDAFVSSCDISLNKAYSACSLKQGTHEIT  Majority
                 50        60        70        80
 40     HGGNTLLMQRMDDAFVTSCDISLNKAYTACCLRQGTHEIT  cfu_orfY.aa
 41     RGGNTLLIQRMDEAFVSSCDISLNKAWSACSLKQGTHEIT  Kpn_orfY.aa

        SAVQPGASLYGLQLTNQQRIVIFGGGLPVILNGQVIGAVG  Majority
                 90        100       110       120
 80     DAVQPGASLYGLQLTNQQRIVIFGGGLPVILNGKVIGAVG  cfu_orfY.aa
 81     SAVQPGQSLYGLQLTNQQRIIIFGGGLPVIFNEQVIGAVG  Kpn_orfY.aa

        VSGGTVEQDQLLAETALDCFSAL                   Majority
                 130       140
120     VSGGTVEQDRLLAETALDCFSEL                   cfu_orfY.aa
121     VSGGTVEQDQLLAQCALDCFSAL                   Kpn_orfY.aa
```

FIG._3

```
                                                                                Majority
MYRIYTRTGDNGTTALFGGSRIDKDDIRVEAYGTVDELIS
                    10        20        30        40

                                                                    cfu_orfW.aa
1   MYRIYTRTGDNGTTALFGGSRIDKDDIRVEAYGTVDELIS
                                                                    kpn_orfW.aa
1   MYRIYTRTGDKGTTALYGGSRIEKDHIRVEAYGTVDELIS

                                                                                Majority
QLGVCYASTRDAGLRESLHAIQQTLFVLGAELASDAKGLT
                    50        60        70        80

                                                                    cfu_orfW.aa
41  QLGVCYASTRQAELRQELHAMQKMLFVLGAELASDQKGLT
                                                                    kpn_orfW.aa
41  QLGVCYATTRDAGLRESLHHIQQTLFVLGAELASDARGLT

                                                                                Majority
RLSQTIGEEDITALEQLIDRNMAESGPLKEFVIPGKNLAS
                    90        100       110       120

                                                                    cfu_orfW.aa
81  RLKQRIGEEDIQALEQLIDRNMAQSGPLKEFVIPGKNLAS
                                                                    kpn_orfW.aa
81  RLSQTIGEEEITALERLIDRNMAESGPLKQFVIPGRNLAS

                                                                                Majority
AQLHVARTLSRRLERLLIAMGRALTLRDAAKRYINRLSDA
                    130       140       150       160

                                                                    cfu_orfW.aa
121 AQLHVARTLTRRLERILIAMGRTLTLRDEARRYINRLSDA
                                                                    kpn_orfW.aa
121 AQLHVARTQSRRLERLLTAMDRAHPLRDALKRYSNRLSDA

                                                                                Majority
LFSMARIEETTPDACA-
                    170

                                                                    cfu_orfW.aa
161 LFSMARIEETTPDVCA
                                                                    kpn_orfW.aa
161 LFSMARIEETRPDACA.
```

FIG._5


DH5a/pHK2826 + t0 ATP UMOLE/mg DRY WT.
DH5a/pHK2826 + t10 ATP UMOLE/mg DRY WT.
DH5a/pDT24 + ATP/Mn T0 UMOLE/mg DRY WT.
DH5a/pDT24 + ATP/Mn T10 UMOLE/mg DRY WT.
DH5a/pHK2826 - ATP/Mn UMOLE/mg DRY WT.
DH5a/pDT24 - ATP/Mn UMOLE/mg DRY WT.
UMOLES ALDEHYDE / mg DRY WEIGHT
INCUBATION TIME (MINUTES)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0
5
10
15
20
25
30

FIG._6


FM5/pM7 + t10 ATP/Mn UMOLES/mg
FM5/pM7 +t0 ATP/Mn UMOLES/mg
FM5/pM11 + t0 ATP/Mn UMOLES/mg
FM5/pM11 +t10 ATP/Mn UMOLES/mg
FM5/pM11 - ATP/Mn UMOLES/mg
FM5/pM7 - ATP/Mn UMOLES/mg
UMOLES ALDEHYDE / mg DRY WEIGHT
INCUBATION TIME (MINUTES)
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0
5
10
15
20
25
30

FIG._7

EcoB I
EcoDR2
UbaEI
PshA I
100
M R Y I A G I D I G N S S T E V A L A T V D D A G V L N I R H S A
Kpn-pdu x
Blp I
BclVI
200
L A E T T G I K G T L R N V F G I Q E A L T Q A A K A A G I Q L S D
Kpn-pdu x
Mly I
BsmE I
Ple I
Tru9 I
300
I S L I R I N E A T P V I G D V A M E T I T E T I I T E S T M I G
Kpn-pdu x

FIG._8A-1

BmrI
BfiI
StyLT I
CATAACCGAAGACACCCGGCGGCGTCGGACTGGGGGTCGGCATCACCATCACACCAGAGGCGCTGCTGTCCTGCTCCGCGGACACTCCCTATATTCTGG 400
GTATTGGGCTTCTGTGGGCCGCCGCAGCCTGACCCCCAGCCGTAGTGGTAGTGTGGTCTCCGCGACGACACAGGACGAGGCGCCTGTGAGGGATATAAGACC
H N P K T P G G V G L G V G I T I T P E A L L S C S A D T P Y I L
Kpn-pdu x
FIG._8A-2
Alw26 I
Bsa I
BsmAI
Eco31I
Bli49 I
500
TGGTCTCCTCGGCCTTTGACTTTGCCGATGTCGCCGCGATGGTCAATCCGGCAACGGCAGCGGGCTATCAGATAACCGGCATTATTTTGCAGCAGGATGA
ACCAGAGGAGCCGGAAACTGAAACGGCTACAGCGGCGCTACCAGTTACGCCGTTGCCGTCGCCGATAGTCTATTGGCCGTAATAAAACGTCGTCCTACT
V V S S A F D F A D V A A M V N A A T A A G Y Q I T G I I L Q Q D D
Kpn-pdu x
Age I
PinAI
CjeP I
TfiI
CjeP I'
600
CGGCGTGCTGGTCAATAACCGGCTACAGCAACCGCTACCGGTGATCGACGAAGTTCAGCATATCGACCGGATTCCACTTGGCATGCTGGCGGCCGTCGAG
GCCGCACGACCAGTTATTGGCCGATGTCGTTGGCGATGGCCACTAGCTGCTTCAAGTCGTATAGCTGGCCTAAGGTGAACCGTACGACCGCCGGCAGCTC
G V L V N N R L Q Q P L P V I D E V Q H I D R I P L G M L A A V E
Kpn-pdu x
FIG._8B-1

FIG._8B-2

FIG._8C-1

Ate I
Bst224 I
Bsp19I
Nco I
Sty I
Van91 I
AlwN I
Bsp87 I
Ppu6 I
BsaA I
Eco72 I
Mja I
Bfa I
MfnZI
Bmg I
1000
A G T N I G G M L E H V R Q T M A E L T N K P A Q E I R I Q D L L
Kpn-pdu x
Bae I
1100
A V D T A V P V S V T G G L A G E F S L E Q A V G I A S M V K S D R
Kpn-pdu x
BstAPI
ApaB I
1200
L Q M A L I A R E I E H K L Q I A V Q V G G A E E A A I L G A L

FIG._8C-2

Acs1371 I
Dsa VI
Rth4273I
Sal I
Acc I
FbiI
Taq II
Aca III
Fsp I
BscJ I
Xcm I
1300
ACCACTCCCGGCACCACGCGCCCGCTGGCGATCTCTCGATCTGGGCGCCGGGTCGACCGACGCCTCCATTATCAATGCGCAGGGAGACATCAGCGCCACTC
TGGTGAGGGCCGTGGTGCGCGGGCGACCGCTAGGAGCTAGACCCGCGGCCCAGCTGGCTGCGGAGGTAATAGTTACGCGTCCCTCTCTAGTCGCGGTGAG
T T P G T T R P L A I L D L G A G S T D A S I I N A Q G E I S A T
Kpn-pdu x
SmiI
Asp697 I
VpaK11A I
Ava II
Eco47I
SinI
Bco63 I
AtuC I
BmeTI
BcI I
BsaB I
BsrE I
Ear I
Bce83 I
BstX I
SgrA I
1400
ACCTGGCCGGCGCCGGCGATATGGTCACGATGATCATCGCCCCGCGAGCTGGGGCTTGAGGACCGCTACCTGGCGGAAGACGATCAAAAAATATCCGCTGGC
TGGACCGGCCGCGGCCGCTATACCAGTGCTACTAGTAGCGGGCGCTCGACCCCGAACTCCTGGCGATGGACCGCCTTCTCTAGTTTTTTATAGGCGACCG
H L A G A G D M V T M I I A R E L G L E D R Y L A E E I K K Y P L A
Kpn-pdu x

FIG._8D-1

DrdI
AAAAGTCGAAAGCCTGTTTCATCTGCGTCATGAAGACGGCAGCGTCCAGTTTTTTCCGTCGGCCTTACCACCGACGGTATTTGCCCGCGTCTGCGTGAAA 1500
TTTTTCAGCTTTCGGACAAAGTAGACGCAGTACTTCTGCCGTCGCCAGGTCAAAAAAGGCAGCCGGAATGGTGGCTGCCATAAACGGGCGCAGACGCACTTT
K V E S L F H L R H E D G S V Q F F P S A L P P T V F A R V C V K
Kpn-pdu x
FIG._8D-2
Syn II
Drd II
Xmn I
Pau I
BssH II
Ape I
Afl III
Mlu I
CCGGATGAACTGGTTCCCCTGCCCGGCGATCTGCCGCTGGAGAAAGTGCGCGCAATTCGCCGTAGCGCCAAATCACCGCGTCTTTGTCACCAACGCCCTGC 1600
GGCCTACTTGACCAAGGGGACGGGCCGCTAGACGGCGACCTCTTTCACGCGCGTTAAGCGGCATCGCGGTTTAGTGCGCAGAAACAGTGGTTGCGGGACG
P D E L V P L P G D L P L E K V R A I R R S A K S R V F V T N A L
Kpn-pdu x
Gsp I
BavI
Pvu II
Bse59 I
BstE II
EcaI
Bsp117 I
Ban II
Eco24I
Ama I
NruI
EcoR124 I
BsmF I
BspLU11 III
FinI
GAGCGTTACGCCAGGTGAGCCCTACCGGCAACATTCGCGACATCCCGTTCGTGGTCTGGTGGGCGGCTCGTCCCTCGATTTCGAGATCCCCCAGCTGGT 1700
CTCGCAATGCGGTCCACTCGGGATGGCCGTTGTAAGCGCTGTAGGGCAAGCACCACGACCACCGCCGAGCAGGGAGCTAAAGCTCTAGGGGGTCGACCA
R A L R Q V S P T G N I R D I P F V V L V G G S S L D F E I P Q L V
Kpn-pdu x

FIG._8E-1

BseMI
BsrD I
1800
CACGACGCGCTGGCGACTACCGGCTGGTTGCCGGGCGCGGCAACATCCGCGGCTGTGAAGGCCCACGCAATGCGGTCGCCAGCGGATTACTCCTTTCC
GTGGCTGCGCGACCGCCGTGATGGCCGACCAACGGCCCGCGCCGTTGTAGGCGCCGACACTTCCGGGTGCGTTACGCCAGCGGTCGCCTAATGAGGAAAGG
T D A L A H Y R L V A G R G N I R G C E G P R N A V A S G L L L S
Kpn-pdu x
TGGCAAAAAGGAGGGCACACATGGAGAGTAG
1830
ACCGTTTTTCCTCCGTGTGTACCTCTCATC
W Q K G G T H G E
Kpn-pdu x

FIG._8E-2


5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
5
10
15
20
25
30
35
40
TIME (HOURS)

FIG._9


35
30
25
20
15
10
5
0
0
10
20
30
40
50
60
70
TIME (HOURS)

FIG._10

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (8-96)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

[X] Declaration Submitted with Initial Filing OR [ ] Declaration Submitted after Initial Filing

Attorney Docket Number	GC369-2PCT
First Named Inventor	Diaz-Torres, Maria
COMPLETE IF KNOWN	
Application Number	
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled :

Method For The Recombinant Production of 1,3 Propanediol

(Title of the Invention)

the specification of which

[ ] is attached hereto
OR

[X] was filed on (MM/DD/YYYY) 13 November 1997 as United States Application Number or PCT International Application Number PCT/US97/20873 and was amended on (MM/DD/YYYY) 12 June 1998 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35 United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES	Certified Copy Attached? NO
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]

[ ] Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)
60,030,601	13 November 1996

[ ] Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/01 (8-96)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
08,969,683 filed: 11/13/97	PCT/US97/20873 filed: 11/13/97		

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Name	Registration Number	Name	Registration Number
Debra J. Glaister	33,888	Christopher Stone	35,696
Margaret Horn	33,401	Susan Faris	41,739
			4

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	Debra J. Glaister				
Address	Genencor International, Inc.				
Address	925 Page Mill Road				
City	Palo Alto	State	CA	ZIP	94303
Country	US	Telephone	650-846-7500	Fax	650-846-6504

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
Maria		Diaz-Torres	

Inventor's Signature: Maria Diaz Torres Date: May 7, 1998

Residence: City	State	Country	Citizenship
~~San Mateo~~ CA	CA	US	US/ES

Post Office Address: 58 North El Camino Real

Post Office Address:

City	State	ZIP	Country
San Mateo	CA	94401	US

☐ Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box → +

PTO/SB/01 (8-96)
Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S) Supplemental Sheet

1.00

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
Nigel		Dunn-Coleman	

Inventor's Signature: [signature] Date: 5.7.97

Residence: City	State	Country	Citizenship
Los Gatos CA	CA	US	GB/US

Post Office Address: 142 Johnson Avenue

Post Office Address:

City	State	Zip	Country
Los Gatos	CA	95032	US

2.00

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
Matthew	W.	Chase	

Inventor's Signature: [signature] Date: 5/7/99

Residence: City	State	Country	Citizenship
Chesterfield MO	MO	US	US

Post Office Address:

Post Office Address: 1052 Westmeade Drive

City	State	Zip	Country
Chesterfield	MO	63005	US

4.00

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.
Donald		~~Primbur~~	

Inventor's Signature: [signature] Date: 5/5/99

Residence: City	State	Country	Citizenship
Redwood City CA	CA	US	US

Post Office Address: 349 Orchard Avenue

Post Office Address:

City	State	Zip	Country
Redwood City	CA	94601	US

Name of Additional Joint Inventor, if any: ☐ A petition has been filed for this unsigned inventor

Given Name	Middle Initial	Family Name	Suffix e.g. Jr.

Inventor's Signature: Date:

Residence: City	State	Country	Citizenship

Post Office Address:

Post Office Address:

City	State	Zip	Country

☐ Additional inventors are being named on supplemental sheet(s) attached hereto